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Abstract
The liver provides a highly immunotolerant environment, that is exploited by hepatotropic
viruses such as Hepatitis B virus (HBV), which establishes persistent infection in more than
350 million people worldwide. In this thesis the potential for myeloid-derived suppressor cells
(MDSC) to exert metabolic regulation in this setting has been investigated. We found a mean
approximate 9-fold expansion of granulocytic MDSC (gMDSC) in patients with chronic HBV in-
fection (CHB) compared to uninfected, healthy controls (p<0.001). The most striking increases
were seen in patients replicating HBV in the absence of immunopathology (p<0.01). gMDSC
expressed high levels of the chemokine receptor, CXCR1, providing the potential for them to
be chemoattracted by liver-derived interleukin-8 (IL-8); consistent with this, they were further
enriched in the intrahepatic compartment. gMDSC from patients with CHB expressed increased
amounts of arginase I, correlating with an increase in serum levels of this enzyme (p<0.01).
Arginase I metabolises the conditionally essential amino acid L-arginine that is required for
proliferating T cells; in line with this was an observed decrease in circulating L-arginine, par-
ticularly in those patients without liver inammation. Liver pathology in CHB is amplied by
the recruitment and activation of bystander (non-HBV-specic) T cells; therefore the potential
of gMDSC to down-regulate such responses was explored. Puried gMDSC from patients with
CHB potently inhibit the expansion of bystander T cells capable of producing pro-inammatory
cytokines or mediating cytotoxicity. This inhibition was blocked using an arginase I-specic
inhibitor, N-hydroxy-nor-arginine (nor-NOHA). Taken together, these data demonstrate the ca-
pacity for expanded arginase I-expressing gMDSC to regulate liver immunopathology in CHB
by depriving T cells of L-arginine.
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Chapter 1
Introduction
1.1 50 Years of HBV
Baruch ˝Barry Blumberg (1925-2011), initially discovered the Hepatitis B virus (HBV) in 1965
[1] and subsequently worked on its identication, origin and spread, for which he received the
Nobel Prize in Physiology or Medicine on 13 December 1976 [2]. Research started by Blumberg,
and continued by others, culminated in the implementation of diagnostic testing and the later
development of an eective and fully-approved genetically engineered recombinant vaccination
(1986). The discovery of HBV in the mid-1960s led to the virus being initially named ˝Australia
Antigen, because this work took advantage of a reaction between an Australian Aborigine's
blood with the serum of an American haemophilia patient. However, in 1967 the ˝Australia
Antigen was renamed HBsAg after it was reported to be part of the virus. The work of Blum-
berg and colleagues triggered research leading to the subsequent identication, prevention and
treatment of the four other hepatitis viruses: Hepatitis A virus (HAV) in 1973 [3], Hepatitis D
virus (HDV) in 1977 [4], Hepatitis E virus (HEV) in 1983 [5], and Hepatitis C virus (HCV) in
1989 [6]. Combined, these ve viruses are responsible for the majority of the world's cases of
acute and chronic hepatitis [7].
Despite the extensive work of numerous scientists and clinicians over the last 50 years, infection
with HBV remains a signicant global health problem. The World Heath Organisation (WHO)
estimates that two billion people have been infected, with more than 350 million individuals
continuing to suer from ongoing chronic infection. Of the ve hepatitis viruses HCV remains
the sole virus for which a successful vaccine is unavailable [7]. However great progress has
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been made recently in the HCV eld, in terms of both treatment and a vaccination [8]. An
eective prophylactic vaccine for HBV therefore does exist, although approximately 600,000
people worldwide still die annually from complications attributed to HBV infection. These deaths
are the result of ongoing bouts of liver inammation leading to progressive brosis extending
to cirrhosis, and ultimately liver failure and hepatocellular carcinoma (HCC) [9]. The existing
therapy regimens for HBV rarely achieve full eradication of the virus from the patient and as yet
no successful therapeutic vaccine has been developed through to the clinic [10]. Despite all of
this, the UK has yet to implement a universal vaccination programme. Ensuring HBV remains
a virus that requires clinical attention and continued research.
1.2 Overview of Hepatitis B Virus
1.2.1 HBV epidemiology, treatment and beyond
Transmission of HBV can occur via a number of dierent routes; parenteral (for example: from
illicit drug use, from transfusion products and/or dialysis), sexual and perinatal (from a carrier
mother to neonate). Perinatal transmission of HBV typically leads to chronic infection (chronic
HBV infection: CHB), whereas in the majority of cases where infection is acquired during adult-
hood, a successful immune response is elicited resulting in disease resolution and subsequent
life-long immunity [11, 12, 13, 14, 15, 16, 17]. Numerically, and more specically, this equates
to HBV persistence in approximately 1.5% of infected adults, 20-30% of those infected as young
children and up to 90% of perinatally infected individuals [18].
The frequency and mode of transmission of HBV infection varies geographically (gure 1.1).
For example, the carrier rate in western Europe and in the USA is low, between 0.1-2%, in-
creasing in areas of high endemicity (sub-Saharan Africa and parts of Asia), to as high 20%
[18]. The most common route of infection also varies between areas; transmission of the virus in
areas of high endemicity is largely perinatally or during early childhood. In contrast, infection
tends to occur during adulthood in low prevalence areas. Given recent changes in migration
patterns into the UK, an area considered to be of low prevalence, the majority of new infec-
tions presenting in the clinic tend to be from individuals born in countries with intermediate
- high prevalence. Data published by Public Health England detailing a study in London not
only conrmed that the main burden of infection with HBV relates to chronicity and its as-
sociated clinical events, but also reported that 19 out of every 20 women testing positive for
HBV in antenatal clinics were born abroad (data quoted from Public Health England, 2012:
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http : ==www:hpa:org:uk=webc=HPAwebF ile=HPAwebC=1317141035027 - 06/09/2014).
Prevalence of HBV infection in adults (aged 19-49)
≥8% (high)
5-7% (high intermediate)
2-4% (low intermediate)
<2% (low)
Figure 1.1: Map showing the global prevalence of HBV infection.
Illustration of global endemicity of HBV infection, based on estimated
and categorised HBsAg prevalence in adults aged 19-49 for 2005. Adapted from
Ott et al. [9].
Patients with CHB often require antiviral therapy, which currently tends to be a lifelong com-
mitment. As a result treatment regimens are not only associated with a high economic burden
but also viral resistance the possibility of drug toxicity in the patient. The current clinical
paradigm for treatment of chronic infection is to reduce the risk of progressive chronic liver dis-
ease (progression through to severe cirrhosis and HCC). Current treatment strategies approved
by the NHS include a short course of pegylated interferon-alpha (peg-IFN) and use of antivirals
(for example: tenofovir, entecavir, lamivudine) [19]. What is however under current debate in
the eld, and remains controversial, is the concept of treating earlier in the course of disease
to reduce ongoing viral transmission and potentially stimulating immune control to enhance
cure rates. This involves looking more closely at the potential to treat younger patients who
typically have extremely high levels of viral replication without any clinically overt liver disease
(immunotolerant individuals, discussed further on in section 1.3.4). These patients constitute a
large infectious reservoir. This question is of particular relevance to the work presented in this
thesis.
1.2.2 HBV virology
HBV is a non-cytopathic, hepatotropic virus that is a member of the Hepadnaviridae family.
This family also includes the following: duck Hepatitis virus, woodchuck Hepatitis virus and
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the virus causing ground squirrel hepatitis [20]. HBV is traditionally classied into nine distinct
genotypes (A-I) based on divergence in the viral sequence. The prevalence of specic genotypes
also varies geographically, and may correlate with clinical outcome and response to treatment.
Figure 1.2: Schematic of the HBV genome.
The innermost circles (black) represent the full length minus ( ) strand
(with the terminal protein attached to its 5' end) and the incomplete plus
(+) strand of the HBV genome. The outermost coloured lines represent the
translated HBV proteins (described in section 1.2.2): large, middle and small
HBV surface proteins, polymerase protein, X protein, and core and pre-core
proteins. Adapted from Rehermann & Nascimbeni [17].
HBV has a relatively small genome of approximately 3200 nucleotides encoding four overlapping
reading frames (gure 1.2). Until recently, the specic details of HBV entry (infection of hepato-
cytes) was less well understood; the hepatocyte-specic receptor for HBV had not been correctly
identied. It was believed to involve viral attachment to liver cell-associated heparan sulphate
proteoglycans [21, 22]. However, a recent study by Yan et al. [23] implicated a novel role for an
already well described bile acid transmembrane transporter exclusively expressed in the liver (on
the basolateral membrane of hepatocytes) in the process of viral entry. This previously elusive
HBV hepatocyte receptor is the sodium taurocholate cotransporting polypeptide (NTCP) [23]
(gure 1.3). The use of experimental hepatocyte infection models expressing the NTCP protein
will no doubt enhance the study of HBV, providing for the rst time a semi-physiological in
vitro system.
After viral entry upon NTCP binding, the process of viral un-coating releases relaxed, partially
21
Chapter 1. Introduction
cytoplasm
nucleus
HBV virions
uncoating and capsid
disassembly
NTCP
cccDNA
formation
RNA
mRNA Envelope
Core
Pol
HBx
Precore
pgRNA
capsid
assembly
ER
extracellular space
HBeAg
ssDNA
rcDNA
secreted
HBV virion
HBx
secreted
HBsAg
secreted
HBeAg
rcDNA
HEPATOCYTE
Figure 1.3: Schematic of the HBV replication cycle.
Schematic depicting the life cycle of HBV after entry into the hepatocyte
via the bile acid transporter sodium taurocholate cotransporting polypeptide
(NTCP). Full details of the HBV replicative life cycle are detailed in the main
text in section 1.2.2. Abbreviations used: covalently closed circular DNA
(cccDNA), relaxed, partially double stranded DNA (rcDNA), single stranded
DNA (ssDNA), endoplasmic reticulum (ER). Adapted from Urban et al. [24].
double stranded circular DNA (rcDNA) into the cytoplasm of the hepatocyte (gure 1.3). The
HBV genome then translocates to the nucleus, where conversion of the rcDNA into covalently
closed circular DNA (cccDNA) minichromosomes occurs. cccDNA act as an ongoing viral tem-
plate whereby its production establishes a reservoir of self-amplifying virus, which can promote
life-long infection [25]. Persistence of cccDNA is one of the main obstacles to overcome in the
development of future treatment regimes. Thus, the current goal is a directed therapy that
eliminates or restricts the formation of cccDNA, as its presence alone can lead to reactivation
of HBV in patients with clinically inactive disease [26]. One recent report by Lucifora et al. [27]
has suggested new targets with the potential for eradication of such cccDNA reservoirs. The
authors demonstrated that by activating lymphotoxin- receptor, the subsequent up-regulation
of apolipoprotein B mRNA editing enzyme, catalytic polypeptide-like 3A (APOBEC3A) and
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APOBEC3B cytidine deaminases promotes the deamination and thereby the destabilisation of
cccDNA, thus potentially preventing the reactivation of HBV [27].
Following the formation of cccDNA, transcription of the four viral RNAs occurs driven by a host
polymerase II enzyme (Pol-II). These newly produced viral RNAs, including the pre-genomic
RNA (pgRNA), are subjected to nuclear export for mRNA translation. The four viral mRNAs
(shown in gure 1.2) function as follows:
1. the pre-core protein; transported to the endoplasmic reticulum (ER) under direction from
a leader sequence, for processing and excretion as the non structural protein - Hepatitis B
precore-core (secreted e antigen: HBeAg),
2. HBX protein; which activates HBV promoter activity in the cytoplasm via interaction with
transcription factors capable of nuclear entry, making it essential for viral replication,
3. the envelope proteins; of 3 dierent sizes, small (S), medium (M) and large (L) which
transverse the ER membrane as integral membrane proteins, and
4. the core and polymerase proteins which are key to capsid assembly around pgRNA, within
which the rst single-stranded DNA (ssDNA) is produced.
After translation, the newly formed ssDNA then functions as the template for second-strand
synthesis, resulting in nucleocapsid formation containing rcDNA. Mature DNA-containing cap-
sids are then either released from the ER membrane upon interaction with the three, newly
formed, envelope proteins, triggering internal budding of secreted infectious virions or returned
to the nucleus for cccDNA amplication [17, 28, 24, 29, 30].
Contrary to all other known mammalian DNA viruses, HBV replicates through reverse tran-
scription of an RNA intermediate. The process of reverse transcription is inherently error-prone.
Consequently, this step is responsible for the emergence of highly heterogeneous viral popula-
tions known as quasispecies. Quasispecies include those containing mutations that aect the
production of HBeAg [25]. This can be seen clinically in a subset of patients who re-enter an
active phase of disease with increased replication despite the lack of HBeAg, often after decades
of inactivity and seroconversion (refer to section 1.3.4).
Another unique feature of HBV is its capacity to secrete large amounts of protein, both circulat-
ing HBeAg and Hepatitis B surface antigen (HBsAg), which do not contain the full HBV genome
and often outnumber infectious virions by a factor of 104 - 106 [31]. These two secretable HBV
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antigens are believed to be immunomodulatory. They have been proposed to have the capacity
to divert the immune response and protect the virus from ongoing immune-mediated deletion.
1.3 Natural History of HBV Infection
HBV is highly replicative in the liver. Reportedly up to 100% of hepatocytes are infected,
compared to infection with HCV which infects up to approximately 50% of hepatocytes [32].
However recent work by our group and others suggests this may not be strictly true, indicating
HBV infection in the liver may be more localised, even ˝patchy, compared to previous reports,
with some areas remaining uninfected. In either HBV or HCV infection, however, the viruses
themselves are generally not directly cytolytic; the ongoing liver injury associated with persistent
infection is the result of continued immune mediated attempts to control infection [33, 34, 35].
This concept is discussed in more detail in sections 1.3.1 and 1.3.3. The work included within
this thesis focuses on patients with CHB. However, the immune response in acute infection is
important to consider as it provides a paradigm of a successful immune response to this virus.
1.3.1 Acute, resolving HBV infection
Much of what we know about HBV infection comes from studies of acute HBV infection in
humans, utilisation of HBV infection models in chimpanzees, and the use of transgenic mouse
models. During acute infection, HBV DNA increases, and subsequently declines before the peak
onset of the clinical symptoms of acute hepatitis (increase in serum alanine transaminase (ALT)
levels, an enzyme released by hepatocytes upon damage and the development of jaundice). Simi-
larly the decline in HBV DNA levels occurs prior to the induction of an adaptive T cell-mediated
immune response (gure 1.4) [36, 37, 38, 39]. Due to this delayed clinical presentation, obtaining
immunological data from the acute phase of HBV infection in humans is challenging. It is also
not usually ethically feasible to study early immunological events in the liver.
In addition to the issue of capturing early acute infection in humans, there is a lack of accessible
and widely available animal models and/or reliable in vitro models for HBV infection that do
not rely on the use of transformed hepatocyte cell lines. The animal models currently available
for the study of HBV infection are hampered by a number of issues. These include the costs and
the ethical concerns relating to their use (particularly the use of chimpanzees), the availability
and production of appropriate reagents for analysis (particularly the case with the woodchuck
model) and technical diculties arising from the derivation of often complex transgenic murine
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Course of acute HBV disease
Figure 1.4: Clinical course of acute, resolving HBV infection.
Typical uctuations observed in clinical parameters over the course of
acute viral infection, through to resolution, including viral load (HBV DNA),
and degree of liver inammation (serum ALT). Resolution provides life-long
immunity and is characterised by eective immune control rather than complete
eradication of the virus. Resolution is typically seen within six months of initial
viral infection. Protection is provided by the induction of neutralising HBV
surface antigen-specic antibodies (HBsAb) and the activation and expansion
of functional HBV-specic T cells. Adapted from Chang & Lewin [38].
models [40] .
Early in the antiviral response innate immune activation is essential; the production of type I
interferons (type-I IFN) acts as a rst-line mechanism in response to pathogenic detection. An
initial up-regulation of a type-I IFN response is observed with viruses such as human immunod-
eciency virus (HIV) and HCV. Unusually, evidence suggests that this is not necessarily the case
upon infection with HBV, therefore HBV is commonly referred to as a ˝stealth virus, largely
attributable to the limited activation of an early innate immune response. A pivotal study of ex-
perimental HBV infection in chimpanzees carried out by the Chisari group demonstrated a lack
of up-regulated type-I IFN-related genes in the liver after entry and the initial expansion phase
of infection [41]. These ndings were corroborated in human studies where levels of circulating
pro-inammatory cytokines, including type-I IFN, were almost undetectable in patients during
early acute HBV infection compared to patients infected with HCV or HIV [39, 42]. These same
patients also lacked the common u-like symptoms. The apparent lack of type-I IFN induction
suggests the virus has an inherent ability to evade innate recognition. This may be due to its
own replication strategy (previously described in section 1.2.2), using cccDNA that is able to
hide in the nucleus from innate sensing mechanisms. More recent data has began to challenge
this viewpoint. One line of evidence argues that HBV is in fact successfully recognised by innate
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immunity and therefore capable of eliciting a type-I IFN response, but that this response is
subsequently rapidly suppressed [39, 33].
Another feature of infection with HBV is the notable delay in viral amplication/replication
and therefore spread of the virus during early infection compared to most viruses which imme-
diately enter a phase of logarithmic propagation post infection. In a typical case of acute HBV
infection HBV DNA (using a polymerase chain reaction: PCR) is detectable, albeit at very low
levels, during early infection, but remains low, not peaking until approximately six weeks post
infection. Serum HBV DNA levels dramatically decrease (by approximately 90%) before the de-
tection of liver disease (increased serum ALT). Most HBV DNA is cleared from the liver (and the
blood) of experimentally infected chimpanzees prior to the detection of a lymphocytic inltrate
made up of both HBV-specic and non-HBV-specic T cells, and evidence of liver damage [34].
HBV-specic CD4+ and CD8+ T cells are commonly detectable in line with the exponential
increase in viral replication [37, 43, 39]. Depletion of the CD8+ T cell compartment following
acute infection of chimpanzees results in viral persistence, demonstrating the importance for
HBV-specic CD8+ T cell in viral clearance.
The majority of virus is however cleared by non-cytopathic mechanisms, maintained by the pro-
duction of key cytokines interferon gamma (IFN) and tumour necrosis factor alpha (TNF),
secreted by a number of cells, including CD8+ T cells [35, 44]. Recruitment of HBV-specic
CD8+ T cells into the liver is driven by chemokines, such as CXCL10 and upon platelet acti-
vation [45] to kill infected hepatocytes. Platelets adhere to the sinusoid via CD44, providing
aggregates for incoming CD8+ T cells to ˝dock to (Matteo Iannacone - personal communi-
cation). Evidence also suggests that production of these cytokines can actively down-regulate
HBV replication. IFN, IFN or TNF non-responsive mice fail to control HBV replication
[46]. The eects of these cytokines is through multiple mechanisms including the destabilisation
of the viral capsid, degradation of viral proteins and the post-transcriptional degradation of viral
DNA. This recruitment of HBV-specic T cells into the liver leads to the subsequent recruitment
of the non-antigen-specic cellular inltrate that amplies liver damage [47].
Following successful control of vireamia, HBsAg is lost from the blood and Hepatitis B surface
antigen-specic antibodies (HBsAb) become detectable (gure 1.4), alongside maturation of the
HBV-specic CD8+ cells into memory cells that persist long after viral control. Together they
mediate protection against subsequent HBV reactivation in the steady-state [48]. The life-long
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immunity resulting from HBV resolution is increasingly recognised to be the result of ongoing
immune control rather than the complete eradication of the virus, leaving the potential for reac-
tivation under conditions of immunosuppression (for example co-infection with HIV, or following
transplantation) [16].
A co-ordinated approach of lymphocytic cytokine production and direct cytolytic function on
infected hepatocytes promotes viral control. But what is essential is the balance between immune
activation to control the virus and an attempt to maintain low levels of collateral cell-mediated
liver damage once immune activation has occurred. The inability to control this balance forms
the basis of CHB pathology.
1.3.2 Chronic infection & immune failure maintaining chronicity
The fact that control of HBV infection occurs in more than 95% of those infected as adults
[19], provides evidence to support the ability of the immune system to successfully deal with
the virus. Although immune control is plausible in all cases, there still remains an issue of
chronicity in the remaining  5% of infected adults or those where infection was acquired early
in life. Understanding the inherent ability and co-ordination of both the innate and adaptive
immune responses during control of infection, and harnessing such responses forms the basis of
targeted strategies in the development of future immunotherapeutics. Given that the goal for
HBV immunotherapeutics is still some way o, it is worth considering how the HBV-specic
immune response required to drive viral clearance, is markedly diminished in patients with CHB
[49, 47]. Mechanisms of immune dysregulation in CHB have yet to be fully elucidated and as
a result are not fully understood. What is well known however, is that failure of the immune
response to control vireamia is multi-factorial and includes:
• HBV-specic immune suppression,
• the continued production of stable forms of HBV,
• the continued presence of cccDNA (clinically measured as the presence of HBsAg) and,
• viral infection in the liver, a known immunologically privileged site.
A characteristic feature of persistent infections is a dysfunctional, weak and mono-specic T cell
response. This is particularly true for patients with CHB who have a profoundly depleted HBV-
specic adaptive immune response, characterised by very few detectable HBV-specic CD8+
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T cells ex vivo [47, 49]. In particular CD8+ T cells directed against the core epitope (region
core 18-27) are almost undetectable in HBeAg positive chronic carriers [50]. In individuals with
high viral loads and extensive liver damage the circulating HBV-specic CD8+ T cells that
are present have a markedly decreased proliferative capacity, compared to those with low level
viral replication, in combination with minimal or absent liver disease [47]. The reduction in T
cell proliferation and functionality seen in CHB is not unique, and is consistent with responses
observed in animal models of other chronic viral infection, specically in the clone 13 strain of
lymphocytic choriomeningitis virus (LCMV) infection model where there is a decrease in TNF
and IFN expressing CD8+ T cells [51].
Work over the last few years by our group and others have described multiple mechanisms for
immune dysfunction in CHB. These include a study using an unbiased gene expression proling
approach which led to the identication of an up-regulation of the pro-apoptotic Bcl-2 interact-
ing mediator (Bim), which resulted in the description of Bim-mediated attrition of T cells as a
key mechanism decreasing HBV-specic T cell numbers [52]. The increased apoptotic propensity
and the resultant premature deletion of these cells is thought to be imposed by the tolergenic
environment of the liver, and further driven by the nature of liver-specic antigen presentation
(described in further detail in section 1.4).
Anti-viral HBV-specic T cells that escape or survive Bim-mediated attrition are often func-
tionally impaired or exhausted. T cell exhaustion is a recognised state of T cell dysfunction,
dened by poor eector function, sustained expression of inhibitory receptors and a transcrip-
tional state distinct from functional eector or memory T cells [53]. Exhausted CD8+ T cells
were initially described during chronic LCMV infection as virus-specic (tetramer positive) T
cells that failed to produce eector cytokines [54]. These cells have subsequently been studied
in numerous chronic viral infections in humans, including HIV [55], HCV [56, 57] and HBV.
Specically in CHB the few HBV-specic T cells that are detectable produce less IFN, pro-
liferate less and exhibit a phenotypic prole characteristic of exhausted cells [47, 58, 59]. This
progressive loss of T cell function and appearance of an exhausted phenotype is inuenced by
ongoing antigenic stimulation, since strong correlations exist between viral load and extent of
exhaustion in LCMV [51]. This is further supported by the fact that in HBV, virus specic T
cells are rarely detectable at viral loads exceeding 107 copies/ml [50].
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Figure 1.5: Overview of selected mechanisms of the immune response in CHB.
A) Interaction of PD-1 on the surface of HBV-specic T cells with PD-L1 on LSEC and/or hepatocytes driving tolerisation and dampening
immune response. B) Direct anti-viral activity of the pro-inammatory cytokine IFN produced by CD8+ T cells, prompting non-cytolytic
clearance of HBV. C) TGF production by KC, activates quiescent HSC, which can up-regulate TRAIL-receptors marking them for NK cell driven
TRAIL-mediated deletion (Singh et al - unpublished). D) TRAIL up-regulation on NK cells results in the induction of apoptosis of HBV-infected
hepatocytes, or HBV-specic T cells that up-regulate TRAIL-R2 via TRAIL-mediated deletion. E) CD4+ T cells required for the priming and
survival of functional CD8+ T cell responses and B cell activation, enabling the production of antibodies against the virus. F) Recruitment and
activation of a non-antigen specic cellular inltrate. Abbreviations used: liver sinosodial endothelial cell (LSEC), hepatic stellate cell (HSC), Kuper
cell (KC), natural killer cell (NK cell), tumour necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL), TRAIL-receptor 2 (TRAIL-R2),
cytotoxic T-lymphocyte-associated protein (CTLA-4), programmed death 1 (PD-1), programmed death ligand 1 (PD-L1)), T cell immunoglobulin-
and mucin-domain-containing molecule 3 (Tim-3).
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The state of exhaustion in CHB is accelerated by a number of candidate co-inhibitory signals
that are known to be up-regulated on HBV-specic T cells. These include an up-regulation
of programmed death 1 (PD-1) [49, 60], T cell immunoglobulin- and mucin-domain-containing
molecule (Tim-3) [61] and cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) [59] expression
that perpetuate the dysregulated cytokine production in response to peptide stimulation [62].
It is hypothesised that a naive T cell encountering HBV antigen in the context of intrahepatic
antigen presenting cells (APC) receives insucient co-stimulation, outweighed by an excess of
co-inhibitory signalling driving exhaustion or a state of T cell tolerance (detailed further in
section 1.4 and summarised in gure 1.6).
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Figure 1.6: Phenotypic balance between co-stimulation and co-inhibition driving
T cell exhaustion in CHB.
Schematic depicting the up-regulation and down-regulation of specic
receptor-ligand interactions maintaining the balance between stimulation and
inhibition of T cells upon interaction with an hepatic antigen presenting cell
(APC). Adapted from Schurich and Maini [62].
Another key aspect of the dysregulated immune response in CHB relates to a component of in-
nate immunity, the natural killer cells (NK cells). NK cells orchestrate immune response through
the production of eector cytokines and cytotoxicity primarily upon recognition of virally in-
fected cells (and tumour cells). NK cell functionality is determined by a balance between positive
and negative signals received through either stimulation of activatory or inhibitory surface re-
ceptors. An aberrant up-regulation of the death ligand tumour necrosis factor (TNF)-related
apoptosis-inducing ligand (TRAIL) promotes NK-mediated deletion of HBV-specic T cells [63].
30
Chapter 1. Introduction
In addition to the profound exhaustion of HBV-specic CD8+ T cells, our group has previously
noted a global metabolic defect in circulating and intrahepatic T cell proliferation and a specic
aect on their ability to produce interleukin-2 (IL-2). These ndings were accompanied by an
observed down-regulation of CD3, the signalling chain of the CD3 molecule at the surface of
global T cells [58].
Down-regulation of CD3 is now widely considered a hallmark feature of nutrient deprivation
[64, 65, 66, 67], suggesting the potential for metabolic regulation of immune responses in CHB.
This defect was associated with preliminary ex vivo evidence of a depletion in circulating levels
of the conditionally essential amino acid L-arginine in patients with active disease, which was
corrected upon L-arginine supplementation in vitro. These ndings were published by Das
et al. [58] (Maini group) and raised a number of exciting and interesting research questions that
inuenced the conception of this project.
1.3.3 Cell-mediated immunopathology in CHB
Before discussing the natural phases of CHB seen in the clinic, it is essential to consider what
causes the immunopathology in CHB. Although HBV-specic T cells are essential for control of
vireamia [35], they are also considered to play a key role in initiating liver inammation (and
the associated immunopathology).
It was initially thought that the cytotoxic functionality of HBV-specic CD8+ T cells was
solely responsible for the destruction of infected hepatocytes during infection. However, this
was disputed by early evidence from the murine and chimpanzee models which suggested a di-
rect involvement of an inux of inammatory granulocytes, induction of chemokine production
and a non-antigen-specic mononuclear inltrate (composed mainly of macrophages, T cells and
NK cells) that is recruited into the liver following initial recognition by HBV-specic CD8+
T cells [68, 69]. In the murine system, adoptive transfer of HBV-specic T cells triggered the
recruitment of inammatory neutrophils and mononuclear cells that were demonstrated to am-
plify liver damage [68]. Subsequent human studies have gone on to support this. An inux of
a non-antigen-specic T cells was reported by Maini et al. [47] to be most evident in patients
with high level, ongoing liver inammation as measured by raised serum ALT levels, highlight-
ing a role for this inltrate in potentiating liver disease. Further evidence in support of this
is the CD8+ T cell driven recruitment of mononuclear cells, by IFN production, which en-
ables the recruitment of NK cells into the liver [70]. Chemokine blockade in the liver has also
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been shown to reduce the extent of the non-antigen specic inltrate, in turn reducing the sever-
ity of associated liver disease, whilst maintaining non-cytolytic clearance of the virus [70, 69, 71].
The question of what licenses the HBV-specic T cells to orchestrate this inux of such an
inammatory inltrate remains to be fully elucidated. It is likely that innate mechanisms are
involved in the amplication of liver pathology. Production of the neutrophil chemoattractant
IL-8 coincides with peak vireamia, proceeding an hepatic are and an increase of IFN with
the onset of the are [72, 73]. Subsequent studies have shown IL-8 to be an essential factor
in the recruitment of both neutrophils and NK cells into the intrahepatic environment [74, 69].
Work by our group has also shown that IL-8 can induce hepatocytes to up-regulate TRAIL
death-inducing receptors, whilst increased IFN production induces expression of the reciprocal
death-ligand TRAIL on the NK cells promoting NK cell-mediated killing of hepatocytes [72]. A
study by Gehring et al. [75] described a population of HBV-specic T cells capable of producing
IL-8 in the inamed liver, which were not detected when inammation subsided during resolu-
tion of acute HBV. Although the study did not address directly whether IL-8 producing T cells
contribute to or initiate the inammatory process [75], it remains possible that T cell production
of cytokines and/or chemokines may be critical for recruiting the liver-damage causing cellular
inltrate in CHB.
Investigation into other changes in the liver mircoenvironment has suggested a role for the
activation of platelets that promote the tracking of leukocytes, including increases in virus-
specic T cells, to the sites of inammation [76, 45]. It has also been noted that many of the
inltrating T cells in the liver express a distinctive ˝liver-homing phenotype. This phenotype is
characterised by expression of CD161, chemokine receptors (CXCR6 or CXCR3) and an invariant
V chain. These cells are capable of producing further pro-inammatory mediators such as IL-17
in the liver, but their exact role in CHB remains to be elucidated [77].
1.3.4 Clinical manifestations in CHB
Infection with CHB results in markedly contrasting outcomes in the liver, which can be recog-
nised as distinct clinical ˝phases of disease. In the categorisation of patients into these phases
a combination of virological, serological and biochemical parameters can be used. Therefore the
natural course of CHB infection can arbitrarily be divided into four phases. These phases include
one where the virus replicates at extremely high levels for many years without any clinically ap-
parent liver disease (known as the immunotolerant phase); or, in contrast, phases characterised
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by an active immune-mediated necroinammatory reaction that attempts to control the virus
(active disease) (see gure 1.7 for full details and a temporal scale). What is essential to keep in
mind is that categorising patients into such phases, while useful clinically, does not necessarily
reect the true immunology and the ongoing immune-mediated response seen during each phase.
The immune mechanisms that distinguish these dierent phases and the transition between them
have yet to be established.
Course of chronic HBV disease
Figure 1.7: Natural course of chronic HBV infection.
Schematic depicting the course of infection a patient with CHB may progress
through. The time-line depicts progression of a typical vertical transmission
(from mother to neonate) case. These phases are clinically dened by a
number of parameters and vary in length. The initial immunotolerant phase is
characterised by extreme levels of viral replication and the presence of secreted
HBeAg in the absence of any liver disease (as measured by serum ALT, an
enzyme released by damaged heptocytes). This phase is then followed by
an immune-active phase, where HBV viral loads typically decline at the cost
of severe liver disease. In the low replicative phase (inactive phase), viral
loads dramatically decrease and serum ALT levels normalise, with liver disease
improving. The phase of inactivity can be life-long, but a subset of patients,
especially immunosuppressed individuals, can experience high level replication
again at the further expense of the liver. The classication and nomenclature
associated with each phase, although not perfect, are an important tool for
categorising patients in a chronically evolving infection. The clinical cut-os
used in the identication of patients into such phases varies between publications
and are discussed in the main text. The exact values used in this thesis are
stated in section 3.3.2. Adapted from Chang & Lewin [38].
The immunotolerant phase is more commonly seen in young patients after vertical infection from
HBeAg-positive mothers. Immunotolerant individuals are those characterised by serum HBeAg
positivity, extremely high viral loads (with a minimum HBV viral load of  200; 000IU/ml but
commonly in excess of 1 107IU/ml), and with a normal or a minimally raised ALT, indicative
of a lack of liver inammation. In this phase liver damage and therefore brosis progression is
commonly limited. This phase is longer in individuals perinatally infected, where it can often
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range from 20-30 years (gure 1.7) in stark contrast to those who acquire HBV infection during
adulthood in whom this period is short or even absent [78]. Despite the absence of liver inam-
mation, these individuals have an enhanced risk of HCC because of the HBV polymerase genes
reverse transcriptase properties, allowing HBV to integrate randomly into hepatocyte DNA.
High level replication over time therefore leads to an accumulation of integration sites [79].
The nomenclature for this particular phase is misleading as there is no clear evidence that these
patients experience an HBV-specic immune response that is considered to be any more tolerant
than either those with active or inactive disease. For example, it has now been suggested that the
T cell response prole of immunotolerant patients may in fact be similar to patients with highly
active disease. In some respects, the response is also less compromised than that observed in
older, more active patients [80]. What fundamentally maintains patients in this immunotolerant
phase remains a key research question.
The mechanisms associated with the loss of immunotolerance and the transition through to ac-
tive disease phase are mostly still unknown. The ˝immune clearance phase (HBeAg+ active
disease, see gure 1.7) is associated with a rapidly falling HBV viral load and a shift of hepa-
tocyte expression of Hepatitis B virus-core antigen (HBcAg) from the nucleus to the cytoplasm
[81]. This rapid decline in viral load is accompanied by an increase in serum ALT (intermit-
tent periods of raised ALT or ares). In this case the rise in serum ALT is attributable to the
immune-mediated response against the virus previously described in section 1.3.3. The immune
response attempting to clear the virus comes at the cost of liver damage, consequently causing
apoptosis and necrosis of infected hepatocytes. During this phase, again which can last for a
number of years, disease activity uctuates and progressive liver disease often occurs. Individu-
als who develop CHB that were infected during adulthood advance through to an immune active
phase rapidly once infected.
Seroconversion from HBeAg positivity to HBeAg specic antibody (HBeAb) positive is usu-
ally followed by a non-replicative or inactive phase, with low-level viral replication (gure 1.7).
During this phase, patients have low level viral replication (often barely detectable HBV DNA)
and hepatocyte destruction ceases, with a concomitant normalisation in serum ALT values [82].
During this phase a small number of patients successfully clear HBsAg, although this tends to
be in only approximately 1% of patients each year [83]. This period of inactive disease can be
long-lasting. A subset of patients develop HBV re-activation, even after seroconversion, with
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recurrent necroinammatory liver disease and high-level replication (eAg- active disease, gure
1.7). This occurs in the presence of either the wild type virus (and reversion to HBeAg positiv-
ity), or HBV variants that limit re-expression of HBeAg due to mutations in either the pre-core
or core promoter region [84].
1.4 Immunology of the Liver
The liver is considered to be the largest internal organ of the body. It functions as the primary
site for the metabolism of often harmless gut-derived carbohydrates, proteins and lipids, primar-
ily from ingested food products. Another key function of the liver is to function as a secondary
lymphoid organ, central to the process of immune surveillance critical to host immunity and
survival. The liver is non-redundant in its role in detecting pathogenic insults and providing
host defence. In doing so, the liver is able to screen and protect against pathogenic insult (with
the exception of encapsulated bacteria which are detected and removed by the spleen). As such,
the liver is widely considered an immunoregulatory organ, whereby it functions to maintain an
adequate balance between immune tolerance (immune hyporesponsiveness), and immune surveil-
lance and activity (priming and eliciting robust immune responses where necessary) [85]. For
example the introduction of live bacteria or specically relevant to the work of this thesis, hepa-
totropic viruses, require a regulated innate and adaptive immune response, that is sucient for
pathogenic elimination or control without disturbing physiological tolerance and function.
The ability of the liver to perform necessary immune surveillance, in other words detecting and
responding to pathogenic insult, is a combined eect of both its anatomy (and blood supply) and
the diverse network of cellular populations resident therein. The liver receives its blood supply
directly from the gastrointestinal tract, meaning it is enriched in both nutrients and numerous
bacterial degradation products that gain access from the gut lumen. This results in a large
number of antigens passing through every minute. The blood ow into the liver is impressive, it
has been reported that 30% of the total blood volume passes through the liver each minute [86].
However, this volume circulates through the liver in a ˝sluggish manner primarily due to the
extensive sinusoidal network. The sluggish movement through the liver promotes interaction of
immune cells with liver resident cells or the inltrating leukocytes within the hepatic sinusoids
[87]. An evolutionary advantage of this slow blood ow may be to ensure pathogens are detected
and responded to appropriately [88]. This exposure of the liver to continued harmless antigenic
stimulation is a physiological state, so must not lead to overt tissue damage resulting from
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activation of immune responses and/or inammation; thus forming the basis of the concept
immune tolerance. A number of mechanisms act to predispose to immune tolerance, including
the nature of antigen presentation. This can be specically harnessed by hepatotropic infections
or tumours of the liver to promote their persistence. In evolutionary terms, the liver has been
specically designed to not only eciently metabolise necessary nutrients and clear toxins but
to maximise its immunoregulatory role. Key features which will be discussed in detail in the
subsequent sections include, the largest single population of macrophages (resident Kuper cells
(KC)), the greatest density of NK cells and natural killer T cells (NKT cells) and the largest
reticuloendothelial network in the body.
1.4.1 Liver sinusoidal endothelial cells
The capacity of liver cells to present antigen and engage with T cells is not limited to classical
dendritic cells (DC), specically, liver sinusoidal endothelial cells (LSEC) are very ecient APC
[89, 90]. Often in response to hepatotropic infections, CD8+ T cells display phenotypic features
of cells that did not receive sucient activation (depicted in gure 1.6). Naive T cells do not
typically enter non-lymphoid tissues without having been activated previously, to mature and
dierentiate into eector T cells. The liver, however, represents an exception to this; it has
the ability to prime naive T cells, that were previously thought to require professional APC in
lymphatic tissue.
The LSEC comprise more than 50% of the non-parenchymal cells in the liver and are critical
in pathogen detection, capture, and antigen presentation [91]. Anatomically, LSEC separate
heptocytes from the blood owing through the sinusoidal lumen, with no organised basement
membrane (gure 1.8). This feature enables the formation of a gap, the Space of Disse, between
the endothelial lining and the underlying hepatocytes [92]. The LSEC do not form tight junc-
tions, preventing total exclusion of heptocytes from the sinusoids. The LSEC are perforated
by fenestrations allowing for the extension of membrane protrusions from both heptocytes and
inltrating lymphocytes [93]. The structural nature enables the LSEC to facilitate direct contact
with heptocytes and lymphocytes, but also allows for the bi-directional ow of metabolites.
Key to their role in antigen presentation, LSEC inherently express a number of the surface
characteristics of classical stimulatory APC, similar to DC. They express numerous pattern
recognition receptors (toll-like receptor* (TLR3), TLR4, TLR7 and TLR9), show constitutive
expression of both major histocompatibility class I (MHC-I) and class MHC-II, co-stimulatory
36
Chapter 1. Introduction
hepatocyte
HSC
LSEC
NK cell
T cell
myeloid
cell?
Kupffer
cell
space of
Disse
Figure 1.8: Schematic view of the mirco-architecture of the hepatic sinusoid.
Hepatocytes are separated from the blood rich in antigen-specic and
non-antigen specic CD8+ T cells, NK cells and myeloid cells, passing through
the sinusoids of the liver lined by non-parenchymal LSEC. LSEC have no
organised basement membrane, forming the Space of Disse between the endoth-
lial lining and the underlying hepatocytes, perforated by numerous fenestrae.
HSC, with an astral phenotype reside in the Space of Disse. Liver resident
macrophages, KC, adhere to the LSEC in the hepatic sinusoid. In the context
of this schematic, myeloid cells encompasses myeloid-derived suppressor cells;
their exact location in the liver is unknown. Abbreviations used: Kuper cells
(KC), hepatic stellate cell (HSC), liver sinusoidal endothelial cells (LSEC) and
natural killer cells (NK cells). Adapted from Knolle & Thimme [94].
molecules (CD80 and CD86) and adhesion molecules such as intercellular adhesion molecule
1 (ICAM-1), which together enable LSEC to function potently as liver resident APC [95, 87].
LSEC also express a variety of scavenger, antibody and mannose receptors, enabling the rapid
uptake of protein and cellular debris by receptor-mediator endocytosis, but more specically
the internalisation of a wide range of pathogens for presentation. LSEC, through expression of
both MHC-I and MHC-II are capable of ecient cross-presentation, resulting in both CD4+ and
CD8+ T cell activation.
Antigen presentation by an LSEC results in local maturation of the particular LSEC as an APC
and the up-regulation of the co-inhibitory signalling molecule, programmed death ligand 1 (PD-
L1). Expression of PD-L1 is crucial to the induction of tolerised T cells that are not fully licensed
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with eector function. Initial CD8+ T cell activation by an LSEC results in T cell proliferation
and release of cytokine (considered transient CD8+ T cell activation) but over time it is the
recognition of antigen in the context of PD-L1 signalling, rather than co-stimulatory molecules,
that results in antigen-specic tolerance [89, 96]. Engagement of PD-L1 with its receptor PD-1
on activated T cells results in a phenotypic drive towards T cell exhaustion (as discussed previ-
ously in section 1.3.2).
Further exposure of LSEC to other soluble mediators, such as IL-10 and transforming growth
factor beta (TGF), promotes the induction of T cell tolerance rather than activation via the
reduction in surface expression of MHC molecules, and some co-stimulatory molecules, which
again limits the capacity of LSEC to elicit immune responses [97]. LSEC also promote tolero-
genic T cells by directly limiting the function of liver-resident DC [98].
While a degree of immune tolerance is essential to maintain normal physiology, and antigen
presentation by LSEC is a critical mechanism involved in such tolerance, it does lead to problems
when attempting to raise an immune response against viral infections or tumours of the liver.
1.4.2 Kuper cells
KC represent the single largest population of macrophages, making up an estimated 80-90% of
all tissue resident macrophages in the body [99]. KC are stationary macrophages, that adhere to
LSEC in the hepatic sinusoids. Similarly to LSEC, KC express a range of scavenger receptors,
complement receptors, TLR, and antibody receptors that detect, bind and enable internalisation
of pathogen. Uptake of such antigens promotes KC activation to produce a number of cytokines
and chemokines, which subsequently alert the immune system, including the production of IL-12,
IL-6 and TGF as depicted in gure 1.5.
As well as being extremely good at the capture and clearance of numerous pathogens, especially
bacteria, KC also represent an important APC population in the liver. As with LSEC, KC
predispose the liver towards immune tolerance. Although they express MHC-I and MHC-II
alongside an array of co-stimulatory molecules, under the steady state KC are poor T cells
activators. Continued exposure to lipopolysaccaride (LPS, from the gut) dampens down their
ability to prime T cell responses [97]. KC also participate in driving immune tolerance through
production of the immune suppressive cytokines IL-10 and TGF and expression of molecules
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such as Fas-ligand (FasL) and PD-L1 [100]. KC also detect low concentrations of TLR ligands
and respond by producing pro-inammatory cytokines such as IL-6 and type I IFN [101].
1.4.3 Hepatocytes
Hepatocytes are the parenchymal cell population of the liver and are primarily responsible for
the metabolic functionality of the liver. They too can act as liver-resident APC, once again cru-
cial to immune regulation via the induction of immune tolerance [102]. Hepatocytes make direct
contact with sinusoidal T cells through the fenestrations provided by the structural nature of
the LSEC [93] and also constitutively express MHC-I and ICAM-1. Although not constitutively
expressed, under inammatory conditions (for example, IFN production), hepatocytes can also
express MHC-II [93, 103, 88, 104]. Evidence suggests that hepatocytes present antigen to naive
T cells in an ICAM-1-dependent manner [88, 93].
As well as being involved in T cell activation, hepatocytes also play an important role in the
regulation of immune surveillance beyond the liver. Such surveillance is achieved via the pro-
duction of serum constituents, for example, secreted pathogen recognition receptors (PRRs),
acute-phase proteins and complement components. These are all important constituents of the
innate immune response against pathogenic insult through processes such as the opsonization of
pathogens for phagocytosis or activation of the complement cascade [105, 87]). IL-6 produced
by KC upon detection of low-level TLR ligands, is able to induce the expression of the acute
phase protein, C-reactive protein, by hepatocytes thereby linking functionality of multiple cell
types of the liver [106].
Also of note is a novel role for hepatocytes that has been described recently by Benseler et al. [107]
whereby the liver further induces peripheral tolerance via a mechanism based on the deletion of
CD8+ T cells that have been activated locally. The authors demonstrated that recently activated
T cells commit ˝suicide by actively invading antigen-expressing hepatocytes; a process coined
˝suicidal emperipolesis. The antigen-specic T cells were shown by microscopy to enter and be
contained within the hepatocytes prior to non-apoptotic, lysosomal degradation before the T cell
could clonally expand and acquire its cytotoxic eector function [107]. This process, although
necessary for the deletion of potentially autoreactive T cells, may be detrimental to the ongoing
and necessary immune responses against hepatotropic infections.
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1.4.4 Hepatic stellate cells
Hepatic stellate cells (HSC) are perivascular cells located in the Space of Disse that exhibit an
astral phenotype. Their anatomical location promotes their interaction with LSEC and hepato-
cytes whilst separating them from the circulating lymphocytes and myeloid cells in the sinusoid
(gure 1.8). Their traditional roles include being the primary site for the storage of vitamin A in
cytoplasmic droplets, the regulation of blood ow through the sinusoids due to their contractile
nature, and the ability to trans-dierentiate from a quiescent state into brogenic, proliferative
myobroblasts upon liver injury to promote repair. They achieve this via the production of large
amounts of extracellular matrix proteins. They are also a potent source of TGF, and so upon
continued liver injury HSC are critically involved in the development of brosis [108, 109].
In addition, a tolerising role has been more recently described for HSC. HSC can produce a
diverse range of chemokines, and are also able to present antigen to T cells [110, 111], although
the fate of these T cells once primed is still under debate. However, not only have human HSC
been demonstrated to suppress T cell activation (via PD-L1) but they have also been shown
to promote the induction of known immunoregulatory cell populations: both regulatory T cells
(Treg) and myeloid-derived suppressor cells (MDSC). T cell activation in the context of HSC
has been reported to result in the induction of CD4+ Tregs [112, 113]. MDSC will be described
in more detail further on in this thesis however human HSC have been shown to promote the
dierentiation/accumulation of MDSC [114, 115, 116], and in doing so confer tolerance, for
example in the context of preventing kidney allograft rejection [114].
1.4.5 Lymphoid & myeloid cells of the liver
The majority of the immunology of the liver covered so far has focused on the non-lymphocytic
liver-resident cells and their ability to detect pathogen and/or their role in immune tolerance.
Some attention should be given to the populations of lymphocytes both resident and transiting
through the liver. Lymphocytes can be found scattered throughout the parenchyma of the liver,
as well as in the portal tracts, with the average human liver containing in the order of 1010 cells
[91]. As already alluded to the composition of the total lymphocyte population of the liver is
unusual.
Between 40-60% of the intraheptic pool of lymphocytes are NK cells, which is more than a
three-fold enrichment compared to the periphery [117, 118]. NK cells respond to a wide-range
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of cell-surface ligands expressed by damaged or infected cells, which ensures self-tolerance is
maintained, whilst responding to infected or transformed cells. NK cells kill target cells via
the formation of an immune synapse to mediate subsequent lysis by releasing cytotoxic gran-
ules (containing perforin and granzyme). However, NK cell functionality is not just restricted
to their capacity to ˝kill as the name might suggest. NK cells also produce and release the
pro-inammatory cytokines, such as IFN and TNF [119, 120].
Also the ratio of CD4+ to CD8+ T cells is altered in the liver. Under homoeostatic condi-
tions CD4+ T cells outnumber CD8+ T cells in the periphery by approximately two to one.
In the liver this ratio is reversed, with CD8+ T cells outnumbering their CD4+ counterparts.
These T cells all express the -chain T cell receptor (TCR) and respond to antigen presented
in the context of MHC molecules [91]. The liver also contains a large number of  T cells
which again have altered frequencies in the intraheptaic environment; in the periphery these
cells normally represent approximately 3% of total lymphocytes, but in the liver these cells can
represent up to 15% [87]. These cells play a predominant role in the presentation of lipid antigen.
Several lines of evidence suggest that the recruitment of leukocytes into the liver during chronic
viral infections is largely mediated by the ability of chemokines to attract leukocytes to specic
sites in the liver. The large majority of T cells inltrating into the chronically inamed liver
express high levels of the following chemokines: CXCR3, CXCR6, CCR1 and CCR5; a tissue-
inltrating phenotype [121, 122, 123, 124]. Induction of the pro-inammatory cytokines IFN
and TNF up-regulates expression of the CXCR3-ligands, CXCL9 and CXCL10. These have
specically been shown to be up-regulated with increased expression of the receptor CXCR3 on
both CD4+ and CD8+ T cells in the liver compared to peripheral T cells in chronic hepatitis
[121]. Importantly, studies using blockade strategies of CXCL9 and CXCL10 in vivo resulted in
reductions in the recruitment of mononuclear cells into the liver, particularly those subsets that
are known to express CXCR3 [71].
The ligand CXCL16 has also been reported to be up-regulated on hepatocytes [123], and en-
gagement of CXCR6-expressing T cells through this interaction is important for the retention
and survival of eector cells in the inamed liver. More recently a subset of CXCR6+ liver-
inltrating CD8+ T cells which co-express the C-type lectin, CD161, capable of producing IL-17
and IFN have been reported in chronic HCV infection. This phenotype characterised by in-
creased CD161+ T cells has also been reported in acute HBV in a limited number of patients.
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Notably this phenotype was absent from HIV- cytomegalovirus (CMV)- and inuenza-specic
T cells [125]. The interaction of CXCR6:CXCL16 has also been shown to be relevant in the
process of hepatic homing of NK and NKT cells [126].
Immune regulation in the liver can also be controlled by myeloid-lineage populations beyond
that of the resident KC. Recent evidence has demonstrated a role for inammatory monocyte-
derived CD11b+ aggregates, that have been termed ˝intrahepatic myeloid cell aggregates for T
cell clonal expansion (iMATE). The authors have described these iMATE as structures that pro-
vide a ˝cocoon-like anatomic framework that enables and promotes the proliferation of CD8+
T cells locally, in the apparent absence of local antigen [127]. The formation of such struc-
tures to enhance antigen-specic T cell numbers may be critical in aiding the immune response
against hepatotropic infections. While myeloid-cell populations/structures like iMATE could be
considered benecial to an anti-viral or anti-tumour immune response, dierent populations of
immature myeloid cells have also been described in the liver. One such subset is the MDSC.
MDSC exhibit a wide-range of immune-suppressive functions, that aect both the innate and
adaptive immune systems. Full description and discussion of these cells occurs throughout the
thesis and will therefore not be covered in detail here.
Finally the liver microenvironment itself, independent of any single cell subset is involved in driv-
ing immune tolerance. In this case the milieu is characterised by a state of nutrient deprivation.
This nutrient-poor environment is achieved by the presence of a number of enzymes, central
to immune regulation and immunometabolism. Examples of such enzymes include tryptophan
2,3-deoxygenase (TDO, an enzyme involved in the metabolism of L-trytophan to N-formyl-
kynurenine), complemented by the action of indoleamine 2,3-dioxygenase (IDO), which when
combined give rise to the immunosuppressive molecule kynurenine. The presence of IDO has
previously been shown to been a critical mediator in the maintenance of the process of materno-
fetal tolerance [128], and in the context of chronic HCV infection, where IDO expression is
increased in the liver of patients [129]. KC and liver-resident DC are potential sources of IDO
especially under inammatory conditions. Yan et al. [130] specically demonstrated T cell inhi-
bition (T cell proliferation and induction of T cell apoptosis) upon enhanced levels of kynurenine
and reduced tryptophan in vitro.
Another key enzyme capable of driving nutrient deprivation is the constitutively expressed
arginase I. This enzyme, capable of metabolising the conditionally essential amino acid L-
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arginine, is constitutively expressed by hepatocytes. Extracellular arginase I when released
from hepatocytes upon damage can deplete L-arginine. Local nutrient deprivation can limit T
cell functionality and proliferation [131, 66, 64], thus potentially preventing successful adaptive
immunity required upon sensing pathogenic insult. It is also possible that this deprivation could
limit immune-mediated damage arising from excessive immune activation in the liver. Interest-
ingly hepatocytes, although potent sources of the enzyme arginase I when damaged, are not the
only source. MDSC can also produce and store large amounts of the enzyme [132]. The concept
of metabolic regulation by cells such as MDSC in the liver is an exciting area of research.
1.5 Overview of Myeloid-derived Suppressor Cells (MDSC)
Myeloid cells represent the most abundant type of haematopoetic cell in the immune system and
have a huge diversity of physiological and pathological function [133]. All cellular components of
the blood fall into two distinct lineages, either lymphoid or myeloid and are all generated from
haematopoietic stem cells of the bone marrow. Mature lymphoid subsets all dierentiate from
a common lymphoid progenitor, and similarly all myeloid subsets arise from a common myeloid
progenitor [134]. Under physiological conditions, common myeloid progenitors migrate out of the
bone marrow into peripheral lymphatic organs having undergone full dierentiation and matu-
ration into classical mature myeloid subsets (neutrophil, monocyte, basophil and eosinophil, see
the dotted lines in gure 1.9). The full developmental pathway of each individual cell subset
and lineage is beyond the scope of this introduction.
What is now widely acknowledged is that under pathological insult or where normal physiolog-
ical conditions are perturbed, classical myeloid cell development can ˝arrest, giving rise to an
heterogeneous population of cells with an immature phenotype. These cells are the MDSC (see
the solid black lines in gure 1.9). The exact origins, dierentiation and development of these
cells remains to be fully elucidated. However, these cells are of particular interest in hepatotropic
infections as they themselves are tolerogenic and immune-suppressive: they could either promote
physiological tolerance or be harnessed by pathogens or tumours to prevent a robust immune
response.
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Figure 1.9: Development and dierentiation of common myeloid progenitors into
myeloid cell subsets.
All myeloid cell subsets arise from a common myeloid progenitor. Solu-
ble mediators, (cytokines, growth factors and chemokines) produced in response
to pathological insult, for example, by a tumour, or upon detection of viral
infection, promote the aberrant dierentiation of common myeloid progenitors,
diverting away from full myelopoiesis into mature myeloid cells. The dotted lines
represent normal, physiological developmental pathways of immature myeloid
precursors into monocytes-macrophages and granulocytes (basophils, eosinophils
and neutrophils), and the solid black lines indicate the aberrant pathways
of myeloid cell development giving rise to MDSC subsets. Recent evidence
suggests a large proportion of gMDSC can arise from further dierentiation
from the mMDSC confounding the idea of MDSC plasticity [135]. Adapted
from Wynn [136].
1.5.1 Brief history of MDSC
Even to date, MDSC remain a relatively newly described cell type that fail to feature in immuno-
logical textbooks. Such cells were originally alluded to in the late 1970s, early 1980s (1978-1984)
in models of tumour development and systemic Bacillus Calmette-Gurin (BCG) infection. At the
time these cells were described as an abnormal population of expanded myeloid cells exhibiting
suppressive activity, therefore these cells were termed ˝natural suppressor cells. With continued
research these natural suppressor cells were shown to lack membrane markers for mature lym-
phocyte populations (B/T/NK cells) and to functionally inhibit lymphocyte proliferation and
function [137, 138]. Even at this early stage, while these cells were yet to be formally described,
it was noted that they possessed the ability to promote tumour growth through inhibition of
anti-tumour responses [138]. The lack of formal description for the cells meant the early study
of MDSC was relatively controversial. It was not until the mid 1990s where further study of
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these cells went on to describe them more concisely as an heterogeneous population of immature
myeloid cells with one key dening feature: the capacity for lymphocyte suppression [139, 140].
From then on the population began to be referred to as myeloid suppressor cells, abbreviated at
the time to MSC. This abbreviation created confusion with mesenchymal stem cells, also com-
monly abbreviated to MSC. However in a letter published in 2007 written by Gabrilovich et al.
[141] the controversy and inconsistency in naming this cellular phenotype and functionality was
highlighted and subsequently the widely accepted nomenclature for these cells as MDSC was
coined [141, 142]. MDSC phenotypic identity, the role and their functionality will be discussed
in detailed in the subsequent chapters of this thesis.
1.5.2 MDSC: akin to neutrophils
Neutrophils are commonly dened as the eector cells of the innate immune response providing
rapid immunity against invading mircoorganisms. Their function involves chemotaxis towards
the invading pathogen, enabling engagement to promote the destruction of the infected cell.
Neutrophils are increasingly being reported to have multiple phenotypes, thus creating a poten-
tial overlap with the granulocytic subset MDSC in the literature, and although their importance
in host defence is still widely agreed, only little is known about the basic immunology of the in-
dividual neutrophil subsets. It is highly plausible that this lack of knowledge has arisen because
of the short-lived nature of these cells. Neutrophils are known to undergo apoptotis in the tissue
after engaging pathogens, or as recently reported undergo reverse migration to move out of the
tissue of interest shortly after eliciting immune control [143].
The half-life of a neutrophil in peripheral blood was originally postulated to be somewhere
between 7-25 hours based on old labelling and tracer experiments using radioactive isotopes
[144, 145]. This is now debated; more recent studies have described the half-life of a neutrophil
anywhere up to 5.4 days [146, 147]. This discrepancy may be explained by either taking into
account the division time of a neutrophil progenitor or allowing for subset dierentiation. How-
ever taken together with the view that neutrophils may not undergo immediate apoptosis after
eliciting eector function (by reverse migration), it is possible that at least a sub-population of
neutrophils survive longer than previously thought. Either way the potential for ˝neutrophil-
like cells to switch phenotypes and exert functionality beyond cytotoxicity against an invading
pathogen exists. One such phenotype considered by many is gMDSC (discussed in more detail
in the subsequent chapters). Consideration detailing the dierences and similarities of gMDSC
and classical neutrophils is under ongoing debate and discussion, especially given the large phe-
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notypic overlap in marker expression in humans (for example common expression of CD16 and
CD66b). This issue with the naming of these cells should not become the focus and distract from
the data as long as the functionality of such cells is considered and reported (if authors wish
to claim eects seen are MDSC-mediated). Authors will often themselves exclude the study of
classical neutrophils by the nature of the common step in PBMC isolations from human samples
using density centrifugation with Ficoll.
1.6 Immunometabolism: an emerging eld
The emerging eld of ˝immunometabolism seeks to combine two historically distinct elds; the
process of energy metabolism and immunity. A lot is known about the biochemical nature of
the pathways involved in cellular metabolism, but surprisingly very little is known about the
regulation of these processes in immune cells. Historically metabolic studies have been restricted
to adipocytes and/or cancer cells and the specic metabolism of the immune system has been
overlooked. It is now emerging that T cell function, survival and dierentiation is linked to
two key intracellular metabolic pathways: glycolysis and oxidative phosphorylation. The eld
of immunometabolism specically focuses on the fact that mounting a successful and eective
immune response requires major metabolic changes in immune cells, to enable rapid cellular
proliferation and mobilisation.
The metabolism of lymphocytes must be tailored to ensure appropriate functionality. A resting
T cell does not require large amounts of synthetic ˝building blocks (primarily, amino acids),
they simply require energy (primarily in the form of ATP-production) to ensure basal cell pro-
cessing to maintain the process of immune surveillance. Upon successful TCR engagement with
its cognate peptide the resting T cell must undergo a dramatic metabolic reprogramming event
to provide the cell with essential biosyntheic components required for nucleotide, lipid and amino
acid synthesis. These building blocks are necessary for rapid cell proliferation and functionality:
promoting eector cell function. Thus to mediate an adaptive immune response the T cell must
signicantly increase its amino acid (and glucose) availability. Stimulated lymphocytes therefore
need to switch their metabolism from the resting state characterised by a bias towards oxidative
phosphorylation to active glycolysis, enhanced glutamine oxidation [148] and more importantly,
increased amino acid uptake.
A recent study by Sinclair et al. [149] suggested a role for the family of cell surface System
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L transporters in immunologically activated T cells. Previous to this publication the relevant
amino acid transporters, required to increase uptake, in active T cells were unclear. The authors
of this particular study demonstrated the dependence of T cells on such System L transporters
when activated by either TCR engagement or pro-inammatory cytokines, such as IL-2. Ex-
perimental triggering of the TCR resulted in enhanced transport of large neutral amino acids
(including leucine, and arginine) across the plasma membranes. Specically, transport of leucine
via these System L transporters was shown to be essential for T cell activity via activation of
the mammalian target of rapamycin (mTOR) pathway. What is essential to bare in mind is that
the ability of the mTOR pathway to sense leucine uptake (and indirectly other amino acids),
enables the modulation of cellular responses to nutrient availability and the required switch in
metabolic state from resting to active T cells.
Notably the System L transporters are composed of a heterodimer of a heavy chain, CD98
(Slc3a2), and either of the following light chains, Slc7a5, Slc7a8, Slc7a7 or Slc7a6 [150, 151]. In
further studies the selective deletion of CD98 conrmed that uptake of leucine (and the indirect
increase in other amino acids) through this transport pathway is critical for the proliferative
expansion of both T and B cell [152, 153]. As already stated a T cell must undergo a metabolic
switch when activated to provide an amino acid (and glucose) rich environment, during this
switch the mTOR pathway is one key pathway that is activated. If mTOR activation is pre-
vented, for whatever reason, the cells fails to successfully activate and as a consequence may
become tolerised or anergic and instead may favour oxidative phosphorylation rather than in-
creased amino acid uptake and glycoylsis. As is discussed later on section 4.2.2, in conditions
of nutrient deprivation, for example in the liver microenvironment in patients with CHB, the
mTOR pathway may be inhibited, so T cells become tolerised and display limited functionality
[154].
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1.7 Hypothesis
It was hypothesised that granulocytic myeloid-derived suppressor cells are capable of limiting
immunopathology in the liver associated with CHB infection by depriving inltrating, non-
antigen specic bystander T cells of the amino acid L-arginine.
1.8 Thesis Aims
• Are gMDSC expanded in the context of hepatotropic infections?
• Do gMDSC contribute to the metabolic regulation of immunity in CHB through L-arginine
deprivation?
• Are gMDSC capable of suppressing the bystander T cell response implicated in amplifying
the liver disease?
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1.9 Thesis Overview
In this thesis an expansion of the granulocytic subset of MDSC (gMDSC), expressing increased
amounts of arginase I, has been described in patients with chronic hepatotropic infections. These
gMDSC accumulate in the liver of such patients (and not in healthy livers), expressing chemokine
receptors that may favour egress from the bone marrow and cellular interaction with hepatic-
resident stellate cells. This study also provides ex vivo evidence of arginase I release into the
circulation and a deprivation in the conditionally essential amino acid L-arginine, most signi-
cantly in patients with ongoing HBV replication in the absence of overt necroinammatory liver
disease. The data presented indicate that this protective eect may be driven by the capacity
of the expanded population of arginase I-expressing gMDSC to potently inhibit T cell responses
by depriving them of L-arginine. The contribution of amino acids to T cell function in CHB
was further supported by a strong ex vivo correlation between their expression of amino acid
transporters and the signalling molecule CD3. Overall the study highlights the capacity of
gMDSC to moderate tissue damage in a common human infection by constraining key nutrient
supplies required by proliferating T cells.
1.10 Thesis Highlights
1. Granulocytic arginase I-positive MDSC accumulate in hepatotropic vial infections
2. gMDSC and arginase I levels segregate with the degree of liver pathology
3. gMDSC can regulate pathogenic T cell responses in CHB by depriving them of L-arginine
4. T cell induction of amino acid transporters implicates metabolic reprogramming in viral
infection
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Chapter 2
Materials and Methods
2.1 Study Participants
This study made use of human samples obtained from patients attending clinics at four separate
sites across London:
1. Mortimer Market Centre (Bloomsbury, London),
2. Royal Free Hospital (Hampstead, London),
3. University College Hospital (UCH, Bloomsbury, London), and
4. Royal London Hospital (Whitechapel, London).
In all cases the study was fully approved by the respective local ethical boards (Camden Primary
Care Trust, Royal Free Hospital, UCH or Royal London Hospital). All study participants also
gave written informed consent and long-term storage of any samples collected complied with the
requirements of the Data Protection Act 1998 and the Human Tissue Act 2004.
A total of 110 patients with CHB, 17 patients with chronic HCV infection and 82 age and sex
matched (where possible) healthy, uninfected control volunteers were used within this study. The
total number of study participants divides into two cohorts of approximately equal size. Full
details of both cohorts of patients and healthy controls are detailed below. Division into either
cohort was dependent on the use of dierent anti-coagulant reagents during sample collection.
All patients with CHB were anti-HCV and anti-HIV antibody negative and were treatment naive
unless otherwise stated. Patients with HCV were all HBV and HIV negative and again treatment
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naive. A smaller cohort of seven patients with CHB sampled during their course of anti-viral
treatment were used, making up a third, separate cohort of study participants. All treatment
naive patients with CHB were stratied by a number of disease parameters throughout the study
(where appropriate). These were all carried out as a part of their routine disgnostic assessments
by the relevant NHS laboratories (virology, biochemistry, histology), and include the following:
1. HBeAg status
2. viral load (determined by real-time polymerase chain reaction PCR)
3. levels of HBsAg (determined by Architect (2step sandwich chemiluminesence mircroparticle
immunoassay))
4. biochemical evidence for liver inammation indicated either by serum ALT levels
5. degree of brosis (determined using histological analysis under the ISHAK* scoring system
by a trained NHS histopathologist)
6. degree of necroinammation in the liver (determined using histological analysis by a trained
NHS histopathologist)
7. presence of ground glass hepatocytes (determined using histological analysis by a trained
NHS histopathologist), and nally
8. CMV seropositivity (determined by measurement of IgG using a commercial assay system
(Abbot Architect))
* ISHAK scoring system: a number ascribed to the histological appearance of brosis on liver
biopsy tissue by a histopathologist - scored from 0-6, with increasing severity [155].
2.1.1 Study cohorts
The two primary cohorts were largely divided for analysis by the dierent anti-coagulant reagents
used during sample collection (ethylenediamine tetraacetic acid (EDTA) or lithium-heparin),
which was recorded for all study participants. Samples from the rst of these cohorts, which
from now on will be referred to as the Central London cohort, were taken in EDTA-containing
BD Vacutainers® (obtained from the Mortimer Market centre, the Royal Free Hospital and
UCH). These patients and controls are fully summarised in table 2.1. Samples from the second
of these cohorts, from now on referred to as the East London cohort, were taken in lithium-
heparin containing BD Vacutainers®, (Royal London Hospital), detailed in table 2.2.
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Where possible intrahepatic lymphocytes were also obtained (in conjunction with peripheral
blood samples) from liver tissue deemed surplus to diagnostic requirement when undergoing
routine clinical biopsies from a select group of patients under Dr. Patrick Kennedy and Dr.
Upkar Gill at the Royal London Hospital. These ˝paired samples are included in the East
London cohort.
The third cohort of patients with CHB were those undergoing routine anti-viral treatment. These
patients were either treated with Entecavir or Tenofovir for at least one year before inclusion in
the study.
It is important to note a fourth cohort of patients were used only to quantify gMDSC. This cohort
was made up of a few unique, extremely valuable patients sampled longitudinally throughout the
course of acute HBV infection, or over the course of a spontaneous hepatic are of HBeAg- CHB.
The caveat to this distinct cohort of patients was the practice of long-term storage of samples
prior to experimentation. Such patients were only used where necessary in specic experiments
and their use is noted in the corresponding gure legends.
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Age (years)
median (range)
Sex (%)
male:female
ALT (IU/L)
median (range)
Viral load (IU/ml)
median (range)
HBsAg (IU/ml)
median (range)
HBeAg (%)
pos:neg
CHB (n=54) 38 (19-72) 61:39 31 (10-586) 9.3104 1085 13:87
(blq-7 107) (43-8:3 104))
control (n=55) 34 (24-64) 45:55 na na na na
Table 2.1: Full details of the study participants of the Central London cohort taken in EDTA.
Abbreviations used for both this table, and table 2.2 below: below the level of quantication (blq), serum alanine transaminase (ALT), not applicable
(na), Hepatitis B surface antigen titre (HBsAg), Hepatitis B secreted e Ag (HBeAg).
Age (years)
median (range)
Sex (%)
male:female
ALT (IU/L)
median (range)
Viral load (IU/ml)
median (range)
HBsAg (IU/ml)
median (range)
HBeAg (%)
pos:neg
CHB (n=64) 37 (17-61) 56:44 35 (10-166) 1.5104 1:2 104 38:62
(blq-1:5 109) (26-1:6 106))
control (n=37) 34 (24-64) 45:55 na na na na
HCV (n=17) age alt VL na na na
Table 2.2: Full details of the study participants of the East London cohort taken in lithium-heparin.
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2.2 Sample Isolation & Preparation
2.2.1 Preparation of peripheral blood mononuclear cells (PBMC)
All venous blood samples were collected in sterile 6 or 9ml BD Vacutainers® containing ei-
ther EDTA or lithium-heparin and processed immediately. Peripheral blood mononuclear cells
(PBMC) were isolated by Ficoll-Plaque Plus™ (GE Healthcare) density gradient centrifugation.
25ml whole blood (diluted where necessary in RPMI 1640 (Invitrogen™)) was layered on 15ml
Ficoll-plaque, followed by centrifugation at 2200rpm at 30℃ for 22 minutes with minimum accel-
eration and brake. PBMC were carefully extracted from the interface using 2ml Pasteur pipettes,
then further diluted 1:1 with RPMI 1640 and washed twice by centrifugation at 1600rpm for
15 minutes. Cell counts were determined using a Neubauer counting chamber under light-
microscopy; cells were pre-diluted in RPMI 1640, then 1:1 in trypan blue (a cell viability dye
that stains nuclei of dead cells). The number of cells was determined using the following formula:
N =M D  104
N = no. of cells/ml
M = no. of cells counted in central grid, and
D = dilution factor
2.2.2 HLA-A2+ screening
All study participants were screened for expression of human leukocyte antigen-A2 (HLA-A2) by
ow cytometry (described below in section 2.3.2). Briey, during PBMC isolation a small aliquot
of isolated PBMC were removed and stained with a directly conjugated monoclonal antibody
(mAb) specic for HLA-A2 (Serotech) in phosphate buered sulphate (PBS: Invitrogen™) for
20 minutes at 4℃ in the dark. Once stained, the cells were washed by centrifugation and xed
using BD Cytox as per the manufacturers protocol (BD Bioscience) for a further 20 minutes.
Once xed the cells were analysed on a BD LSRII™ or BD Fortessa™ ow cytometer (Beckton
Dickinson) for positivity compared to an unstained control. HLA-A2 positive patients were
noted and used for specic experiments.
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2.2.3 Freeze/thawing of PBMC
Isolated cells not used for direct ex vivo experiments were re-suspended at 5  106 cells/ml in
heat-inactivated foetal bovine serum (FBS) (Invitrogen™) supplemented with 10% dimethylated
sulfoxide (DMSO) (freezing media, Sigma-Aldrich®), transferred to cryovials (Corning) and
stored in freezing boxes surrounded by isopropanol (MrFrosty, Fisher Scientic) at -80℃ for a
minimum of 24 hours. After 24 hours, cryovials (Thermo Scientic) were transferred for long-
term storage in gas-phase nitrogen tanks. When required, PBMC were thawed rapidly at 37℃
and washed by centrifugation in 20ml of RPMI 1640. Once washed cells were re-suspended for
use in RPMI 1640 supplemented with:
• 10% heat-inactivated FBS (Invitrogen™),
• 100U/ml penicillin /streptomycin (Invitrogen™),
• MEM essential amino acid (Invitrogen™),
• MEM non-essential amino acids (Invitrogen™),
• hydroxyethyl piperazineethanesulfonic acid (HEPES: Invitrogen™),
• -mercaptoethanol (Sigma-Aldrich®), and
• sodium pyruvate (Invitrogen™).
//NOTE: From this point onwards RPMI 1640 supplemented as above will be referred to as
complete RPMI 1640, abbreviated to cRPMI.
2.2.4 Preparation of serum samples
During sample collection, an extra BD Vacutainer® containing no anti-coagulant was lled.
The BD Vacutainer ® for serum use was left for a minimum of 30 minutes at room temperature
(R.T.) before centrifugation at 1800rpm for 15 minutes. Serum was removed and transferred
(500l per sample) into cryovials and stored at -80℃ for later use.
2.2.5 Preparation of intrahepatic lymphocytes (IHL)
Liver tissue used for extraction of lymphocytes was obtained from liver biopsies once deemed
surplus to diagnostic requirement.
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Mechanical Disruption
Liver tissue samples were re-suspended in RPMI 1640 and macerated with a plunger taken from
a 25ml syringe and a scalpel in small Petri dishes. Following mechanical disruption, the single
cell suspension was passed through a 70m cell strainer (BD Bioscience) followed by multiple
washes with RPMI 1640 to prevent clumping minimising cell loss.
GentleMACS™ Dissociation
If liver tissue was not subjected to mechanical disruption the tissue IHL were extracted using a
bench-top instrument for the semi-automated dissociation of tissues into single-cell suspensions
called a GentleMACS™. In preparation for GentleMACS™ dissociation the tissue was cut-up
into small pieces and incubated at 37℃ in 5ml HBSS (with calcium and magnesium) containing
DNAseI (0.001%, Roche) and collagenase IV (0.01%, Life Technologies) for 20 minutes in ˝C
tubes (Miltenyi Biotec). After the incubation the C-tube was transferred to the GentleMACS™
and run on the program identied as ˝mouse liver three times. The single cell suspension was
then passed through a 70m cell strainer followed by multiple washes with RPMI 1640 to prevent
clumping minimising cell loss as above.
Isolated cells were washed by centrifugation at 1800rpm at 22℃ for 15 minutes. Intrahepatic
lymphocytes (IHL) were gently re-suspended, counted (as before for PBMC) and identied from
other intrahepatic populations by size, shape and granularity at a high magnication. IHL were
always used for direct ex vivo experimentation in this study.
2.3 Multiparametric Flow Cytometry
All antibody staining for ow cytometry was performed on a single cell suspension in either 96
well plates (U-bottomed) or in 5ml polypropylene tubes.
2.3.1 BD TruCount Tubes for gMDSC absolute counts
To determine the absolute number of gMDSC, a small number of controls and patients with
CHB were used. 50l of well-mixed anti-coagulated whole blood was added to a BD TruCount™
Tube (BD Bioscience) after the addition of a mixture of mAb (detailed below) for gMDSC
identication, with the inclusion of CD45. Surface staining of the cells then followed, in the
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presence of a known quantity of beads for 15 minutes at R.T. in the dark. 450l 1x BD™
FACS Lysing Solution (BD Bioscience) was added to ensure full lysis of red blood cells after
staining, prior to ow cytometric acquisition and analysis. Before acquisition on the BD LSRII™,
with the threshold of the machine set to expression of CD45. Once analysed using FlowJo v8.8.7
(TreeStar®), absolute counts for gMDSC were calculated manually using the following equation:
number of events in region containing cells of interest
number of events in absolute count bead region
number of beads per test*
test volume
= absolute count
* = value found on each lot of BD TruCount™ Tube packaging.
2.3.2 Surface staining of PBMC & IHL for MDSC frequency & phe-
notype
To determine MDSC subset frequencies and phenotypes, a minimum of 2 106 freshly isolated
PBMC were used. Cells were washed in 1x PBS and centrifuged at 1600rpm for 5 minutes.
The supernatant was aspirated and cell pellets re-suspended by gentle vortexing. Cells were
initially stained to allow detection and removal of dead cells from analysis using an Invitrogen™
Blue Live/Dead® Cell viability assay by staining for 15 minutes at 4℃. Once stained, the
Live/Dead® protein dye was washed o using 1x PBS and cells were subjected to a blocking
step to prevent unwanted binding of antibody to Fc receptor-expressing cells (FcR blocking
reagent: Miltenyi Biotec®) for 15 minutes at 4℃. Surface staining of cells then followed in the
presence of the FcR blocking reagent by staining with relevant directly conjugated anti-human
mAb for 30 minutes at 4℃ in the dark. Following a washing step with 1x PBS, cells were
xed with 150l/well or 300l/tube with 4% paraformaldehyde (PFA). Cells were transferred to
500l polystyrene tubes for acquisition where necessary. Table 2.3 details the mAb used for the
detection of MDSC extracellular antigens. Data were collected on a BD LSRII™ equipped with
a UV laser and analysed using FlowJo v8.8.7.
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Surface marker Flurochrome Clone Manufacturer Dilution
CD11b PE-Cy7 ICRF44 eBioscience 2:100
CD11b FITC ICRF44 eBioscience 2:100
CD14 BD Horizon V500™ M5E2 BD Bioscience 2:100
CD14 PerCP MQp9 BD Bioscience 3:100
CD15 APC HI98 BD Bioscience 7:100
CD15 FITC HI98 Biolegend 2:100
CD15 AlexaFluor® 700 SSEA-1 Biolegend 5:100
CD16 APC-eFluor® 780 3G8 eBioscience 1:100
CD16 PE DJ130c Miltenyi Biotec 3:100
CD19 PerCP 4G7 BD Bioscience 2:100
CD3 PE-Texas Red® (ECD) UCHT1 Beckman Coulter 3:100
CD33 AlexaFluor® 700 WM53 BD Bio./eBio. 2:100
CD45 AlexaFluor® 488 HI30 Biolegend 2:100
CD63 PE HSC6 eBioscience 2:100
CD66b PerCP-Cy5.5 G10F5 Biolegend 2:100
CD95 (FAS) PerCP-Cy5.5 X10 eBioscience 1:100
CD178 (FAS-L) PE MFL3 Biolegend 1:100
CCR2 (CD192) PE K036C2 Biolegend 1:100
CXCR1 (CD181) FITC 8F1 Biolegend 1:100
CXCR2 (CD182) PE 5E8 Biolegend 1:100
CXCR4 (CD184) PE 12G5 Biolegend 1:100
HLA-DR eFluor® 450 L243 eBioscience 3:100
MICA/B AlexaFluor® 488 6D4 Biolegend 4:100
PD-L1 PE M1H1 eBioscience 5:100
Live/dead® Blue n/a Invitrogen™ 1:1500
Table 2.3: Directly conjugated anti-human mAb against extracellular antigens used in the
identication and phenotyping of MDSC subsets by multiparametric ow cytom-
etry.
2.3.3 Intracellular staining of PBMC & IHL for MDSC phenotype
For detection of MDSC intracellular antigens, cells were blocked and surface stained as described
above. Once surface stained, the cells were washed and re-suspended in BD Cytox/Cytoperm™
for a further 20 minutes at 4℃ in the dark. After xation and permeabilisation, cells were washed
and stained with relevant directly conjugated anti-human mAb in the presence of 0.1% saponin
for 30 minutes at 4℃ in the dark. Appropriate isotype controls were used where necessary. After
staining the cells were washed and re-suspended in 150l/well or 300l/tube and transferred,
where necessary, to 500l polypropylene tubes for acquisition. Table 2.4 details the mAb used for
the detection of MDSC intracellular antigens. Data was collected on a BD LSRII™ and analysed
using FlowJo v8.8.7.
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Intracellular Marker Flurochrome Clone Manufacturer Dilution
Arginase I FITC not available R&D Systems 5:50
Galectin-9 PE 9MI-3 BD Bioscience 2:100
TGF FITC TW4-2F8 R&D Systems 3:100
IL-10 PE JES3-967 Miltenyi Biotec 3:100
CD63 PE HSC6 eBioscience 2:100
CD66b PerCP-Cy5.5 G10F5 Biolegend 2:100
Table 2.4: Directly conjugated anti-human mAb against intracellular antigens used for the
assessment of MDSC phenotype and functionality by multiparametric ow cy-
tometry.
2.3.4 Staining for T cell/NK cell phenotype & functionality
For the analysis of T cell phenotype and/or functionality either ex vivo or after short term
co-culture, cells were stained using a similar protocol to that described in section 2.3.2. In the
case of T cell/NK cell analysis, cells were stained to allow detection and removal of dead cells
from analysis using an Invitrogen™ Blue Live/Dead® Cell viability in conjunction with all other
surface mAb. Tables 2.5 and 2.6 detail the mAb used for the detection of extracellular and
intracellular antigens for analysis of T cell/NK cell function and phenotype. Data was again
collected on a BD LSRII™ and analysed using FlowJo v8.8.7.
2.3.5 Detection of T cell cytokine production
For detection of T cell cytokine production, samples previously frozen down (described in sec-
tion 2.2.3) were used. PBMC were rapidly thawed, washed and re-suspended in cRPMI for
stimulation. 2  106 cells were plated per well in 96-well plates (U-bottomed) and incubated
in the presence of phorbol 10-myristate 13-acetate (PMA) at 3ng/ml, ionomycin at 100ng/ml,
and brefeldin A (BFA) at 1mg/ml, or cRPMI and BFA alone as a negative control for 3 hours.
After incubation the cells were washed and stained for cytokine production as a marker of T cell
functionality as described in section 2.3.4.
2.3.6 Analysis of regulatory T cells
For the analysis of circulating frequencies of Treg, samples previously frozen down (described
in section 2.2.3) were used. All surface staining was done ex vivo as described previously. In
this case the xation protocol was slightly amended. Once stained with extracellular markers
the cells were xed and permeabilised according to the manufacturer's protocol with the human
FOXP3 buer kit (BD Bioscience). For the detection of the T cell transcription factor (FOXP3),
the staining was then carried out after xation in the presence of 1x PBS.
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Surface marker Flurochrome Clone Manufacturer Dilution
CD14 BD Horizon V500™ M5E2 BD Bioscience 2:100
CD16 APC-eFluor® 780 3G8 eBioscience 1:100
CD16 PE DJ130c Miltenyi Biotec 3:100
CD19 PerCP-Cy5.5 HIB19 BD Bioscience 2:100
CD19 BD Horizon V500™ HIB19 BD Bioscience 1:100
CD127 (IL-7R) PerCP-Cy5.5 A019D5 Biolegend 1:100
CD3 PE-Cy7 UCHT1 eBioscience 1:100
CD3 PE-CF594 UCHT1 BD Bioscience 1:200
CD4 APC-eFluor® 780 RPA-T4 eBioscience 1:200
CD4 BD Horizon V500™ RPA-T4 BD Bioscience 3:200
CD4 PE OKT4 Biolegend 2:100
CD56 PE-Texas Red® (ECD) N901 Beckman Coulter 3:100
CD8a AlexaFluor® 700 OKT8 eBioscience 1:200
CD98 FITC MEM-108 Biolegend 2:100
HLA-DR BD Horizon V500™ G46.6 BD Bioscience 1:100
HLA-DR eFluor® 450 L243 eBioscience 3:100
NKp30 (CD337) APC 210845 R&D Systems 1:100
Vybrant® (CSFE) (FITC) n/a Invitrogen™ 1M
Live/dead® Blue (UV) n/a Invitrogen™ 1:1500
Table 2.5: Directly conjugated anti-human mAb against extracellular antigens used for the
identication of lymphocyte subsets and analysis of phenotype by multiparametric
ow cytometry.
Intracellular Marker Flurochrome Clone Manufacturer Dilution
CD3 (CD247) PE 6B10.2 eBioscience 1:200
FOXP3 Pacic Blue 259D Biolegend 4:100
GranzymeB FITC GB11 eBioscience 1:100
IFN BD Horizon V450™ B27 BD Bioscience 3:100
IL-2 PerCP-Cy5.5 MQ1-17H12 eBioscience 1:50
IL-10 PE JES3-967 Miltenyi Biotec 3:100
IL-17 APC BL168 Biolegend 3:100
Ki67 FITC B56 BD Bioscience 10:100
Ki67 PE B56 BD Bioscience 10:100
TNF FITC MAb11 BD Bioscience 1:200
TNF APC 6401.1111 BD Bioscience 1:100
Table 2.6: Directly conjugated anti-human mAb against intracellular antigens used to assess
T/NK cell functionality and phenotype by multiparametric ow cytometry
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2.3.7 Identication of virus-specic CD8+ T cells
The phenotype of virus specic cells from HLA-A2 positive individuals were evaluated directly
ex vivo by HLA-A2-restricted multimer staining using samples previously frozen down (de-
scribed in section 2.2.3). Total PBMC were thawed from liquid nitrogen storage (as previously
described in section 2.2.3) and stained with uorescently-labelled dextramers against HBV epi-
topes: core 18-27, envelope 183-191, envelope 335-343, envelope 348-357, and polymerase 508-510
or uorescently-labelled CMV epitope: CMV pp65 (Immudex), detailed in table 2.7 at 37℃for
15 minutes in 1x PBS. The cells were then washed in cRPMI twice and left to rest for one hour.
The cells were then stained for other surface markers as previously described in section 2.3.4.
A negative control dextramer loaded with an irrelevant peptide was used to aid identication
of genuine dextramer positive cells. During analysis CD19+ and CD14+ cells were excluded
due to their known capability of binding dextramer non-specically. The gating strategy for
identication of virus specic cells is shown in gure 2.1.
HLA-A2 peptide sequence Flurochrome Viral protein Amino acid region
FLPSDFFPSV APC HBV core 18-27
FLLTRILTI APC HBV envelope 183-191
WLSLLVPFV APC HBV envelope 335-343
GLSPTVWLSV APC HBV envelope 348-357
GLSRYVARL APC HBV polymerase 455-463
KLHLYSHPI APC HBV polymerase 502-510
NLVPMVATV PE CMV pp65 495-504
GLCTLVAML APC EBV BMLF-1 n/a
GILGFVFTL APC Flu n/a
control APC irrelevant protein n/a
Table 2.7: Full details of the directly conjugated MHC class I-restricted multimers (dex-
tramers) used in this study, supplied by Immudex. Abbreviation used: not appli-
cable (n/a).
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Figure 2.1: Gating strategy for the identication of virus-specic cells.
Sequential gating strategy used for the identication of dextramer positive
CD8+ T cells. CD3+, live, single lymphocytes were gated on to exclude
CD19+/CD14+ cells. Control dextramers were used to determine background
antibody staining.
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2.4 ImageStreamX
For conrmation of arginase I expression and morphology, novel ImageStream technology was
used (combining ow cytometry with the resolution of uorescence microscopy). PBMC were iso-
lated from fresh blood and stained using the following mAb: CD11b-PE-Cy7, CD15-AlexaFluor700,
CD16-PE, HLA-DR-V500, arginase I-FITC. The cells used for imagestream analysis were xed
and permeabilised using BD Cytox/Cytoperm. The cells was processed on an Amnis Im-
ageStreamX Imaging Flow Cytometer (EMD Millipore Corp.) tted with a 60x microscope
objective. Raw image les were acquired using INSPIRE software (Amnis). After acquisition a
compensation matrix was applied to the data to correct for spectral overlap. Data analysis was
done using IDEAS software, displaying PBMC using gradient RMS for the brighteld channel
to exclude out-of-focus cells and a combined area to aspect ratio dot plot ensured gating on
single-cell events. Cells were then gated as: CD11b+CD15+CD16+ for gMDSC identication,
excluding cells expressing HLA-DR, for the analysis of arginase I expression.
2.5 Amino Acid Composition Analysis
2.5.1 Reagents
Amino acids: L-arginine, L-citrulline, L-ornithine, L-tryptophan, together with kynurenine were
all purchased from Sigma-Aldrich. Stable isotopes were purchased from Cambridge Isotopes
Laboratories Inc. Trichloroacetic acid (TCA), methanol and water (all high-pressure liquid
chromatography mass spectrometry grade) were purchased from Sigma-Aldrich®.
2.5.2 Sample preparation
For determination of amino acid concentrations by mass spectrometry frozen serum samples
were used. Samples were slowly thawed on ice when used. 50l of serum for each individual was
combined with 10l of the internal standard (mixed stable isotope solution for all proteins for
analysis) followed by 100l of cold 10% TCA solution (5g TCA dissolved in 50l milliQ water)
for deproteinisation, vortexed for three minutes and centrifuged at high speed for 10 minutes at
4℃. 60l of cold TCA deproteinised serum was transferred to glass tubes for analysis.
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2.5.3 High-pressure liquid chromatography - tandem mass spectrom-
etry (HPLC-MS)
Measurements were performed by high performance liquid chromatography followed by mass
spectrometry in positive mode (HPLC-MS; Dionex uHPLC system with an Ultimate 3000 RS
autosampler and BD Biphenyl-1.9m, 50x2.1mm column switcher with accompanying Thermo
Scientic Orbitrap XL system and with electrospray source). 5l of each standard or sample
was injected for analysis. Analytical preparation of the amino acid derivatives was achieved by
gradient elution using the following gradient (prepared with 0.1% formic acid - 95% water-0.1%
formic acid (FA): 5% acetronitrile-0.1%FA) equilibrated for three minutes, gradient of six min-
utes up to 10% water-FA: 90% acetonitrile-FA, kept constant for one minute, returned to initial
conditions in 0.5 minutes at a ow of 0.4ml/minute at a column temperature of 40℃. The sam-
ple was injected directly into the mass spectrometer. The mass spectrometer conditions were as
follows: mass spectrometer run time of eight minutes, normal scan, temperature, spray voltage,
sheath pressure as stable measurements after calibration. The HPLC system was controlled
by Chromoleon Xpress (Thermo Scientic Inc.) and collection of the mass spectrometric data
and control of the mass spectrometer was performed by Xcalibur v2.0.7 (Thermo Scientic Inc.).
The reproducibility and recovery of the measurements using the HPLC-MS was determined prior
to full protein quantication using a script kindly written and provided by Dr. Niclas Thomas
in R v3.0.2, an open-source programming language for statistical computing.
2.5.4 Use of stable isotopes
Many elements in nature have isotopes and some of these are stable. The most abundant of
these naturally occurring stable isotopes is C13 (natural abundance of approx. 1.1%). The
consequence of elements having several isotopes is that a given molecule will not show up solely
as a single peak at the calculated mass when analysed by mass spectrometry, but as a set of
peaks, known as the isotopomeric envelope. Consequently, a biological molecule containing ve
carbons has a 5 x 1.1% chance of incorporating the naturally occurring stable isotope C13. When
analysed this feature can be observed as a peak at a mass of +1 (containing one heavy isotope),
+2 (containing two heavy isotopes) and so on higher than the expected molecular mass of the
molecule; with an abundance of 5.5% compared to the peak at the expected mass. Purchased
amino acids with one or two atoms exchanged for (a) stable isotope(s) were used in this study
to determine recovery rates. These amino acids/molecules have the same physical properties as
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their natural counterparts, but with a mass that can be distinguished, allowing their relative
concentration to be quantied.
2.6 Serum Arginase I Quantication
To determine serum concentrations of the enzyme arginase I (liver type arginase - 35kDa) an
enzyme-linked immunosorbent assay (ELISA) (Hycult) was carried out as per the manufacturers
protocol. Briey, serum samples stored at -80℃ from controls and a subset of patients with CHB
and chronic HCV infection, were thawed out and pre-diluted 1:1 in assay diluent. Concentrations
of arginase I were calculated by back calculation to the equation of the line of the standard curves
run in duplicate simultaneously in Microsoft® Excel.
2.7 Suppression Assays
2.7.1 Isolation of gMDSC by magnetic bead isolation
Magnetic-labelled beads were used to enrich/deplete gMDSC from freshly isolated PBMC using
sequential CD14 negative depletion and CD15 positive isolation (a surrogate isolation protocol
for gMDSC). All equipment and reagents used were purchased from Miltenyi Biotec® and used
as per manufacturers protocol.
Briey PBMC were re-suspended in 80l of ice-cold PBS supplemented with 0.5% FBS and
2mM EDTA (Invitrogen) (refereed to from this point on as MACS buer) per 107 cells. PBMC
were incubated with anti-CD14 beads (20l/107 cells) for 15 minutes at 4℃ in the dark. After
incubation labelled cells were washed in 2ml of ice-cold MACS buer and centrifuged for 10
minutes at 300g to remove excess beads. The supernatant was aspirated and discarded and the
pellet re-suspended for column isolation. Sterile MS columns were placed in MACS™ magnets
and washed through with 500l of MACS buer. Up to 107 cells were then passed gently through
each MS column. Columns were washed through with MACS buer to elute unlabelled PBMC.
The CD14 negative fraction eluted from the columns was kept and re-stained for positive selection
under the same protocol with anti-CD15 beads. The second isolation procedure was essentially
the same, however after applying the anti-CD15 stained CD14-negative fraction to the column,
the labelled cells of interest were eluted from the column by addition of 1ml of MACS buer by
rm application of a plunger to the column. Following the sorting process cells were washed and
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re-suspended in cRPMI for use in co-culture experiments. The depleted CD14-CD15- (eluted
fraction) was also kept and used in some experiments were stated (referred to as gMDSC).
2.7.2 Isolation of gMDSC by ow cytometry
In order to deplete or isolate cell subsets using ow assisted cell-sorting, 2 108 freshly isolated
PBMC were obtained from controls. 300l of 1x PBS supplemented with 10% FBS containing
a further 200l of FcR blocking reagent was added for 20 minutes at 4℃. After FcR block-
ing, cells were subjected to antibody staining with a combination of the following mAb: CD33
AlexaFluor® 700, CD11b PE-Cy7/CD11b FITC, CD14 PerCP, CD15 APC/CD15 Viogreen™
for 30 minutes, with gentle shaking every 10 minutes at 4℃. Once stained PBMC were washed
twice in ice-cold MACS buer and re-suspended in a volume of cRPMI corresponding to 5 107
cells/ml. Before acquisition cells were ltered through a 70m lter-capped polystyrene tubes
(BD Bioscience) to prevent cellular clumps blocking the machine.
Cells were sorted on either a FACSAria™ (Beckton Dickinson) by Jamie Evans or a MoFlow™
XDP (Beckman Coulter) by Thomas Adejumo at low speeds. Cells forming doublets were ex-
cluded. Figure 2.2 shows a representative gating strategy used during sorting and the purity
achieved. Depleted or sorted cells were collected into polypropylene tubes (BD Bioscience) con-
taining collection media (cRPMI supplemented with 50% FBS). Following the sorting process,
cells were washed and re-suspended in cRPMI for use in co-culture experiments.
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Figure 2.2: Representative gating strategy used for the identication of gMDSC
during ow cytometric sorting.
The numerical value in the nal plot shows the gMDSC purity after cell
sorting, prior to co-culture experimentation.
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2.7.3 Staining with Vybrant® CFDA (CFSE)
For co-culture experiments where the proliferative capacity of T cell was assessed, PBMC were
stained prior to culture with Vybrant® CFDA (Invitrogen™). 5  106 freshly isolated PBMC
were re-suspended in 1ml of pre-warmed 37℃ 1x PBS containing 1M of carboxyuorescein
succinimidyl ester (CFSE). Cells were incubated at 37℃ for 12 minutes and then the reaction
stopped by the addition of 1ml of heat inactivated FBS, and washed by centrifugation at 1600rpm
for 10 minutes. Cells were then used in co-culture experiments at pre-determined ratios.
2.7.4 Co-culture: gMDSC with autologous PBMC for suppression of
bystander T cell function
To assess the potential gMDSC functionality on bystander (non-HBV specic) T cells, 1 
105 FACS isolated gMDSC or magnetic bead enriched gMDSC PBMC were co-cultured with
autologous total PBMC at pre-determined eector:target ratios in 96 well plates (U-bottomed)
with various stimuli (listed below). In certain experiments the fraction of cells depleted of
gMDSC were also analysed in parallel. Co-culture experiments were all done in the presence of
20IU/ml of recombinant IL-2 (Miltenyi Biotec). The various stimuli used were as follows:
1. 0.5g/ml plate bound anti-CD3 + 0.5g/ml anti-CD28 (eBioscience),
2. 0.5g/ml HLA-A2-restricted NLVPMVATV peptide from CMVpp65 (ProImmune),
3. 0.5g/ml HLA-A and HLA-B-restricted peptide pool spanning the immune-dominant pro-
teins of CMV, EBV and inuenza (CEF) (JPT Peptide Technologies).
All co-culture experiments were incubated for ve days at 37℃. On day four cRPMI was changed
to cRPMI supplemented with 1g/ml BFA and cells that had originally been stimulated with
peptide were re-stimulated with the same dose of the corresponding peptide. In some experi-
ments autologous total PBMC used for co-culture were previously stained with 1M Vybrant®
CFDA (CFSE labelling, as described in section 2.7.3), to allow detection/monitoring of peptide-
specic proliferation. And in other experiments the co-cultures were carried out in the presence
of an arginase I specic inhibitor hydroxy-nor-L-arginine (norNOHA, Calbiochem) at 0.5mM for
the duration of the assay.
After co-culture, cells were stained for ow cytometric analysis to assess T cell eector function-
ality as described above.
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2.7.5 Co-culture: gMDSC with autologous PBMC for detection of
HBV-specic T cell suppression
To assess the potential gMDSC suppression of HBV-specic T cells, a slightly modied version
of the protocol described in section 2.7.4 was used. The methodology was the same with the
following modication: The stimuli used was either 0.1g/ml HBV peptide pool (pool of 15mer
peptides overlapping by 10 residues spanning the core protein of HBV genotype D) for non HLA-
A2+ patients, or a 0.1g/ml pool of peptides representing HLA-A2 restricted viral epitopes,
˝H7 containing HBV envelope epitopes: FLLTRILTI, WLSLLVPFV, LLVPFVQWFV and
GLSPTVWLSV; HBV core epitope: FLPSDFFPSV; and HBV polymerase epitopes: GLSRY-
VARL and KLHLYSHPI (ProImmune). On day ve the cRPMI was changed to cRPMI supple-
mented with 1g/ml BFA and re-stimulated with the corresponding peptide used. If the patient
used was HLA-A2+, the cells were stained with the pool of HBV dextramers as described in
section 2.3.7 before re-stimulation.
2.8 Co-culture: gMDSC with Primary Hepatic Stellate
Cells (pHSC)
2.8.1 Isolation of pHSC
Healthy margins of metastatic liver tissue were obtained in collaboration with Royal Free Hospi-
tal surgical sta from consented patients during surgery. All patients signed informed consent,
approved by the Royal Free Hospital ethics committee. pHSC were previously isolated by either
Dr. Kasha Singh or Harsimran Singh and frozen for long-term storage.
Tissue was digested with DNAseI (0.001%) and collagenase IV (0.01%) before being passed
through a tissue press (2mm diameter). The homogenate was then ltered through a 70m
cell strainer and centrifuged at a low speed (500rpm for two minutes) to remove contaminating
hepatocytes. The remaining cells were layered for density gradient isolation using Optiprep
(Sigma-Aldrich). After isolation, pHSC were suspended in Stellate Cell Medium® (ScienCell
Research Laboratories), plated at a density of 5104cells/cm in tissue culture asks and cultured
at 37℃ in a humidied atmosphere with 5% CO2. On day two-four, cell debris and non-adherent
cells were removed by washing. When cultures reached conuence, cells were trypsinized and
replated; they were passaged twice before freezing as previously described in section 2.2.3.
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2.8.2 pHSC staining & co-culture
Pre-isolated pHSC from at least three dierent donors were thawed and cultured in 25cm2 tissue
culture asks in Stellate Cell Medium® to approximately 90% conuence. Cells were detached
with trypsin, re-plated in 24 well plates in cRPMI and left for 24-48 hours to attach. For
staining, 1g/ml BFA was added for 16 hours prior to cells being detached with MACS buer
and stained for intracellular IL-8 (eBioscience) in the presence of FcR blocking reagent, after
xation and permeablisation with BD Cytox/Cytoperm. pHSC were acquired on a BD LSRII™
and analysed using FlowJo v8.8.7. IL-8 production was determined after exclusion of dead cells
using an Invitrogen™ Blue Live/Dead® Cell viability assay. For co-culture experiments, pHSC
were incubated with 2106 freshly isolated PBMC from either controls or patients with CHB in
cRPMI for six days. After the culture period the cells were removed by vigorous pipetting and
transferred to ltered polypropylene tube prior to staining for gMDSC frequencies as described
in section 2.3.2. In certain experiments, where stated, various cytokines/chemokines/growth
factors were used at a concentration of 10ng/ml. These included CXCL12, IL-8, IL-6, vascular
endothelial growth factor (VEGF), and TNF.
2.9 Statistical Analysis
Statistical analyses were performed in Prism (GraphPad) using the appropriate tests, with sig-
nicant dierences marked on all gures. For all tests, signicance levels were dened as: * =
p<0.05, ** = p<0.005, *** = p<0.001. Multivariate analyses were conducted in R 3.0.2, an
open-source programming language for statistical computing.
2.10 Reagents
Table 2.8: Full details, including manufacturers and catalogue numbers, of reagents used
throughout this study.
* 32 peptides from dened HLA class I-restricted T cell epitopes
Product Manufacturer Catalogue No.
CD3 puried (functional grade, clone OKT3) eBioscience 16-0037-85
CD28 puried (functional grade, clone CD28.2) eBioscience 16-0289-85
mercaptoethanol Life technologies™ 31350-010
L-arg free RPMI (+L-glu,  L-arg +phenol red) PAA T1090,2500
Continued on next page
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Table 2.8 { continued from previous page
Product Manufacturer Catalogue No.
Arginase I ELISA kit Hycult HK322-02
BD™ CompBeads (anti mouse IgG) BD Bioscience 51-90-9001229
BSA Sigma-Aldrich® A9418-50G
Brefeldin-A Sigma-Aldrich® B7651-5MG
CEF extended pool (CMV-EBV-Flu*) JPT Technologies PM-CEF-E
CMV peptide (NLV) ProImmune n/a
Collagenase IV Life technologies™ 17104-019
Cryovials Nunc V7509
BD Cytox/Cytoperm™ BD Bioscience 554722
DNAse Roche 11 284 932 001
DMEM (+L-glu, +Pyruvate, +L-glucose) Life technologies™ 41966-029
DMSO Sigma-Aldrich D2650
DPBS ( Ca,  Mg) Life technologies™ 14190-169
EDTA Life technologies™ 15575-020
BD™ FACS Lysing Solution BD Biosciences 349202
FcR blocking reagent Miltenyi Biotec® 120-000-442
Fetal Bovine Serum (FBS) (heat-inactivated) Life technologies™ 10108-165
Ficoll-Plaque Plus™ GE Healthcare 17-1440-03
BD™ FOXP3 buer kit BD Bioscience 560098
Formaldehyde VWR 20910.328
HEPES buer solution (1M) Life technologies™ 15630-056
HLA-A2-specic FITC-conjugated mAb BioRad MCA2090F
IL-2 (Research Grade) Miltenyi Biotec® 130-093-901
IL-6 (Research Grade) Miltenyi Biotec® 130-095-365
IL-8 (Research Grade) Miltenyi Biotec® 130-093-944
Ionomycin Molecular Probes (Life tech™) I24222
L-alanine (13C) Cambridge Isotope Laboratories CAS-21764-56-7
L-arginine (guanido-15N2) Cambridge Isotope Laboratories NLM-935-PK
L-citrulline (ureido-13C) Cambridge Isotope Laboratories CAS-9470-46-2
L- glutamine (amide 15N) Cambridge Isotope Laboratories CAS-59681-32-2
L-phenylalanine (ring D5) Cambridge Isotope Laboratories CAS-56253-90-8
L-ornithine (15N2) Cambridge Isotope Laboratories NLM-3610-025
Continued on next page
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Table 2.8 { continued from previous page
Product Manufacturer Catalogue No.
Magnetic CD14 Positive Selection Beads Miltenyi Biotec 120-000-305
Magnetic CD15 Positive Selection Beads Miltenyi Biotec 130-046-691
Methyl-L-arginine acetate (L-NMMA) Calbiochem 53308-83-1
MEM Essential amino acids (50X) Life technologies™ 11130-036
MEM Non-essential amino acids (100X) Life technologies™ 11140-035
Hydroxy-nor-L-arginine (norNOHA: ARGI inhibitor) Calbiochem 399275
PBS Tablets Sigma-Aldrich P4417-100TAB
Penicillin /streptomycin Life technologies™ 15140-122
PMA Sigma-Aldrich P8139
Recombinant arginase I R&D Systems 5868-AR-010
RPMI 1640 (+L-gluatamine) Life technologies™ 21875-054
BD TruCount™ Tubes BD Bioscience 340334
Saponin Sigma-Aldrich® 47036-50G-F
Stellate cell media ScienCell Research Laboratories 5301
Sodium Pyruvate (100mM) Life technologies™ 11360-039
Trichloroacetic acid Sigma-Aldrich T9159-500g
TNF (Research Grade) Miltenyi Biotec 130-094-014
Trypan Blue Life technologies™ 15250-061
Trypsin-EDTA (1x) Life technologies™ 25300-062
UV (Blue) Live /Dead Stain Life technologies™ L23105
VEGF (Research Grade) Miltenyi Biotec 130-094-029
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Chapter 3
gMDSC expand in chronic
hepatotropic infections
3.1 Abstract
Work presented in this chapter builds on previous work from our group which pointed towards
a role for nutrient deprivation in driving a global metabolic T cell defect in CHB. The previous
study provided an initial indication that the amino acid L-arginine is depleted and the activity
of arginase I, an enzyme involved in its metabolism, is increased in the HBV-infected liver
[58]. Therefore it was postulated that an expansion of MDSC, a population known to expand
at sites of chronic antigenic stimulation, may contribute to this immunosuppressive milieu in
CHB. Using multiparametric ow cytometry this was addressed by analysing the circulating
and intrahepatic frequencies of MDSC subsets in two separate cohorts of patients with CHB
compared to uninfected, healthy controls. Circulating MDSC with a granulocytic phenotype
(gMDSC) were expanded approximately 9-fold in CHB compared to matched controls. MDSC
with a monocytic phenotype (mMDSC) were not expanded in the context of CHB. The increase in
gMDSC frequencies was most striking in patients replicating HBV in the absence of biochemical
or histological evidence of liver damage (the immunotolerant or inactive phase). It also became
apparent that gMDSC expansion shows a temporal relationship with viremia in acute HBV
infection, and in spontaneous ares of HBeAg- CHB, their decrease coinciding with the onset of
liver inammation. gMDSC only accumulate in the intrahepatic compartment in the diseased
liver; they were not found in the healthy liver. Infection with another hepatotropic virus, HCV,
also resulted in gMDSC expansion in the circulation that was further amplied in the liver
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compartment, whereas CMV serostatus did not aect gMDSC frequencies. Our data therefore
show gMDSC accumulation in hepatotropic viral infections that could have the potential to exert
immune regulation.
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3.2 Introduction
MDSC, as suppressor cells, were rst discussed in the introduction in section 1.5.1. The following
sections discuss their phenotypic identication, proposed mechanisms involved in their expan-
sion/accumulation, and what is already known about MDSC in relation to chronic inammation,
and more specically in relation to viral infection.
3.2.1 Phenotypic identication of MDSC
As already stated, MDSC are still a relatively novel cell type, and as a result their discovery and
study has become the focus of a rapidly expanding eld. Their discovery culminated in them
being described as one of the immunological highlights by eminent immunologists writing for
Nature Reviews Immunology in 2011 [156] (gure 3.1a). The number of reports being published
online citing MDSC has risen dramatically, with an increase in the number of MDSC-related pub-
lications returned from a search of ˝PubMed from 2 in 1982 to 326 last year (2013) (gure 3.1b).
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Figure 3.1: Impact of the discovery of MDSC in the literature.
A) Screenshots from an article published in Nature Reviews Immunology
in 2011 describing the discovery and study of MDSC to be one of the immuno-
logical highlights of the last decade. B) Graphical representation of the number
of publications quoting MDSC published online from the 1970s when they were
rst described to 2013, data obtained from ˝PubMed.
As well as the initial issue of nomenclature that was discussed in section 1.5.1, the study of human
MDSC has been plagued by numerous diculties. In the past (and even recently) phenotypic
identication, and therefore the study of human MDSC, has been challenging and inconsis-
tent. Cellular heterogeneity and a lack of consensus over identication markers has resulted in
investigator-dependent phenotypic marker proles being used when considering a role for MDSC
involvement in immune regulation. This issue is now further confounded by the new concept
of MDSC plasticity [157, 158]). In contrast to the study of human MDSC, the study of murine
MDSC has been relatively clear and more focused. This was largely due to an early literature-led
consensus dening a clear set of identication markers.
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Since early observations in tumour-bearing mice, murine MDSC have been phenotypically iden-
tied by co-expression of the two myeloid-lineage dierentiation antigens CD11b and Gr-1. How-
ever many researchers would now argue that the minimal markers used for the identication of
murine MDSC are insucient and may require further attention from the eld for better phe-
notypic characterisation. Murine MDSC are more accurately divided into two subsets (mono-
cytic and granulocytic) dependent on expression levels of Ly6C and Ly6G. Monocytic MDSC
(mMDSC) have a CD11b+Ly6G-Ly6Chigh expression prole, with monocytic morphology and
preferential expression of inducible nitric oxide (iNOS), whereas granulocytic MDSC (gMDSC)
have a CD11b+Ly6G+Ly6Clow expression prole, granulocytic-like morphology and expression
of arginase I [159]. Clear roles for either subset in the context of pathology has yet to be fully
elucidated, however recent analysis by Youn et al. [159] in ten dierent experimental tumour
models noted that both subsets of MDSC can expand, but the gMDSC subset predominate.
In the same context of experimental tumour models looking to characterise such granulocytic
MDSC further, the authors stressed the fact these particular cells share common phenotypic
markers with mature classical neutrophils, but these cells are considered to be functionally dis-
tinct [160, 161], since neutrophils are not typically immunosuppressive.
Recent progress in the eld of murine MDSC is beginning to extend the phenotypic identi-
cation panel to include consideration of several other markers. These include a lack of CD11c
expression and the presence or absence of IL-4R and CD49d. Consequently gMDSC can be bet-
ter identied as CD11b+Gr-1highLy-6ClowLy-6G+CD49d- while mMDSC as CD11b+Gr-1int.Ly-
6ChighLy-6G-CD49d+ [158, 162].
The lack of a human homologue for Gr-1 has been central to the challenge faced by the eld
of human MDSC. Towards the end of the 1990s, MDSC were beginning to be more extensively
described in humans, specically in patients with granulocyte macrophage colony-stimulating
factor (GM-CSF)-secreting tumours of the head and neck [163]. At the time these cells were
identied on the basis of lineage negativity (no expression of mature lymphocyte markers) and
CD34 expression alongside their capacity to limit T cell proliferation. This work was limited by
the fact that CD34 expression encompasses all haematopoetic progenitors. Therefore it was nec-
essary for the eld to identify and use further markers to enable the identication of MDSC. This
led to the introduction of gating strategies that excluded cells expressing the MHC-II molecule,
HLA-DR, and the inclusion of at least one myeloid-lineage marker.
74
Chapter 3. Results
Since then human MDSC have been described by an expression prole containing at least one
of (or both of) the myeloid-lineage markers CD11b and CD33, a lack of expression of markers of
mature lymphocytes (for example, CD3, CD56, CD19) and a lack of HLA-DR. They are further
dened by expression of either the monocytic marker CD14 or the granulocytic marker CD15.
Expression proles of human MDSC from multiple dierent studies and settings have been re-
viewed extensively in the literature and are beyond the scope of this thesis, but are discussed
in detail in reviews by Gabrilovich & Nagaraj [164], Brandau et al. [165], Khaled et al. [166],
Greten et al. [167], and Poschke & Kiessling [168].
MDSC have been predominantly studied in the context of cancer biology, with dierent phe-
notypes of MDSC being described in cancers of dierent origins. Of note it is these dierent
phenotypes seen that form the basis of the idea of MDSC plasticity. MDSC markedly expand
systemically when mice are inoculated with transplantable tumour cells and upon development
of spontaneous tumours in transgenic murine models with tissue-restricted oncogene expression.
In several tumour models, it has been reported that up to 20-40% of all nucleated splenocytes
are MDSC, in contrast to the 2-4% seen in wild type mice. As in mice, human gMDSC make
up less than  0:5% of isolated PBMC in healthy individuals with reports of up to  10-fold
expansion in the circulation of patients with renal cell carcinoma or colorectal cancer [169, 170].
Such phenotypes and functionality of MDSC specically in cancer have also been extensively
reviewed elsewhere [158, 171, 160, 167, 172, 133]. But two key reviews by Gabrilovich in Nature
Reviews Immunology have gone a long way to resolving the inconsistencies and confusion in the
literature, with the goal of creating a more unied platform for MDSC study in humans [164, 133].
What is evident from the following table, table 3.1 is that human MDSC, either monocytic
or granulocytic, express a large number and wide-range of markers. Without routine analysis
using the latest technology, CyTOF, that fundamentally increases the number of markers that
can be detected simultaneously, considering the expression of all possible markers in one single
multi-colour ow cytometry panel would be impossible.
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Surface Marker mMDSC gMDSC
CCR2 + -
CXCR4 (CD184) + +
CXCR2 (IL-8R) subset +
CD11b + +
CD11c subset subset
CD14 + -
CD15 - +
CD16 subset; low +
CD19 - -
CD3 - -
CD33 + +
CD34
CD39 + +
CD45 + +
CD56 - -
CD62L low low
CD66b - +
CD80 + +
IL-4R (CD124) + +
HLA-DR - /low -
M-CSF + -
MHC-I + +
MHC-II - -
VEGFR1 + +
VEGFR2 + +
Table 3.1: Phenotypic markers expressed by human monocytic vs. granulocytic
MDSC.
+ indicates expression, - indicates lack of expression. Particular pheno-
types that remain debated in the eld are noted as ˝subset. Adapted from
Talmadge & Gabrilovich [173].
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The focus of the following sections is to highlight some of the latest evidence for MDSC in the
context of inammation but more specically in the context of persistent antigenic stimulation.
3.2.2 MDSC: cellular expansion & activation
The initial concept that chronic inammation can contribute to tumour initiation and progres-
sion was rst noted a long time ago. Although at the time this hypothesis was widely overlooked.
It is now well established that a link exists between inammation and cancer [171]. A major
immune-mediated mechanism observed during states of chronic inammation that directly pro-
motes tumour growth is the perturbation of myelopoiesis. Preventing the normal process of
mature myeloid cell development can lead to an overwhelming deciency in functional APC
and an increase in immature myeloid cell inltrates. Such myeloid cell inltration into cytokine,
chemokine and growth factor-rich tumour milieu promotes the development of functional MDSC.
Given the very nature of MDSC, their presence in the tumour microenvironment directly and
indirectly inhibits both innate and adaptive anti-tumour responses.
A wealth of evidence from both experimental tumour-models and human cancers has provided
insight into the induction and/or expansion of MDSC. This has led to the widespread belief
that this process is mediated by the combined eect of a number of factors (including cytokines,
chemokines, growth factors and pro-inammatory mediators). Factors reported thus far include:
cyclooxygenase-2, prostaglandins, stem-cell factor, macrophage colony-stimulating factor (M-
CSF), IL-6, GM-CSF, and VEGF [174, 175, 176, 164, 173, 177]. A number of these factors
promote myelopoeisis and/or inhibit myeloid cell maturation.
These factors are considered to be MDSC expansion-promoting factors that can activate inter-
nal signalling pathways converging on members of the Janus kinase (JAK) protein family and
signal transducer and activator of transcription 3 (STAT3); both of which regulate cell survival,
proliferation, dierentiation and apoptosis. It is currently widely accepted that STAT3 is the
main transcription factor involved in MDSC induction and expansion. Persistent (or aberrant)
activation of STAT3 in myeloid progenitors is directly linked to the expansion of MDSC via the
inhibition of dierentiation into mature myeloid cell populations. Specically in tumour-bearing
mice MDSC expansion is driven by increased expression of phosphorylated STAT3 [178]. In
addition MDSC frequencies dramatically decrease upon ablation of STAT3 signalling either by
using a conditional knock-out model or the use of selective inhibitors; conversely exposure of
haematopeotic stem cells to supernatants from tumour cell cultures activates STAT3 and results
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in an in vitro expansion of MDSC [178, 179].
More recent evidence suggests activation of STAT3 signalling also promotes MDSC expansion
via the induction of S100 calcium-binding protein A8 (S100A8) and S100A9. Both proteins are
involved in the inammatory response and the receptors for which are expressed on the surface
of MDSC. Evidence suggests that blocking the action of these two proteins in vivo limits the
expansion of MDSC observed in tumour-bearing mice [180? ] (discussed in more detail in section
3.2.3).
The importance of STAT3 signalling in MDSC expansion has since been conrmed in human
studies. MDSCs isolated from the tumour site, the draining lymph nodes, and the peripheral
blood of patients with squamous cell carcinoma of the head and neck express high levels of
phosphorylated STAT3 which correlates directly with their suppressive capacity [181].
Recent emerging lines of evidence also suggest that signalling via STAT3 indirectly regulates the
dierentiation of MDSC subsets. Signalling via STAT3 has been implicated in the control of
acute-phase protein expression. The production of such proteins was demonstrated by Sander
et al. [182] to enhance MDSC accumulation and survival. In this model of polymicrobial sepsis,
IL-6-activated STAT3 signalling in hepatocytes, through interaction with the transmembrane
protein, glycoprotein 130 (gp130), resulted in the expression of the acute-phase protein, serum
amyloid A and chemokine CXCL1, which cooperate to promote MDSC accumulation in the
spleen [182].
The functional activity of MDSC is not only dependent on factors promoting their expansion
and survival but also on factors that induce their activation. Candidate MDSC activatory
factors include: IFN, TGF, TLR ligands, IL-4 and IL-13 [164]. These mediators enable
downstream activation within the MDSC of further signalling pathways including STAT6, NKB,
or STAT1. It is currently postulated that signalling via STAT1 in the MDSC is the main
pathway of activation by the pro-inammatory cytokine IFN. STAT1 is the major transcription
factor activated by IFN-mediated signalling and blockade of IFN production abolished MDSC-
mediated T-cell suppression by arginase I [183, 184]. Also MDSC from STAT1 double knock-out
mice fail to up-regulate arginase I and iNOS expression preventing them from inhibiting T cell
responses in vivo [185].
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3.2.3 MDSC: in the context of chronic inammation
In patients with CHB there is continuous, and often high-level antigenic stimulation with re-
peated episodes of liver inammation alongside the local tolerisation of specic lymphocytes,
mirroring the hallmark features observed in chronic inammation and cancer biology. Research
in both these elds provides insight into a potential role for MDSC in specic immunosuppres-
sion in the context of chronic viral infection where MDSC have been relatively under studied.
Under conditions of chronic inammation that result from high bacterial burden, for exam-
ple, secondary lymphatic organs are often characterised by an immunologically suppressive or
altered milieu, including that of CD3 down-regulation accompanied by T cell dysfunction [186].
A handful of published studies present evidence for MDSC-mediated chronic inammation-
dependent immunosuppression [187, 188, 189]. While under some circumstances acute inam-
mation is essential for the clearance of pathogens, excessive or chronic inammation can become
detrimental, potentially preventing the clearance of the initial invading pathogen via the in-
duction of an immunosuppressive environment. In a study by Vaknin et al. [188] MDSC were
suggested to play a role in the maintenance of such an immunosuppressive environment. The
authors specically proposed a role for TLR signalling-dependent induction of MDSC capable of
inhibiting T and NK cell function. The authors discuss the possibility that the immunosuppres-
sion arising from TLR-mediated chronic inammation evolved to limit excessive immunopathol-
ogy that can arise upon chronic stimulation of the innate immune system, and thus preventing
excessive tissue damage [188].
In a more recent study by the same group, Sade-Feldman et al. [189] reported that a TNF-rich
milieu resulting from chronic inammation directly induces an immunosuppressive environment,
primarily through the expansion of suppressive MDSC. The authors not only demonstrated
MDSC expansion through direct inhibition of the physiological process of myeloid cell matura-
tion, in this case via an up-regulation of the proteins S100A8 and S100A9, but also an increase
in the suppressive capacity of the MDSC, with eects on both T and NK cell function. MDSC in
this chronic inammatory setting were reported to up-regulate the activity of two characteristic
enzymes, iNOS and arginase I, involved in the metabolism of L-arginine and increased cellular
production of reactive oxygen species (ROS). Sade-Feldman et al. [189] also demonstrated the
ability to overcome MDSC mediated suppression through the use of anti-TNF therapy. Treat-
ment with etanercept demonstrated the ability to recover expression of the signalling component
CD3 of both T and NK cells with a concomitant increase in cellular functionality [189].
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3.2.4 MDSC: in the context of viral infection
As already stated until very recently MDSC were predominantly studied in cancer, however new
evidence is beginning to detail roles for both subsets of MDSC in mediating or promoting the
pathogenesis of chronic viral infections. Norris et al. [190] have demonstrated a role for MDSC in
chronic, but not acute, infection with LCMV infection. Utilising the clone 13 infection strain to
confer chronic infection, the authors reported a specic role for MDSC not seen in mice treated
with a strain causing acute infection, Armstrong. The authors hypothesised that the two distinct
infection patterns induce diering innate immune responses, leading to dierential induction of
T cell immunity and therefore viral persistence. Within this study the authors reported the
innate immune response in LCMV as two temporal phases: an early DC response during the
rst 72 hours post-infection and a later LCMV-specic expansion of a myeloid cell population.
In the latter stages of both strains of LCMV, the expansion of myeloid cells coincided with a
peak in the CD8+ T cell response. However in chronic infection the expansion of myeloid cells
was sustained and exhibited the phenotypic and functional prole of MDSC. Most importantly
MDSC in chronic infection accelerated T cell exhaustion. Elimination of MDSC in this context
by antibody depletion directly enhanced T cell functionality and reversed the T cell exhaustion
signature.
In other murine models of viral infections, MDSC have also been implicated. Using a model
of acute inuenza A virus infection, Jeisy-Scott et al. [191] demonstrated a role for TLR7 sig-
nalling in the induction of MDSC and in the regulation of their ability to suppress T cell function.
Specically in this case infection with inuenza, in the absence of functional TLR7 signalling
resulted in an accumulation of active MDSC at the site of infection.
MDSC in the context of viral infection have also been studied in a limited number of human
infections. Like HBV, HCV is remarkably ecient at persisting in the presence of an ongoing
immune response. Infection with HCV during adulthood establishes chronicity in the majority
of cases (approximately 80% of individuals). Tacke et al. [192] have reported a role for HCV core
protein in the induction of an MDSC population; the addition of exogenous HCV core protein
to pre-isolated CD33+ resulted in the induction of a population of monocytic MDSC displaying
a CD11b+HLA-DRlow/negCD14+ phenotype. These cells were capable of suppressing T cell
responses, both their IFN production upon stimulation and their proliferative capacity, by in-
creasing the production of ROS [192]. This study was supported by the detection of a similar
population of cells in vivo in the periphery of an extremely small cohort of ve patients chroni-
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cally infected with HCV [192]. Further evidence has gone on to detail the clinical signicance of
these MDSC. In this case the authors showed an increase in mMDSC in treatment-naive chronic
HCV patients compared to controls in an extended cohort. In this cohort MDSC positively
correlated with HCV viral load, extent of liver damage and the activation status of global T
cells. In the same study dramatic decline in MDSC numbers was observed upon initiation of
anti-viral therapy. However, in contrast to the previous report ([192]), the T cell suppression
observed in this study was attributed to arginase I [193]. Notably two further studies have shown
increased numbers of MDSC in HCC resulting from chronic HCV infection. In the context of
HCC, MDSC functionality has been attributed to their ability to induce CD4+CD25+FOXP3+
Treg [194] and the ability to mediated MDSC-dependent inhibition of NK cell function via the
NKp30 receptor-ligand interaction [195].
HCV is not the only chronic viral infection to have been considered. HIV is also a virus capa-
ble of subverting the immune system via the potential induction of MDSC. In a recent report,
as with HCV core protein, incubation of HIV tat protein with a population of healthy PBMC
in vitro gives rise to a population of mMDSC (CD33+CD11b+HLA-DRlow/negCD14+). This
was corroborated by an increase in circulating MDSC in seropositive individuals [196]. Further
evidence also suggests a role for the HIV protein, gp120 (but not gp41) in the induction of func-
tionally suppressive MDSC via the production of pro-inammatory cytokine, IL-6. The authors
of this study demonstrated that the neutralisation of IL-6 abrogated expression of phosphoylated
STAT3 in the myeloid population and, subsequently reduced MDSC frequencies [197]. Mirroring
HCV, treatment with highly active anti-viral therapy results in a signicant decline in mMDSC
numbers, alongside a steep drop in HIV viral load. While Qin et al. [196] failed to see a notable
dierence in the frequencies of circulating gMDSC in HIV, Vollbrecht et al. [198] demonstrate an
increase in gMDSC numbers in patients not receiving treatment compared to uninfected controls.
What is apparent is that MDSC have the potential to expand under conditions of chronic vi-
ral infection. In this study we utilised multiparametric ow cytometric techniques to analyse
valuable patient material. We postulated a subset of MDSC play a vital role in CHB. We also
hypothesised that these cells may home to the site of viral replication where they could ex-
hibit suppressive activity, directly functioning to limit T cell mediated liver damage caused by
lymphocyte inltration into the liver.
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3.3 Results
3.3.1 Challenges in phenotypic identication of MDSC in CHB
To investigate a role for MDSC and their potential to inuence the well-described dysregulated
immune response seen in patients with CHB, it was necessary to rene a method for their iden-
tication. Historically this has been complicated largely due to the heterogeneous nature of
MDSC (as previously discussed in section 3.2.1), and the lack of unique markers for ow cyto-
metric analysis. Very preliminary work from our collaborators in the Bertoletti group looked
at a population of MDSC in HBV infection providing us with a clear grounding, enabling our
initial work to focus on designing a panel of markers and ourochrome combinations to allow
full, reliable and robust identication of both the monocytic and granulocytic MDSC subsets.
Figure 3.2a denes and demonstrates the phenotypic markers and gating strategies used.
The granulocytic subset (gMDSC) were dened throughout by expression of CD11b, CD33 and
CD15, and a lack of HLA-DR and CD14. Conversely, the monocytic subset (mMDSC), were
dened by expression of CD11b, CD33, low levels of HLA-DR and CD14, and a lack of CD15.
mMDSC, as their name would suggest, lack expression of CD16 and CD66b, two granulocytic
markers that are only evident on the gMDSC population (gure 3.2b). Neither mMDSC nor
gMDSC subsets express the classical lymphocytic markers CD3 or CD19 (used for the identi-
cation of T- and B cells respectively) (gure 3.2c). The relative number of circulating MDSC for
each study participant were determined ex vivo from freshly isolated PBMC. The MDSC popu-
lation was continually presented as a percentage of the total myeloid cell population, identied
by high CD11b and CD33 expression (far right hand panel of gure 3.2a).
Prior to full analysis, the gMDSC population in question was conrmed to be granuloyctic in
nature using a dierent technique. gMDSC isolated from two individuals using ow assisted cell
sorting using the panel of markers described and depicted in gure 3.2a, underwent morphological
analysis using cytospin technology and haematoxylin-eosin staining. These cytospins were done
by Muzz Hania during her time in Antonio Bertoletti's group. Figure 3.2d demonstrates the
existence of multi-lobed nuclei, a feature specic to granulocytic cells, conrming the granulocytic
nature of the MDSC population in question in this thesis [165, 132].
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Figure 3.2: Phenotypic identication of monocytic & granulocytic MDSC from
freshly isolated PBMC by ow cytometry.
mMDSC phenotypically dened as: CD11bhighCD33+HLA-DRlowCD15-
CD14+, and gMDSC phenotypically dened as: CD11bhighCD33+HLA-DR-
CD14-CD15+. Analysis was performed by multiparamtric ow cytometry using
freshly isolated PBMC. A) Representative FACS plots showing the gating
strategy used to identify both MDSC subsets. To represent percentages of
circulating MDSC, the MDSC population was calculated as a percentage of
total myeloid cells (CD11bhighCD33+) by superimposing the gated MDSC
population (highlighted on the far right plots) onto the myeloid cell gate
during analysis. B) Representative histogram plots showing CD16 and CD66b
surface expression on both the mMDSC (red) and gMDSC (blue) subsets. C)
Representative histogram plots showing surface expression of CD3 and CD19
on mMDSC, left hand panel, and gMDSC, right hand panel compared to their
matched isotype controls. D) Morphological analysis of the gMDSC subset -
haematoxylin-eosin staining of ow cytometric isolated gMDSC - Attributed to
Muzz Hania.
It is important to note that freshly isolated (in other words, never frozen and thawed) PBMC
were used for the vast majority of this study as we, and others, have shown that gMDSC are
a fragile, cryo-sensitive population [199]. Relative frequencies of gMDSC dramatically declined
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when subjected to an overnight freezing protocol (methodology outlined in section 2.2.3) in six
study participants (gure 3.3a). The study of MDSC using frozen samples is not impossible,
but frequencies are extremely low. This was evident when comparing gMDSC frequencies in a
separate cohort of patients with CHB, where a proportionate loss of gMDSC was noted upon
freezing (gure 3.3b). Notably mMDSC did not show a reproducible, signicant decline in fre-
quencies upon freezing in this extremely small cohort (gure 3.3c).
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Figure 3.3: MDSC are cryosensitive: identication of MDSC subsets using
freshly isolated and frozen and thawed PBMC.
A) PBMC from ve patients with CHB and one control were stained for
CD33, CD11b, HLA-DR, CD14 and CD15 and analysed for gMDSC frequencies.
Representative FACS plots show gMDSC identication in samples stained either
when freshly isolated (upper panel) or after a period of 24 hours freezing in
FBS supplemented with 10% DMSO at -80℃ (lower panel), and cumulative
data. B) Correlative analysis of 10 patients with CHB comparing frequencies of
circulating gMDSC in fresh versus frozen PBMC samples. C) Cumulative data
showing frequencies of circulating mMDSC in the previous six samples (fresh
versus frozen). Error bars represent the mean  SEM. Signicance testing was
carried out using the paired Students t test, and where signicant indicated as:
* p<0.05; ** p<0.01.
Within this study there was the added complication that arose due to the reliance upon mul-
tiple NHS centres for continued patient recruitment and sampling. All NHS centres involved
in this study used BD Vacutainers® for sample collection containing an anti-coagulant. How-
ever, between the centres, the anti-coagulant agents coating the vacutainers varied. gMDSC
survival/maintenance in vacutainers coated with lithium-heparin was better than those taken
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in EDTA providing further evidence for the fragility of these cells (gure 3.4a). Comparative
analysis of isolated PBMC, simultaneously collected into tubes containing either anti-coagulant
agent was done in ve individuals to conrm this observation (gure 3.4b). From this cumulative
data (gure 3.4c) it became apparent that it would be necessary to record the reagent used and
to keep data from each patient cohort separate.
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Figure 3.4: MDSC viability is enhanced in lithium-heparin tubes during sample
collection.
Identication of gMDSC (CD11bhighCD33+HLA-DR-CD14-CD15+) using
11-colour ow cytometry from freshly isolated PBMC. A) Representative FACS
plots of the gMDSC population from the same study participant using PBMC
isolated from blood taken on the same clinic visit in EDTA- or lithium-heparin-
containing BD Vacutainers® with the gating strategy used outlined in red. B)
Cumulative data for three patients with CHB and two controls where paired
samples in both anti-coagulants were obtained. C) Cumulative data for all
study participants from both cohorts of patients: 1) Central London cohort -
taken in EDTA containing tubes - 56 patients with CHB and 54 controls, and 2)
East London cohort - taken in heparin containing tubes - 64 patients with CHB
and 37 controls. Error bars represent the mean  SEM. Signicance testing
was carried out using either the paired or unpaired Students t test, and where
signicant indicated as: *** p<0.001
In summary to begin studying a role for MDSC in the context of CHB, it was essential to ensure
all experiments were done on freshly isolated PBMC (where possible), using the same protocol
for isolation to ensure cell viability. Antibody clones and uorochromes used for all ex vivo work
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to assess MDSC frequencies remained unchanged throughout, to avoid any potential dierences
in gating of small cellular populations.
3.3.2 gMDSC are preferentially expanded in patients who sustain HBV
replication without necroinammatory liver damage
To specically investigate whether MDSC play a role in CHB, their circulating frequencies were
examined in carefully characterized patients with CHB. Having established the need to keep the
cohorts separate according to the anti-coagulant used during sample collection, it was necessary
to classify all study participants into two distinct cohorts: both with age- and sex-matched
uninfected controls where possible (details of both cohorts are described in section 2.1 and sum-
marised in tables 2.1 and 2.2).
Circulating gMDSC are highlighted in red in the two representative examples (one control and
one patient with CHB) shown in gure 3.5a. The frequency of gMDSC was signicantly in-
creased, by a mean of  9-fold, in a cohort of 64 patients with CHB compared to 37 controls
from the East London cohort taken in lithium-heparin (cumulative data gure 3.5b). This nd-
ing was reproducible in a separately sampled cohort of 56 patients with CHB and 54 controls
from the Central London cohort taken in EDTA (gure 3.4c). gMDSC frequencies were pro-
portionately decreased in this second cohort, attributable to a selective loss of gMDSC after
collection of blood in EDTA rather than heparin as already described (gure 3.4c). Further
gMDSC quantication and extensive study on functionality was typically restricted to samples
obtained in lithium-heparin containing BD Vacutainers®. Where relevant, the cohort of patients
with CHB taken in EDTA has been included for reference. Also throughout this study due to
known reduced granulocyte counts in individuals of African-descent, ethnicity was recorded and
were appropriate patients were excluded [200].
The extent of gMDSC expansion was variable within our cohorts of patients with CHB. In some
patients circulating frequencies observed were comparable to controls and in others an  22-fold
expansion in circulating gMDSC was seen (compared to the mean value for controls) (gure
3.5b). The expanded population of gMDSC accounted for as much as 45% of circulating myeloid
cells in some cases. This expansion was a selective expansion in the granulocytic subset of
MDSC, frequencies of mMDSC did not signicantly dier in patients with CHB compared to
controls (gure 3.5c). There was also no clear relationship between frequencies of gMDSC and
mMDSC within individuals (gure 3.5d), reinforcing the idea that the two subsets are distinct
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Figure 3.5: Granulocytic, but not monocytic MDSC expand in CHB.
Identication of gMDSC (CD11bhighCD33+HLA-DR-CD14-CD15+) using
11-colour ow cytometry from freshly isolated PBMC. A) Representative
FACS plots of the gMDSC population, shown in red, from a control and
a patient with CHB, respectively. B) Cumulative data showing circulating
gMDSC frequencies for our cohort of 37 controls and 64 patients with CHB
(East London cohort). C) Cumulative data showing the relative percentages
of monocytic MDSC (mMDSC) (CD11bhighCD33+HLA-DRlowCD15-CD14+)
in the same individuals. D) Correlative analysis of circulating frequencies of
mMDSC and gMDSC (as a percentage of total myeloid cells) within a cohort of
CHB patients. Error bars represent the mean  SEM. Signicance testing was
carried out using the either: the Pearson product-moment correlation coecient
or the Students t test, and where signicant indicated as: *** p<0.001.
and dierentially regulated. Given the:
• dierences in functionality between gMDSC and mMDSC,
• the lack of HBV-driven expansion in the mMDSC subsets, and
• the predominance of gMDSC within the MDSC compartment,
this study focused on gMDSC and their functionality/role in CHB, with comparisons made to
the mMDSC population where appropriate.
Before further evaluation of the data attention turned to consider the total number of circulating
myeloid cells in our cohorts since the relative numbers of MDSC were calculated as a proportion
of the total myeloid cell population. Total myeloid cells were identied as CD11bhighCD33+.
No signicant dierence was seen in the proportion of these cells between controls or patients
with CHB (gure 3.6).
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Figure 3.6: The proportion of total myeloid cells in CHB is unchanged.
Cumulative data showing the frequency of myeloid cells, identied as to-
tal CD11bhighCD33+ cells in the blood of controls and patients with CHB.
Error bars represent the mean  SEM. Signicance testing was carried out
using the Students t test and was deemed non-signicant.
In CHB the degree of liver damage is linked to immune activity rather than viral replication (this
concept is discussed in section 1.3.3). To explore the relationship between gMDSC and disease
activity, we analysed gMDSC frequencies in a specic subset of the East London cohort who
could be clearly classied into a phase of disease as described in section 1.3.4. This was done on
the basis of repeated clinical assessments by their hepatologists, Dr. Upkar Gill and Dr. Patrick
Kennedy. The clinical and virological parameters considered were; serum alanine transaminase
(ALT) levels,  liver histology to assess liver inammation, HBeAg status and viral load. These
well classied patients were then spilt into the four major phases of infection (as shown in gure
1.7), that patients typically progress through over several decades. Diagnostic cut-o values used
to dene patients vary signicantly across publications and those used in dierent NHS centres.
The European Association for the Study of the Liver (EASL) issue regular guidance however
the values used in this study were chosen to be very strict in separating the patients groups to
ensure no overlap between the groups and to exclude borderline patients [19].
The phases and their diagnostic limits used in this study were therefore dened as follows:
• immunotolerants: HBeAg+, HBV DNA >107IU/ml, ALT <40IU/L
• HBeAg+ active disease: HBV DNA >5 105IU/ml, ALT >60IU/L
• inactive disease: HBeAg-, HBV DNA <2000IU/ml, ALT <40IU/L
• HBeAg- active disease: HBV DNA >5 105IU/ml, ALT >60IU/L
In doing so it became apparent that patients with ongoing viral replication, and in some cases
extremely high levels of active replication, in the absence of liver inammation (the patients clas-
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sied as immunotolerant and those with inactive disease) had signicantly more gMDSC than
patients with active liver disease (gure 3.7a). Corroborating this, circulating gMDSC were most
expanded in patients maintaining low level liver damage as reected by their serum ALT levels
(gure 3.7b). In 42 patients, the availability of liver biopsy tissue allowed histological assess-
ment of the amount of immune-mediated pathology by a histopathologist at the Royal London
Hospital. In these patients the percent of gMDSC correlated inversely with hepatic necroinam-
matory score (gure 3.7c). The extent of brosis was also considered, given the signicance in
HBV-related liver injury progressing through to cirrhosis and HCC and the well documented
expansion of gMDSC in cancer [133]. There was no clear relationship observed between the
extent of liver specic brosis measured using the ISHAK scoring system upon diagnostic biopsy
and gMDSC frequencies (gure 3.7d). These data are however limited by a lack of patients with
severe brosis or cirrhosis.
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Figure 3.7: gMDSC are preferentially expanded in patients who sustain HBV
replication without necroinammatory liver damage.
Identication of gMDSC (CD11bhighCD33+HLA-DR-CD14-CD15+) using
11-colour ow cytometry from freshly isolated PBMC. Relative frequencies
of circulating gMDSC from the well-characterised East London cohort were
classied by: A) disease phase basis of repeated clinical assessments (serum
alanine transaminase (ALT) levels,  liver histology to assess liver inammation,
HBeAg status and viral load). These distinct phases of disease were dened
as follows: immunotolerant (HBeAg+, viral load >107IU/ml, ALT <40IU/L),
eAg+ active disease (viral load >55IU/ml, ALT >60IU/L), inactive disease
(HBeAg-, viral load <200IU/ml, ALT <40IU/L), eAg- active disease (viral load
>55IU/ml, ALT >60IU/L); B) by serum ALT (IU/L) alone; and C) by necroin-
ammatory histological analysis (carried out by an NHS histopathologist) in 42
patients with CHB. D) Extent of liver brosis (analysis carried out by an NHS
histopathologist after liver biospy using the ISHAK scoring system). Error bars
represent the mean  SEM. Signicance testing was carried out using either
the: Pearson product-moment correlation coecient or the Students t-test, and
where signicant indicated as: ** p<0.01; * p<0.05.
These ndings were then concisely displayed using a method of hierarchical clustering by Eu-
clidean distance. Patients with CHB were clustered in an unsupervised manner based on the
similarity of their serum ALT levels, hepatic necroinammatory score and circulating gMDSC
frequencies. The dendrogram represents the similarity of each patient to another, and clearly
conrms a high frequency of gMDSC is concordant with low level liver inammation, as reected
by a low ALT value and a low necroinammatory score. Furthermore, patients in the immuno-
tolerant phase of disease and with inactive disease robustly cluster together, those with active
disease forming a separate, distinct cluster (gure 3.8).
From there consideration turned to the question of whether any viral parameters associated
with HBV, or factors relating to the specics of the cohorts used gave an insight into the driving
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Figure 3.8: Hierarchical clustering reveals clear stratication of CHB disease
phases.
Unsupervised clustering based on gMDSC frequencies, serum ALT (IU/L)
and necroinammatory score (as conrmed by an NHS histopathologist). The
data analysis performed in the generation of this gure must be attributed to
Dr. Niclas Thomas.
factor in the gMDSC expansion observed (previously depicted in gure 3.5a,b).
Co-infection of our cohorts with other viruses was considered rst. All patients used in this study
were mono-infected for an hepatotropic infection (only infected with HBV). However study par-
ticipants were often infected with other underlying persistent viral infections, for example, CMV
or epstein bar virus (EBV). To assess whether another chronic infection was capable of driving
gMDSC expansion (or having a synergistic eect) beyond that of HBV infection analysis into
the CMV serostatus was carried out. gMDSC expansion seen in the circulation of patients with
CHB was not inuenced by persistent infection with CMV. In both controls and patients with
CHB, seropositivity for CMV had no inuence on the percent of circulating gMDSC (gure 3.9a).
MDSC expansion has previously been reported to occur with the development of immune senes-
cence [201, 202]. Prior to the analysis by strict disease classication the nature of ongoing
antigenic stimulation seen in patients with CHB led to the hypothesis that gMDSC may accu-
mulate over the course of disease. The most signicant expansion of gMDSC was in the context
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Figure 3.9: gMDSC do not expand in CMV, as a result of aging, or in relation
to a number of HBV virological/clinical parameters.
Identication of gMDSC (CD11bhighCD33+HLA-DR-CD14-CD15+) using
11-colour ow cytometry from freshly isolated PBMC was considerd in relation
to a number of clinically relevant parameters to our cohort of East London
patients with CHB (compared to controls where necessary). Relative frequencies
of circulating gMDSC were classied by: A) CMV serostatus; serology was
obtained for a cross-sectional cohort of controls and patients with CHB; B) by
age of the participants on the date of sampling (years), controls or patients with
CHB respectively; and C) by gender. Patients with CHB were further classied
by virological and clinical parameters including: D) HBV viral load (IU/ml); E)
quantication of HBsAg (IU/ml); F) the presence of circulating HBeAg. Error
bars represent the mean  SEM. Signicance testing was carried out using
either: the Pearson product-moment correlation coecient or the Students t
test, and where signicant indicated as: *** p<0.001; * p<0.05.
of immunotolerant disease, a phase normally restricted to the rst few decades of life, and those
with inactive disease, and therefore minimal antigenic stimulation instantly disputed the orig-
inal hypothesis. However for the majority of patients, the date of infection was unknown and
so impossible to establish accurate durations of infection. For completeness and to ensure there
was no role for immune senescence (ageing) in gMDSC expansion, age on the date of sampling
was used as a surrogate to address this. Correlating the frequency of circulating gMDSC with
age yielded no signicant relationship in either the controls or the patients with CHB (gure
3.9b). Thus implying no signicant role for immunosenescence (ageing) in gMDSC expansion or
continued antigenic stimulation over a number of decades, whether at low levels or not.
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As gMDSC expansion could not be attributed to CMV serostatus or was not a prominent fea-
ture of ageing in our patients as already shown (gure 3.9a,b), another parameter considered
was gender. Gender of patients with CHB is an important factor to consider given that female
patients with CHB are reported to develop less severe HBV-related liver disease than their male
counterparts [203]. Stratication of both cohorts by gender revealed a signicant dierence in
circulating gMDSC frequencies, but only in the cohort of patients with CHB, not in controls.
Female patients with CHB have signicantly higher frequencies of gMDSC than males (gure
3.9c). It has recently been shown in a study by Kostlin et al. [204], that gMDSC expand during
pregnancy and are thought to be involved in the materno-fetal tolerance. The authors of this
study do not attribute any particular factor to driving the initial expansion, but it is however
possible that increases in female hormones during pregnancy could play a role. It is plausible
that gMDSC may respond to hormonal increases, potentially explaining the further increase in
gMDSC frequencies seen in female patients with CHB.
Finally specic examination of HBV-specic virological parameters failed to provide any clear in-
sight into what was the driving factor in gMDSC expansion seen in CHB. Frequencies of gMDSC
failed to correlate signicantly with either: viral load (gure 3.9d), serum HBsAg titre (gure
3.9e) or HBeAg status (gure 3.9f) when considered as independent variables. Additionally,
several multivariate techniques were used to investigate whether a more complex, interdepen-
dent relationship existed between these variables. No signicant relationship was detected using
multiple linear regression. Principal component analysis (PCA) also failed to yield a projection
of the data which showed any clear clustering by gMDSC frequencies. The majority of patients
had similar PC1 and PC2 scores across a large range of both high (red) and low (green) gMDSC
frequencies (gure 3.10).
3.3.3 gMDSC are transiently expanded in acute resolving HBV infec-
tion and decline at the onset of the hepatic are
Results from the cross-sectional analysis of gMDSC frequencies with numerous viral parameters
in gure 3.9 failed to elucidate a conclusive MDSC-driving factor. In a further attempt to de-
termine the factor involved analysis took advantage of samples stored from extremely valuable
patients presenting in clinic in whom the initial pre-clinical HBV replication phase character-
ising acute infection had unusually, been captured. Three such patients were followed through
to resolution of infection. Following the course of acute infection enabled gMDSC frequencies
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Figure 3.10: Principal component analysis (PCA) revealed no clear separation of
gMDSC frequencies based on three viral parameters.
Principal component analysis: using viral load, serum HBsAg titre and
HBeAg status as inputs to yield clear stratication of the patients with
CHB from the East London cohort by gMDSC frequencies. Patients with
low gMDSC frequencies in green and high gMDSC frequencies in red. A)
Represents the full dataset with B) showing a zoomed in section (identied
by the dotted lines), due to the large number of data-points falling in that
region. The data analysis performed in the generation of this gure must be
attributed to Dr. Niclas Thomas.
to be monitored longitudinally in relation to the peak and decline in viraemia alongside the
subsequent hepatic ALT are associated with elimination of the virus. One caveat to these
data is that the samples had been cryopreserved. It has already been shown in gure 3.3a that
gMDSC are a cyrosensitive population indicating that freshly isolated PBMC samples should
be used for gMDSC quantication, but to access these particularly dynamic phases of disease
in a longitudinal fashion using freshly isolated PBMC within the time constraints of this thesis
would not have been possible. Although gMDSC frequencies would be expected to be markedly
diminished in these samples, it was previously demonstrated that gMDSC frequencies in freshly
isolated and frozen samples correlate (gure 3.3b). This validated interpretation of any trends
observed in the datasets for cryopreserved samples from these three acute HBV patients.
Out of the three patients analysed, two individuals were sampled before or coinciding with peak
HBV viraemia. In these two individuals, a clear temporal relationship between the induction of
gMDSC frequencies and viral load was observed. These two parameters decline in parallel. The
third patient (patient A3) did not present in clinic until after peak viraemia, thus making it hard
to draw conclusions about the expansion of gMDSC during the viral ˝ramp-up phase in this
individual. All three patients exhibit the typical delay between peak viraemia and hepatic are
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Figure 3.11: gMDSC transiently expand in acute resolving HBV infection and
decline at the onset of the hepatic are.
Identication of gMDSC (CD11bhighCD33+HLA-DR-CD14-CD15+) us-
ing 11-colour ow cytometry from frozen PBMC samples. gMDSC frequencies
were quantied and presented as a proportion of total circulating myeloid
cells (CD11bhighCD33+) from PBMC cyropreserved from multiple time points
where available. The patients were followed from the onset of viraemia and
through the subsequent hepatic are characteristic of acute resolving infection.
gMDSC frequencies were plotted for three acute HBV patients sampled against
viral load (IU/ml top panel) and serum ALT (IU/l lower panel) over time in
days (numerical from initial presentation in clinic) over 100 days.
(as measured by a serum ALT increase above 2000IU/ml) characteristic of acute resolving HBV
infection (gure 3.11). The ndings presented in gure 3.11 for acute infection mirror the data
previously shown cross-sectionally for chronic infection, whereby an inverse relationship between
serum ALT and circulating gMDSC frequencies was observed (gure 3.7b). Circulating gMDSC
frequencies were highest when high levels of active viral replication are occurring in the absence
of any biochemical evidence of liver-specic inammation. gMDSC numbers rapidly decline at
the onset of the hepatic are. Interestingly these data are in concordance with data reported
by Norris et al. [190] from the LCMV model. The authors demonstrated a transient increase
in MDSC frequencies during acute infection. The authors also showed sustained induction of
gMDSC in the chronic setting. The data from these three valuable sample sets provides further
ex vivo evidence for the induction of gMDSC in the context of viral infection, alongside their
ability to suppress liver inammation.
To ensure the changes in gMDSC frequencies observed over the course of acute disease shown in
gure 3.11 were not due to relative changes in the total myeloid populations, gMDSC frequen-
cies were calculated as a percentage of all leukocytes in parallel. Figure 3.12 shows the same
three patients with gMDSC frequencies displayed as a proportion of total live cells (identied
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using Invitrogen™ Blue Live/Dead®). In all three patients gMDSC frequencies are highest when
high levels of active viral replication are ongoing and in two out of three patients the nding
that gMDSC decline before the onset of the hepatic are was corroborated. In the third pa-
tient (patient A2), when presented as a proportion of live cells, the decline in gMDSC occurs
simultaneously with the hepatic are (gure 3.12). Without having used BD TruCount tubes to
calculate absolute numbers longitudinally it is dicult to comment further.
7
6
5
4
3
2
1
0
H
BV
 v
ira
l l
o
a
d 
(lo
g1
0)
0
0.01
0.02
0.03
0.04
0.05
0.06
0.07
0.08
0.09
gM
D
SC
 
(as
 a
 
%
 
o
f l
iv
e
)
20 40 60 80 1000
number of days 
0
0.01
0.03
0.05
0.07
0.09
gM
D
SC
 
(as
 a
 
%
 
o
f l
iv
e
)6000
5000
4000
3000
2000
1000
0
se
ru
m
 A
LT
 
(IU
/l)
patient A2 (as a % of live)
20 40 60 80 1000
number of days 
patient A1 (as a % of live)
0
0.01
0.03
0.05
0.07
0.09
gM
D
SC
 
(as
 a
 
%
 
o
f l
iv
e
)
0
0.01
0.03
0.05
0.07
0.09
gM
D
SC
 
(as
 a
 
%
 
o
f l
iv
e
)
6
4
2
0
H
BV
 v
ira
l l
o
a
d 
(lo
g1
0)
8
10
3000
2500
2000
1500
1000
500
0
se
ru
m
 A
LT
 
(IU
/l)
7
6
5
4
3
2
1
0
H
BV
 v
ira
l l
o
a
d 
(lo
g1
0) 8
9
0
0.004
0.008
0.012
0.016
0.02
gM
D
SC
 
(as
 a
 
%
 
o
f l
iv
e
)
20 40 60 80 1000
number of days 
0
0.004
0.008
0.012
0.016
0.02
gM
D
SC
 
(as
 a
 
%
 
o
f l
iv
e
)2500
2000
1500
1000
500
0
se
ru
m
 A
LT
 
(IU
/l)
patient A3 (as a % of live)
serum ALT (IU/l)
frequency of circulating gMDSC (as % of live)
HBV viral load (IU/ml)
Figure 3.12: gMDSC, when presented as a proportion of total leukocytes,
transiently expand in acute, resolving HBV infection and decline at
the onset of the hepatic are.
Identication of gMDSC (CD11bhighCD33+HLA-DR-CD14-CD15+) us-
ing 11-colour ow cytometry from frozen PBMC samples. gMDSC frequencies
were quantied and presented as a proportion of total circulating leukocytes
(identied using Invitrogen™ Blue Live/Dead®) from PBMC cyropreserved
from multiple time points. The patients were followed from the onset of
viraemia and through the subsequent hepatic are characterising acute
resolving HBV infection. gMDSC frequencies plotted for three acute HBV
patients sampled against viral load (IU/ml top panel) and serum ALT (IU/l
lower panel) over time in days (numerical from initial presentation in clinic)
for 100 days.
3.3.4 gMDSC are also transiently expanded during spontaneous hep-
atic ares in HBeAg- CHB
Having observed relationships between gMDSC frequencies and both viraemia and inamma-
tion in the setting of acute HBV infection, the same approach was taken for two patients with
HBeAg- CHB, sampled throughout the course of a spontaneous hepatic are. The time-course
of these longitudinal samples of two patients with CHB is in months compared to the acute
HBV patients in days. From the cryopreserved samples obtained from these two patients, the
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inverse relationship between serum ALT and circulating gMDSC frequencies was again observed
(gure 3.13), mirroring both the cross-sectional data in the context of CHB and the longitudinal
analysis of acute HBV infection. The relationship between gMDSC frequencies and vireamia
in the setting of CHB is unclear, suggesting the virus may only play a signicant role in their
primary expansion.
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Figure 3.13: gMDSC decline at the onset of the spontaneous hepatic are in
patients with active HBeAg- CHB.
Identication of gMDSC (CD11bhighCD33+HLA-DR-CD14-CD15+) us-
ing 11-colour ow cytometry from frozen PBMC samples. gMDSC frequencies
were quantied and presented as a proportion of total circulating leukocytes
(identied using Invitrogen™ Blue Live/Dead®) from PBMC cyropreserved
from multiple time points. The patients were followed through a phase of
highly active CHB. gMDSC frequencies plotted for two patients with HBeAg-
CHB against viral load (IU/ml: top panel) and serum ALT (IU/l: lower panel)
over time in months.
Similar to the acute resolving HBV patients, gMDSC frequencies over the course of the spon-
taneous ares in these two patients with CHB were re-plotted as a proportion of total live
leukocytes. The ndings in the setting of CHB were consistent, regardless of how the gMDSC
frequency data was plotted (gure 3.14).
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Figure 3.14: gMDSC, when presented as a proportion of total leukocytes, decline
at the onset of the spontaneous hepatic are in patients with active
HBeAg- CHB.
Identication of gMDSC (CD11bhighCD33+HLA-DR-CD14-CD15+) us-
ing 11-colour ow cytometry from frozen PBMC samples. gMDSC frequencies
were quantied and presented as a proportion of total circulating leukocytes
(identied using Invitrogen™ Blue Live/Dead®) from PBMC cyropreserved
from multiple time points. The patients were followed through a phase of
highly active CHB. gMDSC frequencies plotted for two patients with HBeAg-
CHB against viral load (IU/ml: top panel) and serum ALT (IU/l: lower panel)
over time in months.
3.3.5 Absolute counts: gMDSC expand in CHB
To conrm the nding that gMDSC frequencies increase in patients with CHB compared to
controls (gure 3.5a), further investigation into their absolute numbers was carried out in a
limited cohort of study participants. For this the BD TruCount system was utilised. The system
makes use of an exact volume of whole blood to compare numbers of gMDSC against a reference
bead population. gMDSC were stained and gated in the same way (shown in gure 3.2a), with
the inclusion of CD45 to allow the exclusion of contaminating platelets and red blood cells.
This protocol makes use of a strong x-lyse solution, and samples were always analysed on the
ow cytometer within a 15 minute time-frame to ensure no bias in gMDSC loss, especially due
to their fragile nature. In line with previous ndings, the absolute numbers of gMDSC were
increased in patients with CHB compared to uninfected controls (gure 3.15).
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Figure 3.15: gMDSC increase in absolute cell number in CHB.
Identication of gMDSC (CD11bhighCD33+HLA-DR-CD14-CD15+) us-
ing 11-colour ow cytometry was done using the BD TruCount protocol using
whole blood, lysed with BD FACS lyse solution for a maximum of 15 minutes.
Error bars represent the mean  SEM. Signicance testing was carried out
using the unpaired Students t test, and where signicant indicated as: *
p<0.05.
Data relating to cell counts was also obtained during routine clinical assessment of patients from
the East London cohort, enabling consideration of these counts. One caveat to this dataset is the
lack of equivalent data detailing numbers of leukocytes for the control cohort. Taking the clinical
leukocyte count for each patient and back-calculating with the gMDSC frequencies after FlowJo
anlysis of the ow cytometric data, an absolute increase in gMDSC does occur in the absence
of liver inammation (gure 3.16). However these data should be evaluated with caution, given
the dierences between clinical assessment of leukocyte count using whole blood and the PBMC
isolation protocol used in the lab.
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Figure 3.16: Analysis of the absolute count of gMDSC during the dierent phases
of CHB taking into account clinical luekocyte count.
Numbers of gMDSC were calculated by relating the frequency of gMDSC
as a percentage of all live cells run through the ow cytometer back to the
absolute leukocyte count obtained during routine clinical assessment for the
East London cohort. Patients were classied by disease phase, as dened
previously. Error bars represent the mean  SEM. Signicance testing was
carried out using the unpaired Students t test, and where signicant indicated
as: * p<0.05.
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3.3.6 gMDSC also expand in chronic HCV infection
An expansion of MDSC in another chronic hepatotropic infection, HCV infection, has been
previously described in a number of published studies. In these studies, the subsets of MDSC
analysed were reported to be able to mediate specic lymphocyte suppression [192, 193, 205, 206].
Given the signicant expansion of gMDSC in the circulation of patients with CHB, we sought
to conrm the presence of gMDSC using the same phenotypic panel in HCV. Similarly to CHB,
an expansion in circulating gMDSC was detectable in this cohort of patients with chronic HCV
infection (also from the East London cohort, collected in heparin) (gure 3.17a).
In a published study it has been reported that MDSC expansion in chronic HCV infection pos-
itively correlates with the degree of liver inammation, as measured by serum ALT [193]. Since
only a small cohort of HCV infected individuals were sampled, it was hard to draw any rm
conclusions from our dataset. However the data do suggest circulating frequencies of gMDSC in
chronic HCV infection neither associate with serum ALT nor viral load (gure 3.17b,c) in ac-
cordance with ndings published by Zeng et al. [206]. In contrast to CHB, patients with chronic
HCV infection do not progress through clearly dened phases of disease. However a striking
association was observed between circulating frequencies of gMDSC and age of the patient in
the HCV cohort in line with the hypothesis of gMDSC accumulating over time with ongoing
antigenic stimulation (gure 3.17d).
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Figure 3.17: gMDSC also expand in HCV and signicantly correlate with patient
age.
Identication of gMDSC (CD11bhighCD33+HLA-DR-CD14-CD15+) us-
ing 11-colour ow cytometry from freshly isolated PBMC from a cohort
of patients with chronic HCV infection. Relative frequencies of circulating
gMDSC presented as a proportion of total myeloid cells (as shown in gure
3.2a). A) Cumulative data from the East London cohort (taken in heparin) of
the 37 controls and 64 patients with HBV infection already presented in gure
3.5b, and a further 17 patients with chronic HCV infection. The cohort of
patients with chronic HCV infection were further classied by: B) serum ALT
(IU/L); C) viral load (IU/ml); and D) age of the patient (years) on the date
of sampling. Error bars represent the mean  SEM. Signicance testing was
carried out using either: the Pearson product-moment correlation coecient
or the Students t-test, and where signicant indicated as: *** p<0.001; **
p<0.01.
3.3.7 gMDSC accumulate further in the diseased liver
HBV and HCV specically and exclusively infect hepatocytes of the liver, an organ typically
manifesting a local milieu of immune tolerance rather than immunity, as discussed in section 1.4
[94, 207, 90]. Analysis therefore turned to consider whether the expanded population of gMDSC
circulating in patients with CHB (or chronic HCV infection) could have the potential to accu-
mulate in the liver. Intrahepatic frequencies of gMDSC were determined using valuable paired
PBMC and intrahepatic lymphocytes from liver biopsy tissue deemed surplus to diagnostic re-
quirements (gure 3.18a). 16 out of 19 patients with CHB analysed showed an accumulation of
gMDSC in the liver, in some cases representing up to a maximum of 56% of the intrahepatic
myeloid population (gure 3.18b). Of the three remaining patients with CHB where no liver spe-
cic increase in gMDSC frequencies were observed, no apparent clinical dierences were noted,
providing no evidence for why gMDSC do not accumulate in the liver of some patients.
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Figure 3.18: gMDSC expand approximately 2-fold in the liver mircoenvrionment
in chronic hepatotrophic infections: HBV & HCV.
Identication of gMDSC (CD11bhighCD33+HLA-DR-CD14-CD15+) us-
ing 11-colour ow cytometry from freshly isolated intrahepatic cells. A)
Representative sequential FACS plots showing gMDSC identication using
a paired (peripheral blood (PBMC) and lymphocytes obtained from a liver
biospy (IHL) deemed surplus to diagnostic requirements from the same
individual) sample from a patient with CHB. B) Cumulative data showing
circulating frequencies of gMDSC compared to intrahepatic frequencies
in 19 patients with CHB from the East London cohort. C) Cumulative
data showing circulating frequencies of gMDSC compared to intrahepatic
frequencies in 12 chronically infected HCV patients. D) Cumulative data from
a cross sectional cohort of patients with CHB showing relative frequencies
of myeloid cells (identied as CD11bhighCD33+) between the blood and the
liver compartments. E) Cumulative data showing frequencies of circulating
mMDSC compared to intrahepatic in a cross section of 10 patients with CHB.
Error bars represent the mean  SEM. Signicance testing was carried out
using either: the paired or unpaired Students t-test, and where signicant
indicated as: ** p<0.01.
Intrahepatic gMDSC frequencies were also assessed from a cohort of patients chronically infected
with HCV. Once again gMDSC were expanded in the liver of patients with HCV, at frequencies
comparable to those seen in the CHB cohort (gure 3.18c). The accumulation/expansion of
gMDSC in the liver in both disease states was approximately 2-fold. Notably, proportions of
myeloid cells between the periphery and the intrahepatic environment remained unchanged (g-
ure 3.18d) and there was no specic, consistent accumulation of the monocytic subset of MDSC
in the intrahepatic environment in CHB (gure 3.18e).
This led to the question of whether the accumulation of gMDSC noted in the liver was a gen-
eral feature of the tolerogenic microenvironment or was only observed in certain pathological
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states. In a preliminary attempt to consider this, three intrahepatic samples were obtained
from the healthy margins of metastatic liver tissue during surgery. These samples unfortunately
had no paired blood available for comparison of circulating frequencies. gMDSC frequencies in
these three patients were similar, if not slighlty higher, than those seen in patients with chronic
HBV or HCV infection (gure 3.19). One intrahepatic sample was also obtained from a patient
with HCC on a HBV background. In this sample approximately 20% of the myeloid cells were
gMDSC, in line with the data from patients with CHB (gure 3.19).
In further attempts to assess whether gMDSC accumulation in the liver was a consequence of
local infection/tumours or a generalised phenomenon in the liver (whereby MDSC home to the
liver under physiological conditions), gMDSC frequencies were assessed in the non-diseased liver.
These samples were obtained in collaboration with transplant surgeons, Mr. Francis Robertson
and Mr. Brian Davidson, at the Royal Free Hospital. In this case, biopsies of healthy liver
tissue (from the donor) and the perfusate (wash-out prior to transplantation) of such tissue were
obtained before liver transplantation into the recipient, providing unique access to non-diseased
liver tissue. Analysis of gMDSC frequencies in these samples showed that gMDSC do not ex-
pand in the healthy liver (gure 3.19), with frequencies analogous to circulating gMDSC in the
healthy cohort of study participants (gure 3.5a,b).
gM
D
SC
 
(as
 a
 
%
 
o
f m
ye
lo
id
)
HBV HCV healthy
margins
metastasis
HCC
(HBV)
0
2
20
40
60
80
healthy
Figure 3.19: gMDSC accumulate in livers with viral hepatitis or tumours, but
not in the healthy liver.
Identication of gMDSC (CD11bhighCD33+HLA-DR-CD14-CD15+) using
11-colour ow cytometry from freshly isolated intrahepatic cells. Cumulative
data from all intrahepatic samples analysed for gMDSC frequencies, including
all 19 patients with CHB, 12 patients chronically infected with HCV, three
samples isolated from the healthy margins of liver tissue from patients
undergoing surgery for metastatic liver disease, one patient with HCC on the
background of CHB and two samples from non-diseased liver tissue obtained
from a healthy donor prior to transplantation into its recipient.
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3.3.8 Potential factors driving the accumulation of gMDSC in the dis-
eased liver
The accumulation of gMDSC in the diseased liver but not the healthy liver led to a question
regarding their homing and survival/expansion of gMDSC under these conditions. To address
this, circulating gMDSC (using isolated PBMC) were stained with monoclonal antibodies di-
rected initially against a selected panel of three chemokine receptors postulated to be relevant
to liver MDSC homing based on recent studies reviewed by Talmadge & Gabrilovich [173].
The rst of these chemokine receptor was CCR2, a receptor reported to be critical in the homing
of MDSC in LCMV infection [190]. CCR2 has also recently been implicated in allowing the egress
of murine inammatory monocytes from the bone marrow to sites of infection, where they further
dierentiate into cells with a mMDSC phenotype and the ability to mediated iNOS-dependent
suppression [208]. Staining was carried out to assess expression of this chemokine receptor on
both subsets of MDSC (gure 3.20a, upper panel), which was found to be expressed at very high
levels on the surface of mMDSC compared to the matched isotype control. It is possible then
that CCR2 expression on human mMDSC allows for their egress into the circulation. CCR2
was, however, barely detectable on gMDSC from either the uninfected controls or in the cohort
of patients with CHB (gure 3.20a, bottom panel).
The second chemokine receptor considered was CXCR4, which was again found to be expressed at
lower levels on the gMDSC subset compared to the mMDSC subset. More interestingly however,
levels of CXCR4 were lower on the expanded population of gMDSC in patients with CHB com-
pared to controls (gure 3.20b). Full maturation into mature granulocytes under physiological
conditions occurs in the bone marrow. An interesting report by Ma et al. [209] demonstrated that
mature granulocytes are prematurely released into the bloodstream of CXCR4 decient mice,
resulting in an over-abundance of immature granulocytes in the circulation. Down-regulation
of CXCR4 on the surface of neutrophils is critical for their mobilisation from the bone marrow
in response to GM-CSF, and infection with Listeria monocytogenes [210]. Decreased expression
of CXCR4 on gMDSC raises the possibility that a down-regulation of this chemokine receptor
enables accelerated egress of these immature myeloid cells from the bone marrow into the circu-
lation of patients with CHB [209].
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Figure 3.20: Selected chemokine receptor expression on the surface of gMDSC
and mMDSC.
Representative histogram plots and cumulative data showing the com-
parison of chemokine receptor expression on the surface of mMDSC and
gMDSC compared to their matched isotype controls between controls and
patients with CHB for: A) CCR2; B) CXCR4; and C) CXCR1. Error bars
represent the mean  SEM. Signicance testing was carried out using the
paired Students t-test, and where signicant indicated as: *** p<0.001; **
p<0.01; * p<0.05.
The third chemokine receptor considered was the IL-8 receptor. Although there are two chemokine
receptors, CXCR1 and CXCR2, that have similar anities for IL-8, the process of neutrophil
chemotaxis is primarily mediated by CXCR1 [211]. In contrast to the previous two chemokine
receptors, CXCR1 expression was signicantly higher on gMDSC than mMDSC in both controls
and patients with CHB (gure 3.20c). For completeness, expression of the other IL-8 receptor,
CXCR2 was briey considered on both MDSC subsets (gure 3.21a). Expression of CXCR2
mirrored expression of CXCR1, being expressed at signicantly higher levels on gMDSC than
mMDSC in both controls and patients with CHB (gure 3.21b). However levels of CXCR2 were
signicantly lower on gMDSC in patients with CHB compared to controls.
Expression of both IL-8 receptors (CXCR1 and CXCR2) on the surface of gMDSC led to the
hypothesis that these could contribute to their homing (accumulation) and/or interactions within
the liver. IL-8 is a neutrophil chemotactic cytokine that can be produced by several cell types,
including hepatocytes, in CHB [72]. Therefore it was postulated that gMDSC expressing the
IL-8 receptor could be chemoattracted into the liver by an IL-8 gradient and/or may be able to
specically interact with an IL-8 producing hepatic cell types.
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Figure 3.21: gMDSC also express CXCR2, IL-8R.
A) Representative histogram plots and cumulative data showing the
comparison of CXCR2 expression on the surface of mMDSC and gMDSC
compared to matched isotype controls. B) Cumulative data showing CXCR2
expression levels on mMDSC and gMDSC between controls and patients with
CHB. Error bars represent the mean  SEM. Signicance testing was carried
out using the paired Students t-test, and where signicant indicated as: **
p<0.01; * p<0.05.
3.3.9 A potential interaction of gMDSC with hepatic stellate cells
A number of recent reports have demonstrated a role for hepatic stellate cells (specialized,
liver-resident myobroblasts, described previously in section 1.4.4) in the induction of MDSC
[114, 195]. In these papers the authors describe expansion of MDSC from pre-isolated mono-
cytes upon co-culture with primary stellate cells. Isolated primary hepatic stellate cells (pHSC),
from healthy resected liver tissue, were used to test whether they could promote MDSC sur-
vival/expansion. Full details on the isolation of pHSC can be found in section 2.8.1, but briey:
liver tissue was obtained from patients undergoing surgery for metastatic liver disease at the
Royal Free Hospital (in collaboration with Mr Giuseppe Fusai). The healthy margins of liver
tissue from these patients were used to isolate pHSC using a density gradient, excluding all
other non-parachymal cells of the liver. Isolated quiescent pHSC were then passaged in culture
to ensure full activation of these cells prior to experimentation.
The subsequent experiments were done in conjunction with Dr. Kasha Singh (Maini group).
Analysis of these pHSC prior to co-culture experimentation revealed that these cells can produce
high levels of the pro-inammatory cytokine IL-6 ex vivo, without the need for any stimulation
(gure 3.22a). IL-6 is believed to promote MDSC expansion [177, 212]. It was also observed
that these isolated pHSC were capable of producing IL-8 which was previously postulated to be
involved in the potential gMDSC accumulation and interaction in the liver (gure 3.22b). It is
possible that production of IL-8 by pHSC promotes their interaction with the CXCR1-expressing
gMDSC, although this remains to be conrmed.
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Figure 3.22: pHSC produce two candidate cytokines, IL-6 and IL-8, ex vivo.
Primary hepatic stellate cells (pHSC), isolated by density centrifugation
and cryopreserved, from margins of metastatic livers. Prior to co-culture
experimentation pHSC were stained for production of two candidate cytokines
without stimulation. Representative histogram of ex vivo intracellular A) IL-6
and B) IL-8 staining. The staining and analysis used in the generation of this
gure is attributed to Dr. Kasha Singh.
Upon co-culture, activated pHSC were able to support short-term expansion and/or enhance the
survival of gMSDC from PBMC isolated from either controls or patients with CHB, compared
to cultures in the absence of pHSC (gure 3.23). What remains to be elucidated is whether the
increase in gMDSC frequencies seen upon co-culture with pHSC is the consequence of direct con-
tact between the gMDSC and the pHSC or whether a soluble mediator is released by activated
HSC. Also without the use of staining for proliferation, for example CSFE or Ki67 staining, at
this stage it is not possible to ascertain whether it is active induction of new gMDSC. The fact
that an increase in gMDSC frequencies in the control samples occurs upon co-culture with pHSC
may be indicative of MDSC induction from immature precursors or possible transdierentiation
of other subsets, as gMDSC are rarely observed in control individuals.
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Figure 3.23: pHSC promote gMDSC survival/accumulation in vitro.
Primary hepatic stellate cells (pHSC) isolated and cryopreserved from
margins of metastatic livers were thawed and passaged to ensure activa-
tion before use in co-culture experiments with either PBMC from controls
or patients with CHB. PBMC were removed from pHSC six days post
co-culture and stained for gMDSC frequencies. gMDSC were identify as
CD11bhighCD33+HLA-DR-CD14-CD15+ using 11-colour ow cytometry.
PBMC from six controls and four patients with CHB were co-cultured with or
without pHSC. Error bars represent the mean  SEM. Signicance testing was
carried out using the paired Students t-test, and where signicant indicated
as: * p<0.05. The data presented in this gure was generated in collaboration
with Dr. Kasha Singh.
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3.4 Conclusions & Discussion
CHB is a highly prevalent disease worldwide, that is characterised by a failing antiviral im-
mune response which drives a non-antigen specic intrahepatic lymphocytic inltration. This
inltration results in collateral damage to the tissue of the liver. Previous work by our group
suggested that this dysregulated response occurs in association with nutrient deprivation. As
a direct result of the dierential regulation of this immune-mediated tissue damage in patients
with CHB, contrasting outcomes of infection are clearly evident. In the data presented in this
chapter it has been shown for the rst time that an expansion of a subset of cells with the char-
acteristics of immature neutrophils (the gMDSC), using primary human samples occurs in CHB.
In studying this expanded population it has also been shown that gMDSC have the ability to
accumulate at the site of viral replication, which is a highly immunosuppressive and tolerogenic
environment. More specically, by taking advantage of paired samples where is was possible
to obtain and isolate cells from both the blood and the liver of a well-characterised cohort of
patients during diering clinical phases of disease, it has been demonstrated that MDSC fre-
quencies correlate with the degree of liver immunopathology. gMDSC expansion is most evident
in patients with CHB in whom HBV replicates at extremely high levels without any biochemical
or histological evidence of liver pathology (the ˝immunotolerant phase).
The ndings reported in this chapter are strongly supported by a recent urry of publications
demonstrating MDSC functionality in chronic viral infections [190, 189, 198, 196]. Two of these
publications focused on a role for MDSC in HIV infection; these groups reported an expansion of
MDSC in uncontrolled HIV infection, contributing to the HIV-1-specic and antigen-non-specic
impaired T cell responses characteristic of progressive disease. The authors attribute this T cell
eect to the enzymatic function of arginase I, in a cell-contact dependent manner. Another key
recent report by Norris et al. [190] demonstrated an accumulation of MDSC with the ability to
suppress T cell function in the murine model of chronic LCMV infection. The authors suggest
that MDSC, along with other previously described suppressive mechanisms, counter bystander
activation of cellular populations capable of causing immunopathology and inammation often
seen in persistent infections. This likely role for gMDSC mirrors the intricate role for regulatory
B cells recently described by our lab in the context of chronic HBV infection [213].
Prior to embarking on this study, no known relationship between gMDSC and HBV infection
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had been reported in humans. A publication by Chen et al. [214] reported a role for the local-
isation and function of hepatic MDSC in ˝normal and HBV transgenic mice. Frequencies of
hepatic MDSC in the context of HBV were approximately twice that of the wild-type mice, but
equally as suppressive in either setting [214]. A handful of reports also studied MDSC in the
context of HCV in patients and in vitro. In the context of HCV, the majority of papers report
a role for the monocytic subset of MDSC via arginase I-mediated or ROS-mediated suppressive
mechanisms [192, 193, 206, 205]. One very recent paper however failed to show an expansion
of either gMDSC or mMDSC in the circulation of patients with HCV compared to controls
[215]. This lack of expansion of MDSC is inconsistent with data from this study and previous
published studies [192, 193, 205, 206]. The cohort used within this thesis showed a signicant
ten-fold expansion of gMDSC in the circulation of patients with chronic HCV infection, with no
signicant expansion of mMDSC compared to controls. The cohort studied here do have variable
gMDSC frequencies, so it is possible the patients are markedly dierent to those included in the
study by Nonnenmann et al. [215], or the cells were processed dierently, given their fragility.
It is also possible that the mean age of the cohorts used were signicantly dierent given the
relationship between age and gMDSC frequencies.
A key unanswered question, that arises from the work presented in this study, is whether the
enhanced accumulation of gMDSC in HBV (and HCV) is driven by a liver-derived or viral factor
or both. This has not been fully addressed within the scope of this study. Taken together, the
data in this report do raise some potential hints to answer this question. Although no clear
cross-sectional correlation between gMDSC frequencies and any viral parameters was noted, a
key piece of evidence supporting a role for a viral factor in driving their initial expansion was
presented. Data from the acute HBV setting, supports a contribution from the virus in driving
initial gMDSC expansion as the peak accumulation of gMDSC coincides with peak viraemia
and not the height of liver inammation. It is possible that a factor induced by the process
of ongoing viral replication in the liver drives gMDSC induction, or indeed a viral protein, as
reported for the viruses HCV and HIV [192, 197] .
A number of other candidate drivers identied in the setting of tumours, including TNF, VEGF,
and hypoxia-induced HIF-1 [133, 216, 189] would merit future investigation to assess their po-
tential contribution to the dierential accumulation of gMDSC seen in the distinct phases of
CHB. Of particular note are IL-6 and VEGF [164]. IL-6 is believed to be critical to the early
control of HBV infection. It is released by KC and leads to the activation of signalling pathways
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that limit HBV replication in hepatocytes shortly after infection (to prevent the death of hepato-
cytes) [217]. It is possible that this early production of IL-6 is responsible for MDSC expansion
as it has previously been implicated in the accumulation of MDSC with suppressive activity
in the tumour microenvironment, down-stream of IL-1-mediated inammation [177]. IL-6 has
also been shown to oer hepatocyte protection from T cell damage in murine Con-A-induced
hepatitis by signalling through the gp130 receptor, initiating a STAT3-signalling cascade, induc-
ing production of acute phase proteins [218, 182]. It is possible therefore that IL-6 can either
directly interact with inltrating immature myeloid cells by a similar mechanism to initiate
STAT3 signalling, widely accepted as the main transcription factor involved in MDSC induction
and expansion [219, 178, 179, 164] or via the indirect induction of acute phase proteins in the
HBV infected liver. In addition the combination of IL-6 with GM-CSF has been reported to
promote the dierentiation of isolated CD33+ (myeloid cells) into a suppressive population with
MDSC characteristics in vitro [212, 220].
The other particularly relevant mediator is VEGF. The Gabrilovich group has extensively shown
a correlation between levels of VEGF and numbers of immature myeloid cells capable of sup-
pressing antigen-specic T cell responses in cancer [169, 221]. More recently circulating MDSC
from renal cell carcinoma patients have been shown to express high levels of the VEGF recep-
tor 1 (VEGF-R1) [132]. Although MDSC reportedly express the receptor for VEGF, its role
in MDSC expansion is still debated. In patients with renal cell carcinoma, treatment with an
anti-VEGF antibody did not alter MDSC frequencies [132], whereas the use of this antibody in
mice, caused a decrease in MDSC numbers [222]. If VEGF does promote MDSC expansion in
CHB, this may be particularly relevant due to the suggestion that ground-glass hepatocytes in
the HBV-infected liver produce VEGF [223]. Expression of this VEGF has been proposed to
facilitate HCC progression, but it may also induce suppressive MDSC [224].
It must not be forgotten that HBV exclusively infects the liver. The observation that gMDSC
frequencies are increased in hepatotropic infections (HBV and HCV) but not the pleotropic
virus, CMV, and are further enriched in frequency in the intrahepatic compartment, implies a
potential role for the liver milieu itself. Amongst the specialized resident cell types in the liver,
HSC are stromal cells that are best known for their capacity to dierentiate into pro-brogenic
myobroblasts. Recent studies have illustrated their additional capacity to promote immuno-
suppression through several mechanisms, including the generation of MDSC [114, 115, 116]. The
co-transplantation of pHSC promotes the survival of islet allografts and this eect can be reca-
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pitulated by the MDSC that are induced [114]. pHSC isolated from murine and human livers
have also been shown to potently expand MDSC in vitro [114, 115, 116], analogous to the eects
presented in this chapter. The pathways involved, and whether they induce MDSC proliferation
and/or enhance their survival, remain to be elucidated. However the ability of pHSC to produce
the chemotactic cytokine IL-8 could facilitate interactions between pHSC and gMDSC, which
express high levels of the IL-8 receptor (CXCR1) in our patients. IL-8 has also been implicated
as one of the acute phase proteins produced by the liver that can mobilise immature myeloid
progenitors from the bone marrow [182]. Likewise, loss of CXCR4 signalling is a key step in pro-
moting the egress of immature granulocytes from the bone marrow [210, 209]. This mechanism
is implicated by the reduced levels of CXCR4 found on the expanded population of gMDSC
circulating in the context of CHB.
To address the impact of the liver in the steady state, independently of the virus, it was essential
to know intrahepatic gMDSC frequencies in the healthy state. To address this, gMDSC frequen-
cies were initially assessed using lymphocytes obtained from the healthy margins of liver tissue
extracted during the surgical removal of metastases in the liver. gMDSC in this liver tissue are
still present, and at high frequencies. Tissue of this type fails to let us rule out the possibility of
a distant eect from the tumour itself in gMDSC induction, given the fact it is well documented
that gMDSC expand in the context of tumours [158, 166, 171, 133]. In healthy mice gMDSC
have been shown to home to the liver and accumulate there [225]. However in the limited tissue
we have obtained from healthy livers gMDSC appear to not be expanded. Further tissue from
healthy liver must be assessed in the future to conrm this nding.
There is accumulating evidence suggesting a complex immunoregulatory role for gMDSC in
multiple pathologies, including, cancer, infectious diseases, trauma and autoimmunity. In the
context of chronic bacterial infection, gMDSC have been shown to not only expand but to increase
their functional activity, specically driven by the inammatory mediator TNF. Increased serum
TNF levels directly intensify local immune suppression by arresting myeloid cell maturation,
giving rise to an MDSC population and enhancing key suppressive activity [189]. Not only
has TNF been described to inuence MDSC expansion, but also the combination of IL-6 and
GM-CSF has the potential to give rise to cytokine-induced MDSC [212]. Increased expression
of TNF [39] and IL-6 occurs during HBV infection, with a key role for KC-produced IL-6 in
the control of early infection [217]. It is therefore possible that inammatory-mediator driven
induction of gMDSC accumulation occurs in viral hepatitis, especially in the liver. This local
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increase in numbers of gMDSC suggests a role for MDSC in maintaining the mechanisms of
tolerance required for the liver's vital metabolic and clearance functions involved in the uptake
of nutrients, waste products and pathogens from the blood [207]. Liver specic expansion of
gMDSC emulates ndings in the murine model showing preferential homing of MDSC to liver
and spleen [225]. There is a possibility that gMDSC accumulate in all livers with inammation/
pathology where HSC are activated. It would be interesting to consider MDSC populations in
livers taken from individuals with non-viral hepatitis, for example alcoholic and non-alcoholic
steatohepatitis.
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Chapter 4
MDSC limit hepatic
immunopathology in an arginase
I-dependent manner
4.1 Abstract
The data presented in this chapter builds directly on the data presented in the previous chapter
and the direct hypothesis that an expansion/accumulation of an MDSC population with a gran-
ulocytic phenotype could mediate, or limit, the immune-mediated pathology observed in CHB.
One key function of gMDSC is their production of immune suppressive regulators, including the
L-arginine metabolising enzyme, arginase I, which depletes the amino acid L-arginine required
for T cell eector function. Using combined methodology of ow cytometry and isolation tech-
niques for cell culture, the functionality of the expanded gMDSC was assessed. This revealed
that gMDSC express large amounts of arginase I and show an enhanced degranulation capacity
in CHB. gMDSC expansion directly correlated with increases in circulating arginase I and a
congruent depletion of L-arginine. gMDSC potently inhibited the proliferation of both HBV-
specic and functionally active bystander T cells in an arginase I-dependent manner. Finally
the dierential expression of amino acid transporters on ex vivo T cells provided evidence for the
metabolic reprogramming of T cells in CHB. Taken together the data in this thesis demonstrate
the capacity of expanded arginase I+ gMDSC to regulate liver immunopathology by depriving
T cells of L-arginine.
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4.2 Introduction
4.2.1 MDSC-mediated immune suppression
MDSC exploit a number of dierent mechanisms to suppress both arms of the immune system;
the innate and the adaptive. Given their heterogeneous phenotype, the suppressive activity of
MDSC ultimately serves as the dening characteristic for these cells. Their mechanism of action
often depends on the monocytic or granulocytic nature of the cells in question, with researchers
tending to focus on either one of the two subsets. Previous research has also tended to focus on
just one mechanism at a time. Little is known to date about whether the dierent candidate
mechanisms of suppression can act in parallel, in synergy or only independently.
It is possible to broadly summarise the functions of MDSC that have already been described
[164, 133] into four major categories. These are as follows:
1. nutrient deprivation from the local microenvironment,
2. interference with lymphocyte tracking and cell viability,
3. generation and induction of oxidative stress, and
4. expansion and activation of other regulatory cell populations.
These functions are summarised in gure 4.1 over the page.
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Figure 4.1: Summary of selected mechanisms of MDSC functionality aecting both innate and adaptive immunity.
Abbreviations used: reactive nitrogen species (RNS), reactive oxygen species (ROS), arginase I (ARG), nitric oxide synthase (NOS), indoleamine
2,3-dioxygenase (IDO), tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL), programmed death ligand 1 (PD-L1), programmed
death 1 (PD-1), T cell immunoglobulin- and mucin-domain-containing molecule 3 (Tim-3), galectin-9 (Gal-9), T cell receptor (TCR). Adapted from
[133].
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The work presented in this chapter concentrates on delineating the rst of these mechanism
of MDSC suppression in CHB. The potential role for additional mechanisms have been briey
considered or discussed in chapter 5.
4.2.2 A role for MDSC in amino acid metabolism
Historically, the primary suppressive mechanisms of MDSC is their direct role in L-arginine
metabolism. MDSC can deprive lymphocytes of a number of vital amino acids essential for
cell growth and dierentiation. To date MDSC have been reported to play an important, well
described role in depriving the immune system of the host of three amino acids; L-arginine,
L-tryptophan and L-cysteine. Deprivation of L-phenylalanine has been recently, albeit briey,
described in the murine system, but as yet no translation through to the human system has
been reported [226, 227]. It it also worthy of note that MDSC driven amino acid deprivation has
only thus far been described for T cells. It is plausible that other lymphocytes require the same
amino acids for cellular processes. For example NK cells also express the CD3 chain which is
the main signalling transduction component of the TCR, down-regulation of which is considered
to be a hallmark feature of amino acid deprivation [64].
L-arginine metabolism
The most widely studied of these amino acids subjected to MDSC-mediated metabolic regulation
is L-arginine. L-arginine is a conditionally essential amino acid, meaning it must be supplied in
the diet during discreet (such as pregnancy) or pathological insult (such as sepsis and trauma),
in which the requirement exceeds the body's own production. Under the physiological steady
state, L-arginine is however primarily a non-essential amino acid because it is synthesised en-
dogenously via the metabolic pathways of proline, glutamine, or glutamate. Normal serum levels
of L-arginine range from 50-150M [66]. Therefore a signicant depletion of L-arginine would be
viewed as below 50M, whereby profound eects on the immune response would be expected.
These eects are a down-regulation of CD3 and proliferative arrest [66].
It is well described that L-arginine is used in the regulation of multiple biological systems, in-
cluding the biosynthesis of proteins, creatine and agmatine, as well as the immune response.
Key to MDSC function is the role L-arginine metabolism plays in modulating immunity. An
association of L-arginine and immune regulation was initially suggested in the 1970s in reports
demonstrating that injection of L-arginine in mice undergoing extensive surgery prevented the
117
Chapter 4. Results
phenomenon of post-surgical thymus involution and appeared to increase T cell numbers [228].
L-arginine is mainly metabolised to regulate immune responses by two catabolic enzymes, both
of which are expressed at high levels by MDSC. These enzymes both exist as multiple isoforms:
nitric oxide synthases (NOS1, NOS2, and NOS3) and the arginases (arginase I and arginase
II). Metabolic degradation gives rise to the products nitric oxide (NO) and L-citrulline, and
urea and L-ornithine, respectively. L-arginine is also the substrate for two further enzymes:
arginine:glycine amidinotransferase (AGAT) and L-arginine decarboxylase (ADC) (gure 4.2).
Although limited information about the regulation and immunological roles for AGAT and ADC
currently exists.
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(for cell proliferation)
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Figure 4.2: Multiple mechanisms involved in the metabolism of L-arginine.
Schematic showing the metabolism of the conditionally essential amino
acid L-arginine, via the four major enzymes. Two of these catabolic enzymes,
arginase and nitric oxide synthase (NOS), metabolise L-arginine, into compo-
nents suggested to be involved in immune modulation (highlighted in the red
box). The key pathway for the work presented in this thesis is the metabolism
by arginase I into L-ornithine and urea. All proteins with enzymatic activity
are highlighted in blue text. Abbreviations used: L-arginine decarboxylase
(ADC), arginine:glycine amidinotransferase (AGAT), nitric oxide synthases
(NOS), asymmetric dimethylarginine (ADMA), nicotinamide adenine dinu-
cleotide phosphate (NADPH), L-ornithine aminotransferase (OAT), L-ornithine
decarboxylase (ODC).
Tight control over amino acid levels has emerged as a mechanism for limiting over exuberant
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expansion of highly activated proliferating cells. From recent data it is clear there is a close re-
lationship between the availability of L-arginine and the regulation of both CD4+ and CD8+ T
cell proliferation and function [64]. Cells deprived of L-arginine arrest in the G0-G1 phase of the
cell cycle [229]. Consumption of amino acids from the local environment alters T cell processing
through two down-stream signalling pathways; by activation of the internal stress response by
general control nonrepressible 2 (GCN2) kinase and through inhibition of mTOR activation [226].
As a direct consequence of an amino acid-poor environment, GCN2 kinase senses and binds
uncharged aminoacyl transfer RNA (tRNA), and reacts by phosphorylating serine-51 of the -
subunit of eukaryotic translation initiation factor (eIF2) [64, 230]. Phosphorylated eIF2 sub-
sequently binds more tightly than usual to eIF2B (and catalyses the exchange of GTP for GDP
in the eIF2 complex). Once eIF2B is bound to phosphorylated eIF2 it is unable to exchange
GDP for GTP. This lack of exchange inhibits the binding of the eIF2 complex to methionine-
bound tRNA, thus inhibiting the process of translation initiation (gure 4.3) [226, 231]. The
presence of phosphorylated eIF2 halts translation of newly synthesised mRNA, and manifest
as a down-regulation if CD [232].
Amino acid availability also regulates the mTOR pathway. Specically in conditions of low
L-arginine, or amplied urea production, mTOR activity within the cell is suppressed [233].
mTOR activation subsequently phosphorylates at least two proteins critical for translation initi-
ation (and therefore protein synthesis); these are phosphorylation of the 70kDa ribosomal protein
S6 kinase (p70 S6: gure 4.3) and an inhibitor of translation initiation, the eukaryotic transla-
tion initiation factor 4E-binding protein 1 (4E-BP1). Withdrawal of amino acids results in the
rapid deactivation, by dephosphorylation, of both the 70kDa S6 kinase and 4E-BP1 ultimately
decreasing protein synthesis. The re-addition of amino acids to mammalian cells, previously
nutrient deprived, promotes the rapid reversal of this dephosphorylation, therefore, increasing
the extent of p70 S6 kinase [234]. Notably inadequate mTOR activation can result in the in-
duction of ˝infectious tolerance exemplied by conversion of naive T cells into regulatory T
cells [235, 154]. Of note, amino acid deprivation is not the only factor able to modulate the
mTOR pathway, changes in the process of glycolysis or increased cell stress also regulate the
phosphorylation status of the p70 S6 subunit [233].
Preliminary unpublished work from the Stauss group failed to demonstrate a role for the GCN2
pathway in L-arginine-depletion driven immune suppression. The use of short-hairpin RNA
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targeting of the GCN2 pathway failed to recover T cell proliferation and cytokine production
after polyclonal activation under conditions of nutrient deprivation, specically low L-arginine.
Instead impairment in the ability to phosphorylate the p70 S6 kinase was observed in both the
GCN2 knock-down and wild type cells when deprived of L-arginine. These data, together with
reports in the literature [234] implicate inhibition of the mTOR pathway, independently of the
GCN2 signalling cascade and its role as a critical nutrient-sensing mediator. Articial, ex vivo
activation of the mTOR pathway could render lymphocytes resistant to conditions of L-arginine
deprivation (personal communication - Mathias Zech and Hans Stauss).
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Figure 4.3: Eect of amino acid starvation on T cell functions.
gMDSC have the capacity to deplete essential amino acids (those depicted
here: L-arginine, L-tryptophan and L-cysteine) by either ezymatic degration or
via the sequestration of synthetic intermediates. Amino acid deprivation has
profound eects on the T cell, reducing both functionality, and proliferation.
T cells sense amino acid levels via two main pathways: the GCN2 and mTOR
pathways. Full details of the pathways and eects of amino acid starvation
have been detailed in the main text in relation to L-arginine in section 4.2.2,
but also apply to the other amino acids. Abbreviations used: arginase (ARG),
indoleamine-2,3-dioxygenase (IDO), mammalian target of rapamycin (mTOR),
inducible nitric oxide synthase (iNOS), general control nonderepressible 2
(GCN2), eukaryotic translation initiation factor 2 (eIF2), nitrix oxide (NO),
transfer RNA (tRNA), human antigen R (HuR).
Evidence is also emerging describing a role for L-arginine deprivation in driving other down-
stream eects beyond defective ribosomal translation of newly synthesised transcripts. The
depletion of cytosolic L-arginine by arginase I, also results in the transfer of electrons from the
reductase and oxygenase subunits of the often co-expressed enzyme iNOS to surrounding oxygen,
generating superoxide species (gure 4.3). This production of superoxide can combine to gener-
ate several reactive nitrogen species (RNS). More specically superoxide can combine with NO,
a by-product of L-arginine degradation, to generate peroxynitrite (ONOO-) (gure 4.1). Perox-
ynitrite is an highly oxidising reagent that subsequently damages numerous biological targets.
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Peroxynitrite molecules achieve this by crossing membranes within or between cells functioning
as intra- and inter-cellular signalling molecules capable of inducing the post-translational modi-
cation of proteins, through tyrosine nitration. A study by Brito et al. [236] demonstrated that
the extracellular addition of peroxynitrite to human T cells primes them to undergo apoptotic
cell death. This pathway was noted to be particularly prevalent amongst activated T cells and
was achieved by inhibition (nitration) of necessary signalling proteins, preventing the ongoing
phosphorylation of downstream signalling molecules [236]. More recently it has also been re-
ported that production of peroxynitrite, driven by MDSC-mediated metabolism of L-arginine,
is capable of direct nitration of the TCR. Such nitration of the TCR prevents successful antigen
peptide-MHC interactions and the subsequent loss of cell surface signalling components, dra-
matically limiting T cell responsiveness to antigenic stimulation when in close cell to cell contact
[237].
L-tryptophan metabolism
Metabolism driven by TDO and/or IDO result in local depletion of another key nutrient, in
this case the essential amino acid L-tryptophan. Metabolism of L-tryptophan results in the
increased production of kynurenine-based metabolites. Similarly to L-arginine, the combined
eects of L-tryptophan degradation have been shown to limit T cell proliferation and induce T
cell apoptosis via the GCN2 pathway (gure 4.3) [230].
IDO is a rate limiting enzyme in the metabolism of L-tryptophan along the immunomodulatory
kynurenine pathway. Consequently IDO is well-established as a predominant endogenous sup-
pressive factor of host immune responses, being implicated in the maintenance of materno-fetal
tolerance, transplantation and tumourigenesis. Expression of IDO as an immune regulator by
inhibitory DC induces immune tolerance in cancer patients and tumour-bearing animal models
[128, 238]. Pro-inammatory cytokines, such as IFN and TNF have been implicated in the
induction of IDO in DC [239, 240].
The specic role for IDO in immune suppression is well accepted. The a role for TDO, however,
is less well characterised, but perhaps more relevant to the study of hepatotropic infections, since
TDO is predominantly expressed in the liver. A study by Schmidt et al. [241] demonstrated the
ability of TDO-expressing cells to inhibit T cell proliferation and their production of IFN. TDO
could therefore also act as a key regulator of immune tolerance essential to the homoeostasis
of the liver. Although this particular study only showed the potential role for TDO in immune
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tolerance during liver transplantation [241]; the evidence for its role in vivo during hepatotropic
infections remains unclear.
More recently studies have begun to provide evidence that one mechanism of MDSC-mediated
immunosuppression can be attributed to L-tryptophan metabolism via their production and
expression of IDO (gure 4.3). Recent work by Yu et al. [242] reported that not only was a
population of MDSC (with a granulocytic phenotype) increased in breast cancer tissue but that
these cells expressed IDO. The up-regulation gMDSC IDO at the tumour site correlated signif-
icantly with an inltration of suppressive Treg. Further use of an experimental IDO-inhibitor
(1-MT) partially inhibited the T cell suppression observed. The exact molecular mechanism
involved in the up-regulation of IDO expression in MDSC is currently unknown and therefore
requires further investigation, but some recent reports from studies looking at the function of
plasmacytoid DC in cancer have reported that arginase I and IDO can act simultaneously [243],
indicative of the induction of an immunosuppressive ˝program by an MDSC to limit the avail-
ability of multiple amino acids.
In addition in a relevant study by Larrea et al. [129], the authors demonstrated an up-regulation
of IDO in the liver of both experimentally infected chimpanzees and patients with chronic HCV
infection. The up-regulation of the enzyme was attributed to HCV-induced IFN production,
and that persistent IDO expression in the liver microenvironment contributed to T cell tolerance.
The authors did not however conrm the source of the increase in IDO expression: it is possible
MDSC, known to increase in chronic HCV infection [192, 193] are responsible for the IDO
increase observed.
L-cysteine metabolism
Another amino acid that has been implicated in MDSC immunomodulation by nutrient de-
privation is L-cysteine. As with L-arginine, L-cysteine is a conditionally essential amino acid
(therefore needed in the diet when requirement exceeds the synthetic capacity). L-cysteine is
therefore also critical for the synthesis of new proteins (protein translation), and so availability of
L-cysteine is essential for proliferation and function. L-cysteine, under physiological conditions,
is generated by a cell via two dierent pathways. The rst of these pathways requires expression
of the plasma membrane cystine transport xc- that enables the import of disulphide-bonded cys-
tine (the metabolic intermediate) from the oxidising extracellular environment. Once in the cell,
the reducing intracellular environment reduces the imported cystine to cysteine [244]. The other
122
Chapter 4. Results
of these pathways relies on expression of the enzyme cystathionase. Cystathionase catalyses the
conversion of intracellular methionine to cysteine [245].
A major problem for T cells is that they express neither the xCT chain of the xc- transporter
nor the enzyme cystathionase [246]. As such, T cells are dependent on other cells to provide
them with L-cysteine. Macrophages and DC largely produce this L-cysteine and export it for
T cell use through their plasma membrane via an ASC neutral amino acid transporter [247, 248].
Srivastava et al. [131] hypothesised and subsequently demonstrated that MDSC modulate T cell
function by limiting extracellular concentrations of not only L-arginine and L-tryptophan but also
L-cysteine. The authors showed that MDSC can express the xCT chain of the cystine transporter,
enabling them to acquire cystine from the extracellular environment, but lack the ASC neutral
amino acid transporter needed for export, meaning MDSC are unable to export L-cysteine.
As a consequence, MDSC limit the extracellular availability of L-cysteine by sequestering the
metabolic intermediate during L-cysteine synthesis. Limited pools of L-cysteine predispose T
cells to oxidative stress, again limiting T cell functionality.
L-phenylalanine metabolism
Finally metabolism of L-phenylalanine has also be reported to be involved in the process of immu-
nunoregulation by MDSC (reviewed in [227]). Most of the data depicting a role for its metabolism
have arisen from in vitro studies and are still rather limited. Interleukin-4-induced gene 1 (IL4I1)
is a secreted L-phenylalanine oxidase that produces hydrogen peroxide and phenylpyruvate fol-
lowing the oxidative deamination of L-phenylalanine. Human and mouse IL4I1 can be expressed
by APC, including studies showing expression in murine MDSC [249, 250]. A study by Boulland
et al. [249] specically reported the role for L-phenylalanine mediated metabolism by IL4I1 in
the inhibition of T cell proliferation that was associated with a transient decrease in CD3 ex-
pression akin to studies looking into a role of L-arginine and L-tryptophan. Further investigation
is required.
4.2.3 Overview of the L-arginine metabolising enzyme arginase I
As mentioned previously, two genetically distinct isoforms of arginase exists in mammals, that
dier in their tissue distribution and sub-cellular location. These two isoforms are: arginase I,
also known as the liver-type arginase, is predominantly found in the cytoplasm of hepatocytes,
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where it plays a key role in the nal step of the urea cycle; and arginase II, the kidney-type,
present in numerous tissues (including the brain, kidneys, small intestine, liver and skeletal
muscle), where it associates with the mitochondria, but is not essential to the urea cycle. Mice
lacking expression of arginase II show elevated L-arginine levels, providing some limited evidence
for arginase II playing a physiological role in arginine homoeostasis [251]. Arginase I however
is much more widely studied. Arginase I, although highly expressed by hepatocytes has also
been shown to be produced by a number of cells of the innate immune system. In rodents
macrophages constitute a major but not sole source of arginase I. Arginase I activation has also
been put forward as a hallmark of the alternatively activated macrophage. These cells represents
the predominant cell among tumour inltrating macrophages, in numerous human and murine
tumours where they have been reported to suppressor anti-tumour immune responses [67].
Arginase I is also constitutively expressed by granulocytes [252]; death (by apoptosis or necrosis)
of such cells at sites of inammation allows for the release of the enzyme, capable of inducing pro-
found suppression in T cell proliferation and cytokine synthesis [253]. Murine granulocytes also
deplete L-arginine by uptake through the cationic amino acid transporter 2B (CAT-2B) [254].
In contrast the mechanism by which human granulocytes, including MDSC, deplete L-arginine
remain unclear. It has been proposed that viable human granulocytes expressing arginase I,
including MDSC subsets expressing high levels of CD66b, actively degranulate, and thus release
the metabolically active enzyme arginase I into the extracellular milieu [132].
MDSC are now widely accepted to be a further potent source of arginase I [170, 255, 181] that
inhibits lymphocyte function [67, 66]. What is not known is whether the expanded population
of gMDSC seen in our patient cohort (seen in chapter 3), express high levels of the enzyme
or whether arginase I mediated immune suppression is a key mechanism involved in the im-
munopathogenesis of CHB, similar to that reported in a number of other settings [256, 166, 164].
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4.3 Results
4.3.1 gMDSC express high levels of arginase I
As shown in gure 4.2 arginase I is one of four enzymes central to the metabolism of L-arginine
[67]. An increase in its enzymatic activity in CHB was previously reported by our group [58].
As extensive literature describes gMDSC as a potent source of arginase I it was postulated
that gMDSC could suppress inammation in the liver (implicated in gures 3.7 and 3.8) by
production of this enzyme. Ex vivo ow cytometric analysis of gMDSC was carried out to de-
termine expression of arginase I using a directly conjugated antibody (gure 4.4a). gMDSC
showed strong staining for the enzyme, with low-density neutrophils (CD14-CD15+CD16+) the
only other circulating cell type expressing analogous levels (gure 4.4b). Notably the monocytic
MDSC subset expressed much lower levels of arginase I than gMDSC (gure 4.4b). Using the
latest ImageStream technology (which combines ow cytometry with the resolution of uores-
cence microscopy), conrmation of the capacity of gMDSC to produce and store large amounts
of arginase I was observed (gure 4.4c). The comparison of a large number of study partici-
pants revealed that the percentage of gMDSC expressing arginase I in controls and patients was
analogous. This was true for both cohorts (the Central and East London); what was striking
was the dierence in percentage of arginase I positivity in gMDSC of patients in relation to the
anticogulant used during sample collection. When taken in lithium-heparin, gMDSC expressed
a mean  SEM of 81.23.2% (gure 4.4d, right-hand panel) compared to a mean  SEM of just
56.24.2% when taken in EDTA (gure 4.4d, left-hand panel).
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Figure 4.4: Arginase I expressing gMDSC are increased in CHB.
A) Representative FACS plots showing gMDSC arginase I staining com-
pared to a matched isotype control from a patient with CHB. B) Analysis
of PBMC subsets for expression level (mean uorescence intensity, MFI) of
intracellular arginase I. Lymphocyte subsets were identied as: CD3-CD19+ B
cells, CD14-CD16+CD15+ low density neutrophils, CD3+ T cells, CD3-CD56+
NK cells, and HLA-DR+CD14+ monocytes. C) Representative ImageStream
ISX with a 60x objective showing a CD11b/CD15/CD16 co-expressing cell
displaying granular arginase I staining. D) Cumulative data showing the
percentage of gMDSC expressing arginase I in controls and patients with CHB
from the Central London cohort (taken in EDTA) and the East London cohort
(taken in lithium-heparin), respectively. E) Arginase I expressing gMDSC from
a subset of patients who were well classied on the basis of repeated clinical
assessments (East London cohort) (serum alanine transaminase (ALT) levels, 
liver histology to assess liver inammation, HBeAg status and viral load) into
distinct phases of disease as dened in section 3.3.2. F) Cumulative data for
arginase I levels in relation to the percentage of arginase I-expressing gMDSC
as a proportion of the total myeloid cell compartment (CD11bhighCD33+). G)
Categorisation of arginase I+ gMDSC as a percentage of total myeloid cells by
disease phase. Error bars represent the mean  SEM. Signicance testing was
carried out using the unpaired Students t-test, and where signicant indicated
as: *** p<0.001; ** p<0.01; * p<0.05.
Upon further analysis of gMDSC expressing arginase I using a subset of the East London cohort,
who were classied into distinct phases of disease, there seemed to be a stepwise trend towards
126
Chapter 4. Results
decreasing arginase I production as CHB disease progresses (gure 4.4e). There was a marked
increase in the proportion of arginase I+ gMDSC circulating in patients with CHB compared to
controls when analysis took into account the increased frequency of circulating gMDSC present
in these patients (gure 4.4f). The percent of arginase I+ gMDSC was signicantly higher in the
immunotolerant phase of disease and those with inactive disease than those with active disease
(gure 4.4g), mirroring the data showing gMDSC frequencies depicted in gure 3.7a.
In an attempt to assess the suppressive capacity of intrahepatic versus circulating gMDSC, the
extent of arginase I expression was assessed (using MFI values). Intrahepatic gMDSC express
more arginase I than their circulating counterparts (gure 4.5). This suggested that intraheptic
gMDSC may have an enhanced potential to mediate immunosuppression through the depletion
of local concentrations of L-arginine compared to those in the periphery of patients with CHB.
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Figure 4.5: Enhanced arginase I expression in intrahepatic compared to periph-
eral gMDSC.
Freshly isolated PBMC or intrahepatic lymphocytes were stained for CD33,
CD11b, HLA-DR, CD14 and CD15 and gated as shown in gure 3.2a to identify
gMDSC. Mean uorescence intensity (MFI) of arginase I expression between
circulating (PBMC) and intrahepatic (IHL) gMDSC using seven paired samples
from patients with CHB. Error bars represent the mean  SEM. Signicance
testing was carried out using the paired Students t-test, signicance indicated
as: * p<0.05.
4.3.2 The degranulation capacity of gMDSC is enhanced in CHB
Arginase I is thought to be stored in azurophilic granules, expressing CD63, in the cytoplasm of
gMDSC [252, 257]. Upon activation, it is believed gMDSC can degranulate and therefore release
these granules. This capacity to degranulate can be measured by incorporation of CD63 at the
cell surface of gMDSC [258], thus allowing for its detection by ow cytometry (gure 4.6a).
Patients with CHB express more CD63 on the surface of their gMDSC compared to controls
(gure 4.6b), implying an enhanced capacity for degranulation. In an attempt to address this
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Figure 4.6: gMDSC have an enhanced capacity for degranulation in CHB.
Freshly isolated PBMC were stained for CD33, CD11b, HLA-DR, CD14
and CD15 and gated as shown in gure 3.2a to identify gMDSC. A) Repre-
sentative FACS plots showing extracellular surface staining for the auzophilic
granule marker, CD63 in a patient with CHB. B) Cumulative data of the mean
uorescence intensity (MFI) of CD63 expression on the surface of gMDSC from
10 controls and 30 patients with CHB. C) Co-staining of arginase I expression
by an MDSC with CD63 expression on its surface in two representative patients
with CHB. Error bars represent the mean  SEM. Signicance testing was
carried out using the unpaired Students t-test, and where signicant indicated
as: ** p<0.01.
postulate, arginase I was co-stained with CD63 (gure 4.6c) in a limited number of patients. This
showed a clear population of gMDSC that co-stain for surface CD63 and intracellular arginase I,
suggesting the potential for the release of arginase I by gMDSC degranulation (gure 4.6c). The
percentage of the total arginase I stored in gMDSC found to co-stain with CD63 was however
highly variable between patients (gure 4.6c), implying that not all of the arginase I that a
gMDSC can produce is stored in CD63-expressing granules. What remains to be elucidated is
whether the proportion of arginase I stored in CD63-expressing granule varies between patients
with CHB and controls, or between peripheral gMDSC or intrahepatic gMDSC. It is possible that
more arginase I is stored in these granules, poised for release in the liver or in immunotolerant
patients (and those with inactive disease).
4.3.3 Serum arginase I levels are increased in CHB
Consistent with the expansion of gMDSC with an enhanced degranulation capacity, a signicant
increase in serum arginase I was detected by ELISA in patients with CHB compared to controls
(gure 4.7a). A robust correlation was observed between the concentration of serum arginase
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I and circulating gMDSC frequencies (gure 4.7b), supporting the notion that gMDSC can act
as a major source of arginase I in CHB. The preferential expansion of arginase I+ gMDSC in
patients in the immunotolerant phase was mirrored by the most signicant increase in serum
arginase I in these patients (gure 4.7c). Taken together these data suggest gMDSC may have
the capacity to suppress liver inammation through an arginase I-dependent mechanism. This
was further reinforced by the fact that the concentration of circulating arginase I correlated
inversely with serum ALT (gure 4.7d,e).
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Figure 4.7: Serum levels of arginase I are increased in patients with CHB.
Circulating arginase I levels were determined by ELISA using stored serum
samples. A) Serum concentrations of arginase I (ng/ml) from 16 uninfected
controls and 41 patients with CHB. B) Correlation of serum arginase I levels
with circulating frequencies of gMDSC previously assessed in a cohort of the
East London patients with CHB. Further cross-sectional analysis of arginase I
levels in the CHB cohort by C) disease phase (as previously dened ); D) and E)
by degree of liver inammation, as measured by serum ALT (IU/L). Error bars
represent the mean  SEM. Signicance testing was carried out using either:
the Pearson product-moment correlation coecient or the unpaired Students
t-test, and where signicant indicated as: *** p<0.001; ** p<0.01.
4.3.4 Circulating L-arginine levels are depleted in CHB
The role arginase I plays in the depletion of the conditionally essential amino acid L-arginine
has been well described and reviewed extensively [67]. L-arginine metabolism by arginase I gives
rise to the metabolites L-ornithine and urea (see gure 4.2). Previous work from our group
reported a depletion of L-arginine in a small group of patients with high levels of HBV-related
liver inammation [58].
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To further test the functionality of the increase in arginase I+ gMDSC and serum arginase
I already presented, tandem high-pressure liquid chromatography mass spectrometry (tandem
HPLC-MS) was employed to measure levels of circulating amino acids and derivatives using
stored serum samples. In this current study the cohort size analysed was greatly increased
(to include 69 patients with CHB) and the same nding was observed; enhanced L-arginine
metabolism occurs in CHB (gure 4.8a). In line with their lower levels of arginase I+ gMDSC
and serum arginase I, some patients with raised ALT had higher levels of L-arginine (gure 4.8b).
Corroborating arginase I driven metabolism of L-arginine, a non-signicant trend towards an
increase in circulating levels of the metabolite L-ornithine was observed (gure 4.8c).
The amino acid L-tryptophan, also implicated in immune regulation [259], showed a non-
signicant trend to decrease in CHB (gure 4.8d). The amino acid L-phenylalanine did not
dier between controls and patients with CHB (gure 4.8e); although a study by Boulland et al.
[249] reported a potential role for L-phenylalanine metabolism in immune regulation by murine
MDSC, this did not seem to be evident in human CHB infection.
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Figure 4.8: Levels of the amino acid, L-arginine, are depleted in CHB.
Tandem high-pressure liquid chromatography mass spectrometry analysis
of circulating amino acids. A) Cumulative data showing the circulating
L-arginine concentrations (M) in the serum of 36 controls and 69 patients
with CHB. B) Analysis of the CHB patients by serum ALT (IU/L). Cumulative
data showing concentrations (M) of: C) L-ornithine; D) L-tryptophan; and
E) L-phenylalanine in sera from controls and patients with CHB. Error bars
represent the mean  SEM. Signicance testing was carried out using the
unpaired Students t-test, and where signicant indicated as: *** p<0.001; **
p<0.01.
4.3.5 Similarly to CHB, circulating levels of arginase I are increased,
and levels of L-arginine are decreased in chronic HCV infection
The notion that gMDSC are capable of suppressing liver inammation through an increase in
numbers and functioning through an arginase I-dependent metabolism of L-arginine in CHB was
conrmed in another hepatotropic virus, HCV. In chronic HCV infection, gMDSC expand to
analogous frequencies to those seen in patients with CHB (previously shown in gure 3.17a). It
was postulated that the same mechanism of immunosuppression could be relevant in HCV. In a
small number of patients with chronic HCV an increase in serum arginase I compared to controls
was detected by ELISA (gure 4.9a). This increase was similar to that seen in patients with
CHB (gure 4.7a) and was corroborated by a signicant decrease in the amino acid L-arginine
(gure 4.9b).
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Figure 4.9: Serum arginase I levels are enhanced in HCV, alongside a decrease
in circulating L-arginine levels.
A) Serum concentrations of arginase I (ng/ml) determined by ELISA in
16 controls and 11 patients with chronic HCV infection. B) Tandem high-
pressure liquid chromatography mass spectrometry analysis of circulating of
L-arginine in 37 controls and 11 patients with chronic HCV infection. Error
bars represent the mean  SEM. Signicance testing was carried out using the
unpaired Students t-test, and where signicant indicated as: *** p<0.001; *
p<0.05.
4.3.6 Levels of L-arginine recover on antiviral treatment in CHB
In using cross-sectional studies of patients who have had a highly dynamic disease for many years,
it was dicult to distinguish whether the reduction in L-arginine levels (and the associated accu-
mulation of gMDSC) was the cause or result of reduced HBV-related liver inammation. MDSC
have been shown to be induced by chronic inammation [186, 187], and more recently by TNF
[189]. Once induced, gMDSC could result in suppression of bystander inammation in the liver,
resulting in their association with less active disease. To probe the postulate that initial expan-
sion of arginase I+ gMDSC is driven by HBV-related inammation, we analysed an additional
small cohort of patients with CHB in whom the burden of viral replication and resultant degree
of liver inammation was manipulated by the introduction of antiviral therapy. Using samples
obtained from seven patients before and during antiviral therapy, L-arginine levels were noted to
be partially restored in ve out of seven of these patients once HBV replication was suppressed
(gure 4.10a). The degree of L-arginine increase correlated with the extent of disease suppression
as measured by a normalisation in their serum ALT (gure 4.10b).
In line with this, in a very limited number of patients on anti-viral treatment, serum arginase I
concentrations decreased to values in line with those seen in controls (gure 4.11a), and gMDSC
frequencies declined (gure 4.11b). One important caveat to these data is that these patients
were sampled at one-o time points whilst on antiviral treatment, and as a result the pre-
treatment gMDSC frequencies were unknown. It is important to consider that these patients
on antiviral therapy are likely to be patients who had ongoing high level viral replication and
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Figure 4.10: Levels of circulating L-arginine recover on antiviral treatment.
Tandem high-pressure liquid chromatography mass spectrometry analy-
sis of circulating amino acids. A) L-arginine concentrations (M) from seven
patients with CHB sera before (pre-tx) and during (on tx) antiviral therapy
(* patients had been treated for >1 year) and B) correlation between decrease
in ALT and recovery in circulating L-arginine. Error bars represent the
mean  SEM. Signicance testing was carried out using either: the Pearson
product-moment correlation coecient or the paired Students t-test, and
where signicant indicated as: ** p<0.01; * p<0.05.
liver disease (active disease patients, see gure 3.7a) and therefore unlikely to have had a high
frequency of gMDSC prior to commencing therapy. It remains to be elucidated what the eect
on gMDSC frequencies would be if patients with either inactive disease or in the immunotolerant
phase were treated in clinic; it is these patients in whom gMDSC frequencies would predictably
be high to begin with.
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Figure 4.11: Serum arginase I levels and gMDSC frequencies normalise on
antiviral therapy.
A) Serum concentrations of arginase I (ng/ml) determined by ELISA in
16 controls, 41 patients with CHB and a small cross-sectional analysis of
ve patients with CHB during treatment (at least one year of treatment
with antivirals). B) Circulating gMDSC frequencies in an extended cohort of
patients with CHB to include six individuals during ongoing antiviral therapy
(at least one year). Error bars represent the mean  SEM. The statistical
testing for the controls compared to patients with CHB was done in previous
gures. For comparison with antiviral therapy signicance testing was carried
out using the unpaired Students t-test, and where signicant indicated as: *
p<0.05.
4.3.7 MDSC potently suppress T cell responses
Functional evidence was sought to determine whether the expanded population of arginase I+
gMDSC seen in patients with CHB could limit adaptive immunity against the virus, by speci-
cally inhibiting T cell functionality. To address the suppressive capacity of gMDSC in the context
of CHB, an assay was established to assess T cell responsiveness in vitro after co-culture with
autologous gMDSC. To accurately identify gMDSC from PBMC samples multiple markers are
required (see gating strategy shown in gure 3.2a), making it dicult to isolate these cells with-
out multiparametric ow-assisted sorting. To bypass the need for a biosafety level three FACS
sorter (unavailable during the course of this study), an approach was adopted that utilised mag-
netic beads. It was not technically possible to isolate gMDSC using the full panel of markers
with magnetic beads and so an enrichment for gMDSC was adopted. gMDSC were enriched
using a two-step process: CD14 negative selection, to remove contaminating monocytic cells and
a subsequent round of CD15 positive selection, ensuring all granulocytic cells were included.
Using a pool of overlapping peptides spanning the HBV core region, PBMC were cultured either
in the absence of physiological frequencies of gMDSC (gMDSC depleted: gMDSC) or after the
addition of an autologous magnetic bead-enriched population of gMDSC. T cell functionality
was assessed by monitoring the production of IFN, over and above baseline stimulation in the
absence of peptide. As depicted in the representative plots (gure 4.12a), removal of suppressive
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gMDSC during peptide stimulation enhanced the response, indicating that the population of
gMDSC has sucient potency to suppress HBV-specic T cell responses at frequencies circu-
lating in vivo. Conversely T cell production of IFN following HBV-peptide stimulation was
almost completely abrogated by the addition of an enriched gMDSC population (gure 4.12a,
far right panel). In the four patients with CHB in whom a detectable HBV-specic response
was observed to HBV core peptide stimulation, gMDSC-mediated suppression was observed,
albeit with variable responses to peptide-stimulation (gure 4.12b). As very few HBV-specic
T cells are detectable in the majority of patients [260] HBV-specic suppression assays need to
be carried out in more patients to conrm these ndings that gMDSC can limit the antiviral T
cell response.
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Figure 4.12: gMDSC are capable of suppressing HBV-specic T cells in vitro.
gMDSC were enriched or depleted using sequential magnetic bead isola-
tion (CD14-CD15+, Miltenyi) from PBMC obtained from patients with
CHB, for co-culture with autologous PBMC. gMDSC-enriched, depleted,
or un-depleted PBMC were cultured with 20IU/ml recombinant IL-2 for
ve days and tested for HBV-specic T cell responsiveness by intracellular
cytokine staining following HBV peptide stimulation (using a peptide pool of
peptides overlapping the core region). A) Representative FACS plots showing
the IFN T cell response from a patient with CHB in total PBMC with or
without HBV-peptide stimulation, after gMDSC depletion (gMDSC) and
the addition of an enriched gMDSC population (+gMDSC) from day zero.
B) Cumulative data for CD8+ and CD4+ responses (after subtraction of
background response from the unstimulated wells) in PBMC  gMDSC (n=4).
As described in the introduction (sections 1.3.1 and 1.3.3), failure of the HBV-specic T cells in
the liver to control vireamia results in the recruitment of an inammatory inltrate of antigen
non-specic or bystander T cells. It is the response of these cells locally that is critical to the
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amplication of the HBV-related immunopathology seen in CHB [47, 28]. Bearing this in mind,
functional evidence was sought to determine whether the same expanded population of gMDSC
could suppress bystander T cell responses in CHB.
To specically investigate the capacity of gMDSC to limit bystander T cell functionality, T cell
responsiveness to inuenza, EBV and CMV, viral infections that many of our cohorts have been
exposed to, was assessed in vitro using a similar assay to that described previously. In this
case PBMC from patients with CHB were stimulated with CEF, a pool of peptides representing
the immunodominant T cell epitopes from inuenza, EBV and CMV, restricted by a range of
HLA-A and B alleles. T cell responses were once again assessed, with or without the removal
or addition of a magnetic bead-enriched gMDSC population. T functionality was monitored by
intracellular cytokine staining.
As illustrated in the representative plots (gure 4.13a), the CEF peptide-specic IFN response
from T cells was similarly enhanced upon depletion of gMDSC. Conrming the ability of these
gMDSC to potently suppress T cell function, production of IFN following CEF stimulation
was again completely abrogated after the addition of enhanced frequencies of gMDSC (gure
4.13a). All 11 patients with CHB in whom a detectable CD4+ and CD8+ T cell IFN response
to CEF was seen, showed consistent suppression after the addition of gMDSC (gure 4.13b).
Using CEF stimulation, the functional capacity of gMDSC showed a dose-response, conrming
their high potency by the ability to maintain some suppression at an eector:target ratio of 1:4
in two independent experiments (a representative example is shown in gure 4.13c).
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Figure 4.13: gMDSC are capable of suppressing bystander T cell responsiveness
in vitro.
gMDSC were enriched or depleted using sequential magnetic bead isola-
tion (CD14-CD15+, Miltenyi) from PBMC obtained from patients with
CHB, for co-culture with autologous PBMC. gMDSC-enriched, depleted, or
un-depleted PBMC were cultured with 20IU/ml recombinant IL-2 for ve days
and stimulated to test the bystander T cell responses by intracellular cytokine
staining following CEF peptide stimulation (an HLA-A and HLA-B-restricted
peptide pool spanning the immune-dominant proteins of CMV, EBV and
inuenza). A) Representative FACS plots showing the IFN T cell response
from a patient with CHB in total PBMC with or without CEF stimulation,
after gMDSC depletion (gMDSC) and after gMDSC enrichment (+gMDSC)
from day zero. B) Cumulative data for CD8+ and CD4+ responses (after
subtraction of background response in unstimulated wells) in PBMC  gMDSC
(n=11). Error bars represent the mean  SEM. Signicance testing was
carried out using the paired Students t-test, and where signicant indicated
as: ** p<0.01; * p<0.05. C) Representative example: CD8+ T cell IFN
response to CEF stimulation after co-culture with reducing gMDSC:PBMC
ratios in a patient with CHB.
These results were in keeping with their postulated role in suppressing T cell responses capable
of mediating non-antigen specic liver damage. The Maini lab [58], and others [261, 65], have
previously shown that down-regulation of -chain component of the CD3 signalling complex and
a block in proliferation are hallmarks of nutrient deprivation, specically the deprivation of L-
arginine. In line with this, T cells cultured with gMDSC showed a down-regulation in expression
of CD3 (gure 4.14a) and impaired proliferative capacity, assessed by both CFSE dilution and
Ki67 expression (gure 4.14b).
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Figure 4.14: gMDSC limit the capacity for T cell proliferation and can down-
regulate CD3 expression.
gMDSC were enriched using sequential magnetic bead isolation (CD14-
CD15+) from PBMC obtained from a patient with CHB for co-culture
with autologous PBMC. Enriched or undepleted PBMC were cultured with
recombinant IL-2 for ve days and stimulated to assess T cell phenotype and
functionality in response to either an HLA-A and HLA-B-restricted peptide
pool spanning the immune-dominant proteins of CMV, EBV and inuenza
(CEF) or to an HLA-A2-restricted CMVpp65 peptide (NLV). A) CD3
expression in CD3+ T cells after addition of gMDSC and B) intracellular
Ki67 staining of CD3+ T cells upon depletion (gMDSC) or enrichment of
gMDSC (+gMDSC), CFSE dilution at day ve.
Since we did not have access to a biosafety level three sorter during this study, corroboration
of the ndings that gMDSC enriched cultures can suppress both antiviral and bystander T cell
responses obtained with magnetic bead-enriched MDSC was sought using FACS-sorting of blood
from a control without HBV infection. This allowed the isolation and experimentation of a highly
puried population of gMDSC (gure 4.15a). These cells similarly suppressed T cell production
of IFN and TNF (gure 4.15b) and down-regulated CD3 expression (gure 4.15c). All these
data combined indicate that gMDSC could impede the functionality and expansion of T cells
capable of driving liver pathology by depleting their L-arginine supply.
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Figure 4.15: T cell eector function is suppressed by the addition of a highly
puried gMDSC population.
T cell functionality was assessed in response to stimulation with plate-
bound anti-CD3 and soluble anti-CD28 with or without the addition of
FACS-puried gMDSC at an eector:target ratio of 1:2 on day ve of
co-culture. A) Gating strategy used on the BD FACSAria to isolate a 97%
pure population of gMDSC. The cells were stained and isolated using the
following phenotypic marker criteria: CD33+CD11b+CD14-CD15+ from
freshly isolated PBMC for a control study participant. B) T cell production
of IFN and TNF and C) CD3 expression on the CD3+ T cell population.
4.3.8 The eect of gMDSC-mediated suppression in vivo during acute,
resolving infection and spontaneous ares of HBeAg- CHB
Having observed gMDSC-mediated suppression of T cell proliferation, cytokine production and a
down-regulation of CD3 in vitro, evidence was sought to conrm these eects in vivo. This was
done using the cryopreserved longitudinal sample sets from the three patients with acute HBV
and the two spontaneously aring HBeAg- patients with CHB that were analysed previously to
establish the temporal evolution of gMDSC frequencies (gures 3.11 and 3.13). Longitudinal
analysis of a patient sampled through the course of acute HBV infection showed a temporal
correlation between serum L-arginine and the hallmark feature of nutrient deprivation, T cell
CD3 down-regulation (gure 4.16).
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Figure 4.16: Eect of L-arginine deprivation on T cell CD3 expression in vivo
during acute, resolving HBV infection.
Serum concentration of L-arginine (M), measured using tandem HPLC-MS
and T cell expression of CD3 on CD3-expressing cells was plotted over the
course of infection in a patient with acute, resolving HBV infection (days
numbered from the date of presentation in clinic). The dotted line shows the
viral load in the individual throughout the phase of disease captured.
T cell CD3 expression showed some temporal correlation with L-arginine concentrations in
gure 4.16,. Further analysis was carried out for all the longitudinal patients (3 patients with
acute HBV and 2 with CHB) using T cell expression of CD3 as a surrogate marker for L-arginine
availability in vivo where serum L-arginine measurements were not available. In all cases an
inverse relationship was observed between the frequency of arginase I-expressing gMDSC and
T cell expression of CD3 over the course of disease, suggesting potential metabolic nutrient
deprivation driven by gMDSC in vivo (gure 4.17).
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Figure 4.17: Relationship between CD3 expression and circulating frequencies
of gMDSC through the course of acute, resolving HBV infection
and spontaneous ares of HBeAg- CHB disease.
Identication of gMDSC (CD11bhighCD33+HLA-DR-CD14-CD15+) us-
ing 11-colour ow cytometry was done on frozen PBMC samples. gMDSC
frequencies were plotted for three patients with acute, resolving HBV infection
over time in days from presentation in clinic as already depicted in gure 3.11
(red line), alongside expression of CD3 (presented as MFI) on all T cells
(blue line) in the upper panel. The lower panel depicts the same analyses for
two patients through spontaneous ares of HBeAg- chronically evolving HBV
infection (CHB) over time in months.
4.3.9 gMDSC potently suppress T cell function in an arginase I-dependent
manner
To further conrm gMDSC-driven suppression of T cells observed in vitro and ex vivo (gures
4.12 and 4.13) was mediated by their capacity to deplete L-arginine, their suppressive activ-
ity in the presence or absence of the specic arginase I inhibitor, N-hydroxy-nor-L-arginine
(norNOHA), was assessed. This was done by returning to the in vitro suppression assay de-
scribed in section 4.3.7. In this case, upon addition of the enriched population of gMDSC,
norNOHA was also added at the time of CEF-peptide stimulation and left in culture for the
duration of the assay. Addition of norNOHA to the culture abrogated the suppressive activity
previously seen, enabling the restoration of T cell IFN responses (gure 4.18a). gMDSC could
likewise suppress CD8+ T cell TNF and granzyme B activity, two mediators critical in driving
cell-mediated pathology in the liver, in an arginase I-dependent manner (gure 4.18b,c).
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Figure 4.18: gMDSC suppress T cells in an arginase I-dependent manner.
gMDSC were enriched using sequential magnetic bead isolation (CD14-
CD15+, Miltenyi) from PBMC obtained from patients with CHB, for
co-culture with autologous PBMC. gMDSC-enriched, or undepleted PBMC
were cultured with 20IU/ml recombinant IL-2 for ve days and stimulated
to test bystander T cell responses by intracellular cytokine staining following
CEF peptide stimulation (an HLA-A and HLA-B-restricted peptide pool
spanning the immune-dominant proteins of CMV, EBV and inuenza). A)
Cumulative data showing fold change in CD8+ IFN response to CEF in
gMDSC enriched cultures in the presence or absence of an arginase I specic
inhibitor norNOHA (n=3). Representative examples showing B) CD8+ TNF
and C) CD8+ cytotoxicity (granzyme B accumulation) in the presence or
absence of gMDSC and norNOHA.
4.3.10 Regulation of amino acid transporters on T cells aects their
metabolic reprogramming in CHB
The system L amino acid transporters have recently been shown to play a critical role in
the metabolic reprogramming required for a proliferative response to TCR-mediated signalling
[149, 262]. The family of System L amino acid transporters (Slc7a5, Slc7a6, Slc7a7, Slc7a8) that
form heterodimers with the CD98 heavy chain [149, 151] in peripheral T cells has been shown to
be required for arginine uptake; deletion of Slc7a5 in immunologically activated T cells prevented
their arginine uptake [149]. T cells from patients with CHB were therefore stained for CD98.
As expected, ex vivo levels of CD98 on global T cells were low but the percent of positive cells,
and their levels of expression were increased in some patients with CHB compared to controls
(gure 4.19a). Although CD98 has been reported to reect T cell activation [151], the variabil-
ity of its expression on T cells within the CHB cohort did not correlate with their expression of
the activation marker HLA-DR (gure 4.19b). Instead, there was a strong positive correlation
between levels of expression of CD98 and expression of CD3 in CD3+ T cells in CHB (g-
ure 4.19b). Suggesting that those T cells with low level CD98 expression had been unable to
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compensate for arginine deprivation by enhancing their amino acid uptake. This is in line with
the nding that genetic deletion of Slc7a5 prevents increases in L-arginine uptake in antigen-
stimulated murine T cells [149].
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Figure 4.19: Dierential CD98 expression on T cells in CHB.
A) Cumulative data showing expression levels (% and MFI) of CD98 on
CD3+ T cells from 16 controls and 26 patients with CHB. B) Cumulative
data for CD98 MFI in relation to surface HLA-DR and CD3 expression on T
cells (identied by CD3 expression) from the CHB cohort. C) Representative
histogram of CD98 expression levels on peripheral (PBMC) and intrahepatic
(IHL) CD3+ from a patient with CHB, and the cumulative data for six
patients with paired PBMC and IHL samples. Error bars represent the
mean  SEM. Signicance testing was carried out using either the: Pearson
product-moment correlation coecient or the paired or unpaired Students
t-test, and where signicant indicated as: *** p<0.001; ** p<0.01; * p<0.05.
It has previously been shown that levels of Slc7a5 on rat hepatocytes can increase in response
to arginine starvation [263]. It was therefore hypothesized that T cells inltrating the extensive
liver vasculature that may be subjected to prolonged periods of L-arginine deprivation could
have a ˝compensatory increase in CD98 expression. To investigate this, paired blood samples
and surplus liver biopsy tissue from six patients with CHB were used for the comparison of
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circulating and intrahepatic T cells. The number of T cells expressing CD98 directly ex vivo,
and the level of their expression, was increased in the intrahepatic (IHL) compared to circulating
(PBMC) compartment in all the patients with CHB examined (gure 4.19c).
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Figure 4.20: Dierential CD98 expression on virus-specic T cells in CHB.
A) Representative histogram plot of CD98 expression levels on global
(non-HBV specic) CD8+ T cells and HBV-specic (dextramer+) T cells and
the cumulative data from six patients with CHB. B) Representative example
of identication of paired HBV and CMV-specic CD8+ T cells using the
relevant HLA-A2 dextramers and comparison of their CD98 expression in
six patients with CHB. Error bars represent the mean  SEM. Signicance
testing was carried out using either: the Pearson product-moment correlation
coecient or the paired or unpaired Students t-test, and where signicant
indicated as: *** p<0.001; ** p<0.01; * p<0.05.
Further investigation determined the expression of CD98 on HBV-specic CD8+ T cells, which
are known to have encountered their antigen in the tolergenic liver milieu, identied directly ex
vivo by HLA/peptide dextramer staining (directed against a panel of HLA-A2-restricted HBV
epitopes). HBV-specic CD8+ T cells had signicantly higher expression of CD98 compared to
global CD8+ T cells in all six patients examined (gure 4.20a). For comparison, CD8+ T cells
directed against an HLA-A2 restricted immunodominant epitope from CMV in these same six
patients with CHB were examined; HBV-specic CD8+ T cells had consistently higher CD98
than their CMV-specic counterparts (gure 4.20b).
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4.4 Conclusions & Discussion
The ex vivo data presented in this chapter, including strong intracellular antibody staining, the
ELISA data and the in vitro suppression assays, all implicate arginase I as a major eector
mechanism of the expanded gMDSC population in CHB. In patients with CHB (and controls),
a large proportion of gMDSC are capable of expressing this enzyme that has immuno-regulatory
potential, whilst the level of arginase I expressed per gMDSC is increased in the liver compared
to the circulating fraction. However, it is possible that this expanded population of gMDSC
could utilise supplementary suppressive mechanisms, as summarised by Gabrilovich et al. [133].
It is possible that other mechanisms of suppression relating to amino acid metabolism, could
function in synergy with arginase I. For example, via the production of peryoxnitrites as a result
of co-expression of arginase I with another L-arginine metabolising enzyme iNOS. In addition
to suppressing T cells that could mediate cytolytic destruction of hepatocytes and produce pro-
inammatory cytokines, it remains to be determined whether MDSC are able to exert other
anti-inammatory eects in the HBV-infected liver, potentially through inhibition of other in-
ltrating leukocytes [133, 164, 171]. This is particularly relevant as L-arginine-depleting MDSC
have the potential to down-regulate pro-inammatory immune responses mediated by local NK
cells or macrophage populations such as KC. Previous work in murine models has revealed that
the production of pro-inammatory cytokines by macrophages can be inhibited by MSDC [182]
and more specically by L-arginine deprivation [264]. This may be especially critical to the
dampening down of liver damage during the immunotolerant phase of disease, when viral repli-
cation is extremely high in the absence of overt liver disease.
Human MDSC have been shown to be able to release arginase I upon degranulation [132]. This
is consistent with the observation of an increase in the degranulation marker CD63, eluding to
the storage of arginase I in cytoplasmic granules, and the close correlation between frequencies of
gMDSC and serum arginase I concentrations. gMDSC potently suppressed T cell eector func-
tion and proliferation, in an arginase I-dependent manner, limiting the proliferative expansion of
bystander T cell responses that have previously been implicated in causing the liver damage trig-
gered by ongoing HBV infection [47]. Further work is needed to conrm the direct link between
enhanced arginase I production by the expanded gMDSC population and increased L-arginine
metabolism observed in CHB? It still remains to be established whether the CD63-expressing
granules actively release arginase I into the serum, or whether L-arginine can be taken up by
the gMDSC for internal degradation, as described for murine MDSC. Human gMDSC do not
express CAT-2B used by murine MDSC to take up L-arginine [254]; whether another mecha-
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nism is utilised for L-arginine uptake in humans is unclear. It is also plausible that the relatively
short-lived nature of gMDSC (and neutrophil subsets) is critical for their arginase I-dependent
immunomodulation; necrotic cell death of gMDSC may be essential for arginase I release [253].
Activation and/or the activity of arginase I may also be dependent on the surrounding condi-
tions; for example, environments low in NO (dierential activity of iNOS) can actually promote
enhanced arginase I activity, through nitroslytation of internal cysteine residues in the enzyme
[265]. Arginase I activity in CHB may also be directly related to the hypoxic liver micronenvi-
ronment [266], since MDSC under conditions of hypoxia (via the mediator HIF-1), up-regulate
arginase I [216], with a simultaneous down-regulation in other MDSC functionality (specically
ROS production). The authors of this particular study attribute the ability of MDSC to sup-
press non-antigen specic responses to this up-regulation of arginase I activity. It is thought
MDSC in peripheral lymphoid organs primarily mediate antigen-specic T cell inhibition via
the production of ROS (and subsequent peroxynitrite production) and exert their eect only via
close cell to cell contact, with little eect driven by arginase I [237, 267]. With this in mind
the hypoxic environment of the liver, may directly inuence the increase in arginase I expression
seen in intraheptic gMDSC via HIF-1, enabling them to limit the non-antigen-specic bystander
T cells, with a less profound inhibitory eect on liver-resident or inltrating HBV-specic T cells.
Hepatocytes are another notable source of the enzyme arginase I; it was rst recognised almost
thirty years ago that the previously isolated hepatic soluble lymphocyte inhibitory factor [268]
was arginase I, released by damaged hepatocytes [269]. Subsequently, our group, and others,
showed that arginase I could be transiently induced in acute [270] and spontaneous ares of
HBeAg- chronic [58] HBV infection and postulated that it might derive from damaged hepa-
tocytes. Although hepatocytes constitutively express arginase I, they cannot degranulate, so
can only release it when apoptotic or necrotic [271, 272, 273]. In this thesis, evidence presented
demonstrates enhanced arginase I release in the immunotolerant and inactive phases of CHB,
where there is minimal hepatocyte damage. This implies that the increases in serum arginase I
seen in these phases are likely to predominantly derive from increases in arginase I+ gMDSC.
It is likely that the depletion of L-arginine noted in the circulation is further accentuated in
the liver milieu, since in the liver gMDSC express more arginase I and are likely to be brought
into prolonged, close contact with inltrating T cells in the narrow-lumen sinusoidal vasculature.
Activation of locally inltrating MDSC to express more arginase I, allowing enhanced suppres-
sion of neighbouring bystander T cell responses, has similarly been reported in a murine tumour
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model [216].
As mentioned in the introduction in section 1.6, the emerging eld of immunometabolism is a
novel and exciting area of research. More specically, the metabolic regulation of T cells is key to
their function and dierentiation, yet has been relatively understudied. The robust correlations
observed between circulating gMDSC frequencies, arginase I, and the degree of liver pathology,
point towards the relevance of metabolic immunoregulation in vivo in CHB. This is further re-
inforced by novel data presented in this chapter showing dierential expression of amino acid
transporters on global T cells, and more importantly on intrahepatic and HBV-specic T cells.
Depriving T cells of adequate supplies of L-arginine in vitro has been shown to inhibit their
proliferative potential by causing T cell arrest in the G0/G1 phase of the cell cycle [64]. It
was previously reported by our group that this was reected in the hallmark down-regulation
of CD3 on the global T cells in our patients, and was associated with defects in the expansion
of functional responses in CHB [58]. The evidence in this chapter suggests that virus-specic T
cells can dierentially regulate their expression of key amino acid transporters in vivo, providing
an additional rheostat to modulate the intracellular availability of amino acids to T cells in
persistent viral infections. This is supported by recent work demonstrating that a light chain of
the system L transporter, Slc7a5, functions as a critical checkpoint in controlling the metabolic
response of T cells to antigen [149]. It is possible that a compensatory up-regulation of amino
acid transporters in response to extracellular availability of amino acids [263] facilitates the re-
programming of metabolically stressed cells more generally, for example by enhancing T cell
access to the amino acid leucine that, that like arginine, regulates eector function through the
mTOR pathway [149, 234].
It is worth bearing in mind that it is likely that CD98 is not the transporter required for the
direct uptake of extracellular L-arginine. It is thought that an up-regulation of CD98 indirectly
increases intracellular levels by allowing for the direct uptake of other neutral amino acids, for
example, leucine, that is required for the synthesis of other cellular transporters critical for
L-arginine uptake (personal communication - Doreen Cantrell). However the up-regulation of
surface CD98 seen particularly on intrahepatic T cells in CHB does imply an indirect increase
in arginine uptake, along with a bystander eect of increasing uptake of other key amino acids,
indicative of the requirement for T cell metabolic reprogramming in CHB. To take this novel
nding further it would be essential to assess other components sensitive to altered amino acid
transport and metabolism in the T cells from our patients with CHB. One important down-
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stream mediator to consider would be c-Myc, which is particularly sensitive to changes in the
metabolism of glutamine and glucose. It is also well-characterised that amino acid deprivation
of T cells results in the rapid inactivation of the mTOR complex, mTORC1. This can be exper-
imentally assessed as the loss of p70 S6 of the mTORC1 complex. Particular attention should
be given to the mTOR pathway to further the work presented in this thesis. The postulate that
T cells in CHB undergo metabolic reprogramming, may well be supported by considering the
intracellular levels of p70 S6, since amino acid deprivation inactivates the mTORC1 complex
by decreasing the levels of p70 S6, across all patients, but specic analysis into the dierent
phases of disease. Preliminary unpublished data from our group suggests that HBV-specic T
cells express higher levels of p70 S6 when compared to global T cells, or their CMV-specic
counterparts (Schurich et al - unpublished).
Leucine uptake via the System L transporters (components of CD98) was demonstrated to be
critical for sustaining mTORC1 activity in activated T cells, suggesting the ability of mTORC1
to sense leucine uptake allows this kinase pathway to modulate cellular responses to nutrient
availability. Therefore up-regulation of CD98, and a subsequent up-regulation in leucine uptake,
may be critical to T cells function in CHB when attempting to overcome gMDSC-mediated
L-arginine depletion. Assessment of the levels of leucine in the context of CHB (or more locally
in the liver during infection) would be an interesting future development.
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Discussion and Outlook
This study has shown that a subset of cells with the characteristics of immature neutrophils
(gMDSC) expands in the circulation and liver, particularly in those patients in whom virus
replicates at high levels without triggering liver disease. The focus of this thesis was on one of
the mechanisms gMDSC can harness to mediate immunomodulation in the context of chronic
hepatotropic infections. In this nal chapter preliminary data is presented and discussed that
attempts to address a number of further questions raised by this study, including consideration
of other potential MDSC-mediated mechanisms of immune modulation.
5.1 Further unanswered questions relating to MDSC
The evidence presented in this thesis, showing an expansion in circulating and intrahepatic
gMDSC, an increase in serum arginase I, a depletion of L-arginine, functional suppression by
these cells and increased amino acid transporter expression on T cells, all favour the postulate
that gMDSC drive a state of altered immunometabolism in CHB. It is plausible that this then
promotes ne tuning and essentially the ˝toning down of the global T cell response in chronic
hepatotropic infections. Therefore it is reasonable to extrapolate that this eect on bystander T
cells, particularly as these eects are seen in the circulation and not just at the site of infection,
is able to confer a state of generalised immune suppression in our patients. This however is not
observed clinically; patients with either chronic HBV or HCV infection do not show overt signs
of generalised immune suppression. This is in contrast to patients with persistent HIV infection
where patients do show clinical signs of viral-mediated immune suppression. The answer to this
conundrum is beyond the scope of the work. For example, it is possible that the levels of arginase
I (or L-arginine depletion) in the circulation is not able to mediate signicant immunosuppres-
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sion. It is likely that this eect may require close contact between gMDSC and T cells in the liver
microenvironment, where these eects may be more pronounced and able to essentially limit T
cells primed and functioning within the liver sinusoids. Whether the same level of L-arginine
depletion (or enhanced arginase I expression/activity) also occurs in the lymph nodes, the sites
of antigen priming to new infections [274] is unknown.
To consider this question further, focused epidemiological studies analysing large cohorts of
patients in relation to specic defects in immune responses and whether subtle, underlying, gen-
eralised immune suppression does exist would need to be done. At the time of nishing this thesis
it was unknown whether patients with CHB have higher titres of other commonly acquired viral
infections, such as CMV or EBV, compared to their non-HBV infected counterparts of similar
ages/genders. Patients with CHB may have subtle defects in immune responses raised against
other non-cytopathic infections that rely on CD8+ T cell function. Nor is it known whether
the global T cell defects reported in CHB promote the reactivation of previously controlled viral
infections. It may be possible that in CHB, compensatory mechanisms are employed to main-
tain adequate immunity to other infections; these could include (but are not limited to) the
observation that a state of enhanced global T cell activation occurs in CHB (Schurich et al -
unpublished), or as a result of metabolic reprogramming eluded to in this study resulting in
enhanced both glucose and amino acid transport (Schurich et al - unpublished).
The eld of study relating to MDSC is still in its infancy. It is likely, as with the eld of T
cell biology, that over time the complexity of MDSC, and their potential subsets with dier-
ent phenotypes and functions will be more comprehensively dened. The concept of further
MDSC subsets being identied has already been initiated by a recent study that evaluated all
reported myeloid subsets in humans during a clinical trial. This proposed six human MDSC phe-
notypes, using one single multiparametric staining panel: MDSC1 (CD14+IL-4R+), MDSC2
(CD15+IL-4R+), MDSC3 (lineage-HLA-DR-CD33+), MDSC4 (CD14+HLA-DRlow), MDSC5
(CD11b+CD14-CD15+), and MDSC6 (CD15+FSClowSSChigh) [275]. It is possible therefore
that in this study, MDSC have been studied in a crude way and further subset characterisa-
tion of the expanded gMDSC populations may provide better understanding of their role in
the pathogenesis of CHB. The study of MDSC would be greatly enhanced if better ˝tools were
available, for example, if reliable in vitro techniques existed for their expansion or a standardised
isolation protocol. Current methodology makes use of exogenous cytokines (such as GM-CSF
and IL-6) or the use of tumour cell-lines to derive MDSC-like cells [220, 212], although it is quite
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likely that such cells would change their phenotype over time in vitro.
The study of MDSC would also be greatly enhanced by the identication of a unique set of
markers, or approaches to enable gMDSC separation from the overlapping fraction of low-density
neutrophils which may also have the ability for immunosuppression. Emerging techniques may
rely on the identication of candidate peptide molecules that exclusively bind MDSC; the novel
peptide-Fc fusion proteins (peptibodies) described by Qin et al. [276] may pave the way for future
MDSC identication. The use of these newly described peptibodies as treatment, identied
MDSC specically, as their use as a depletion strategy did not aect other immature myeloid
cells [276].
5.2 Can gMDSC induce regulatory T cells in CHB?
The established link between gMDSC and the induction of Treg has primarily come from evi-
dence provided by the study of the tumour microenvironment. In addition to inltrating myeloid
cells, tumours attract large numbers of immunosuppressive Treg. This inltrating population
often includes both thymus-derived natural Treg (nTreg) and locally induced Treg (iTreg), both
of which utilise contact-dependent and contact-independent mechanisms of immune suppression.
The dierent mechanisms will not be discussed, but include the production of the immunosup-
pressive cytokines IL-10 and TGF and altered adenosine triphosphate (ATP) metabolism via
expression of the ectonucleotidase CD39, capable of producing the immunosuppressive and anti-
proliferative nucleoside, adenosine [277].
CD4+ T cells can be converted to iTreg as a consequence of exposure to antigen in the presence
of an immunosuppressive milieu, for example environments rich in TGF and/or IL-10. The
particular role MDSC play in the induction of either Treg subset remains an area of increasing
interest. By virtue of their suppressive capacity, and the fact MDSC expand at sites of chronic
inammation [187, 188, 189], their role in relation to Treg expansion was considered in patients
with CHB.
MDSC have previously been shown to promote the induction of Treg in vivo. One of the
initial studies to show this by Huang et al. [278] demonstrated that murine mMDSC (Gr-
1+CD115+F4/80+) were capable of inducing a population of Treg, expressing FOXP3 and
CD25, in vitro. Additionally, adoptive transfer of mMDSC induced IL-10 and IFN-dependent
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FOXP3+CD25+ Treg in vivo that were capable of suppressing anti-tumour responses. Another
study by the same group went on to demonstrate that expression of CD40 on the surface of
MDSC was necessary for the induction of Treg [279]. Further support for the requirement of
MDSC-mediated cell contact in Treg induction was provided by studies in ovarian tumour models
where the authors reported the induction of Treg required an up-regulation of CD80 [280]. There
is also recent evidence that supports an interaction of MDSC and Treg in humans. Hoechst et al.
[194] reported a role for CD14+HLA-DR  MDSC from patients with HCC in the induction of
functional CD4+CD25+FOXP3+ Treg when co-cultured with autologous T cells. Again the au-
thors attributed this to a cell contact-dependent mechanism; the eect was completely abrogated
when MDSC and T cells were separated experimentally [194]. It seems plausible that MDSC
may be involved in Treg dierentiation in the context of CHB, although conicting reports on
the impact of Treg in CHB pathogenesis exist: circulating Treg numbers have previously been
reported to be increased in CHB in some studies [281, 282, 283, 284], but not in others [285, 286].
The hypothesis that the expanded population of gMDSC are capable of inducing Treg, and as
such altering the balance between regulatory and inammatory CD4+ T cell subsets was briey
addressed. This involved analysis to assess whether there was any correlation between the fre-
quencies of CD4+ Treg and gMDSC frequencies ex vivo. These data utilised frozen PBMC
samples from the cohort of well characterised East London patients with CHB from the same
time point as those used to assess circulating gMDSC frequencies previously (gure 3.5a). The
following data were obtained and analysed by a BSc student, Jia Ying Toh, under my supervision.
Analysis of 27 patients with CHB failed to show a correlation between circulating frequencies
of gMDSC and Treg (identied as: CD4+CD127+FOXP3+, gure 5.1a). Neither was a corre-
lation observed with the potently suppressive subset of Treg, those expressing the cell surface
ectonucleotidase CD39+ (therefore identied as: CD4+CD127+FOXP3+CD39+, gure 5.1b)
[287].
The lack of a direct ex vivo relationship between gMDSC and Treg frequencies prompted the hy-
pothesis that gMDSC may instead promote a T cell cytokine prole considered more ˝regulatory
than ˝inammatory. Using cryopreserved PBMC samples from patients in whom the gMDSC
frequencies were already known, stimulation for a short time period with PMA/ionomycin was
carried out to monitor the cytokine production of both CD4+ and CD8+ T cells from unin-
fected controls and patients with CHB. The cytokines included were IL-10, IL-2, IFN, and
TNF (gure 5.2a), but of specic interest were the percentage of T cells producing either the
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Figure 5.1: gMDSC do not induce regulatory CD4+ T cell subsets in CHB.
Cyropreserved PBMC samples were stained for regulatory CD4+ T
cell subsets ex vivo and anlysed by ow cytometry. Correlative anal-
ysis of frequencies of gMDSC in patients with CHB with: A) the
percentage of CD4+CD127+FOXP3+ cells and B) the percentage of
CD4+CD127+FOXP3+CD39+. Signicance testing was carried out us-
ing the Pearson product-moment correlation coecient and was deemed
non-signicant. Staining and data analysis performed in the generation of this
gure is attributed to Jia Ying Toh.
pro-inammatory cytokine, IFN or the regulatory cytokine, IL-10. No signicant dierences
were observed in the capacity of either T cell subset to produce IFN from controls or patients
with CHB (gure 5.2b). CD4+ T cells from patients with CHB produced more IL-10 than their
control counterparts (gure 5.2c), this increased production of IL-10 failed to correlate with
gMDSC frequencies (gure 5.2d).
Taken together, these data imply no direct induction/alteration in the frequencies or function-
ality of regulatory CD4+ T cell subsets by gMDSC in CHB. What was more striking was the
notable trend towards increased production of IL-10 from the CD8+ T cell compartment in the
context of CHB (gure 5.2e) and the robust correlation of circulating frequencies of gMDSC
with IL-10 production by CD8+ T cells (gure 5.2f). Although gMDSC appear to be unable to
promote regulatory CD4+ T cell function in CHB, it remains possible that gMDSC mediated the
suppressive (or immune regulatory) capacity of CD8+ T cells. This could be further explored by
testing the capacity of gMDSC to induce CD8+ T cells capable of producing IL-10 in co-culture
experiments.
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Figure 5.2: gMDSC frequencies correlate with the production of IL-10 from
CD8+ T cells but not CD4+ T cells.
Cyropreserved PBMC samples from patients with CHB (East London co-
hort) were stimulated with PMA/ionomycin in the presence of BFA. CD4+ and
CD8+ T cell function was assessed by intracellular cytokine staining. CD3+
cells were identied after exclusion of dead and doublet cells, then analysed
for expression of CD8/CD4. A) Representative examples of CD4+ (upper
panel) and CD8+ (lower panel) production of IL-10, IL-2, IFN, and TNF
respectively. B) IFN production from 10 controls and 27 patients with CHB
by CD4+ and CD8+ T cells. C) IL-10 production from CD4+ T cells. D)
Correlative analysis of gMDSC frequencies with IL-10-producing CD4+ T cells.
E) IL-10 production from CD8+ T cells. D) Correlative analysis of gMDSC
frequencies with IL-10-producing CD8+ T cells. Error bars represent the
mean  SEM. Signicance testing was carried out using either: the Pearson
product-moment correlation coecient or the unpaired Students t-test, and
where signicant indicated as: *** p<0.001; * p<0.05. The staining of cells
used in the generation of this gure is attributed to Jia Ying Toh, although the
gating and analysis was done by myself.
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5.3 Can MDSC produce immunosuppressive cytokines?
During extensive phenotypic analysis of the expanded gMDSC population, another known func-
tion of MDSC was considered: their production of immunosuppressive cytokines. The postulate
that MDSC are a potent source of the well described immune regulator TGF [278] was briey
addressed. TGF production by gMDSC is thought to drive the induction of regulatory T cell
subsets [288], and has more specically been reported to play a role in chronic viral infection
[198]. TGF is also a key modulator in the process of liver brogensis. As a pro-brogenic
molecule, TGF is directly involved in the activation of HSC [108, 109]. Given the expan-
sion/accumulation of gMDSC in the liver, MDSC production of TGF could be particularly
relevant in HBV, where brosis/cirrhosis related to the virus kills approximately 300,000 people
a year [9].
Circulating and intrahepatic gMDSC were assessed for their capacity to produce TGF. This
was done using a directly conjugated monoclonal antibody without in vitro stimulation or Golgi
blockade (gure 5.3a). gMDSC have the capacity to produce relatively large amounts of TGF ex
vivo. However, no signicant dierence was seen in either the percentage of circulating gMDSC
expressing TGF or their expression level on a per cell basis (using MFI values) in a cohort of
24 uninfected controls and 50 patients with CHB (gure 5.3b). Stratication of the patients by
the extent of liver inammation, as measured by serum ALT or the presence of HBeAg failed to
show a dierence in gMDSC production of TGF. Further stratication by viral load revealed
a signicant increase in gMDSC TGF production. gMDSC from patients with less ongoing
viral replication produce more TGF (gure 5.3c). Clearly apparent was the marked increase in
the proportion of TGF+gMDSC circulating in patients with CHB compared to controls when
analysis took into account the increased frequency of gMDSC (gure 5.3d), and interestingly the
proportion of gMDSC able to produce TGF was signicantly enhanced in the liver compared to
the periphery (gure 5.3e). The functional eect of gMDSC producing TGF was not considered
experimentally. An important future experiment would be to co-culture gMDSC and T cells in
suppression assays (similar to those described in section 4.3.7) in the presence of TGF blockade.
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Figure 5.3: Ex vivo staining of gMDSC for TGF.
Freshly isolated PBMC were stained for CD33, CD11b, HLA-DR, CD14
and CD15 and gated as shown in gure 3.2a to identify gMDSC. A) Repre-
sentative FACS plots showing gMDSC TGF staining ex vivo compared to its
matched isotype control from a patient with CHB. B) Cumulative data showing:
percentage and mean uorescence intensity (MFI), respectively, of gMDSC
expressing TGF in 24 controls and 50 patients with CHB. C) Percentage of
gMDSC expressing TGF from the cohort of patients with CHB was further
classied by serum ALT (IU/L), the presence of HBeAg, or viral load (IU/ml)
using EASL guidelines [19]. D) Cumulative data for TGF levels in relation to
the percentage of TGF-expressing gMDSC as a proportion of the total myeloid
cell compartment (CD11bhighCD33+). E) Percentage of TGF+ gMDSC in the
peripheral (PBMC) and liver gMDSC (IHL). Error bars represent the mean 
SEM. Signicance testing was carried out using either the: paired or unpaired
Students t test, and where signicant indicated as: *** p<0.001; ** p<0.01; *
p<0.05.
5.4 Can MDSC modulate NK cell function in CHB?
Recent work within our group has led to a number of publications demonstrating a role for NK
cells in CHB; work has shown both diminished antiviral function in the context of CHB [289]
and killing of both hepatocytes and T cells, via the TRAIL pathway [72, 63]. It was therefore
important to investigate whether gMDSC can regulate not only T cell, but also NK cell function
in CHB. To date very limited data exists considering MDSC and NK cells. There is some existing
evidence that suggests gMDSC can suppress NK cell function, although these data are rather
limited.
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5.4.1 A potential role for the NKG2D pathway
A study by Li et al. [290] have demonstrated that a state of heptic NK cell anergy seen in
tumour-bearing mice could be attributed to membrane-bound TGF on the surface of MDSC.
The authors showed that upon co-culturing MDSC with NK cells, the MDSC were able to limit
NK cell cytotoxicity and IFN production and cause a signicant down-regulation in expression
of NK cell activatory receptor, NKG2D. Blockade of TGF signalling or the experimental sep-
aration of MDSC and NK cell during co-culture restored NK cell function. A similar eect was
demonstrated by Mauti et al. [291], where the authors described an increased permissiveness
for metastasis during pregnancy in mice and attributed this to decreased NK cell cytotoxicity
and proliferation/viability in the presence of increased numbers of gMDSC [291]. The outcome
of MDSC-mediated regulation of NK cell function remains controversial. Further reports have
observed that MDSC can activate NK cells, and therefore enhance NK cell function. Nausch
et al. [292] demonstrated expression of NKG2D ligands on murine MDSC which potently ac-
tivated NK cells to produce increased amounts of IFN whilst maintaining the well-described
MDSC-mediated suppression of T cells [292]. It therefore appears a bi-directional cross-talk may
occur between NK cells and MDSC.
MDSC in CHB but not from controls express low, but potentially functionally signicant, levels
of MICA/B, one of the known ligands for the activatory receptor NKG2D (gure 5.4). Recent
unpublished work by our group has demonstrated a role for this particular pathway in interac-
tions between NK cells and T cells; up-regulation of T cell expression of NKG2D-ligands drives
NK cell activation and cytotoxicty (Huang et al - unpublished). It is therefore possible that
gMDSC act the same way as T cells and thereby promote NK cell activation. It is also possi-
ble that MICA/B may be expressed at higher levels on intrahepatic than peripheral gMDSC,
perhaps contributing to the increased NK cell activation seen in the liver [72]. What remains
unknown is whether gMDSC are capable of expressing other NKG2D-ligands, such as ULBP1-6
[293], and the exact function of this interaction.
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Figure 5.4: gMDSC from patients with CHB express increased levels of the
NKG2D ligands, MICA/B.
Freshly isolated PBMC were stained for CD33, CD11b, HLA-DR, CD14
and CD15 and gated as shown in gure 3.2a to identify gMDSC. A) Representa-
tive examples of NKG2D-ligands MICA/B expression on the surface of gMDSC
from one uninfected control and one patient with CHB. B) Summary data of six
uninfected controls and six patients with CHB. Error bars represent the mean
 SEM. Signicance testing was carried out using the unpaired Students t test,
with signicance indicated as: * p<0.05.
5.4.2 A potential role for the NKp30 pathway
It also appears that MDSC have the capacity to interfere with multiple signalling pathways that
can either activate or inhibit an NK cell. Another NK cell pathway that has previously been
implicated in relation to MDSC through another NK cell activatory pathway, the NKp30 path-
way. A previous study by Hoechst et al. [195] demonstrated a link between MDSC and NK cell
function whereby they showed a counter-intuitive inhibition of NK cell function by an expanded
populations of MDSC that was primarily mediated through NKp30. The authors discuss how
the level of inhibition or activation of the NK cell by a MDSC through NKp30 may be dependent
on the density of the corresponding ligand(s) on the MDSC surface.
Using cryopreserved PBMC samples from patients with CHB in whom gMDSC frequencies had
previously been assessed, NK cell expression of NKp30 was ascertained (gure 5.5a). The cu-
mulative data for receptor expression showed no signicant dierence in expression between
controls and patients with CHB in this small cohort. The data pointed towards the notion that
NKp30 expression on the NK cells in CHB is, however, variable (gure 5.5b). Notably, a positive
correlation was observed between the extent of NKp30 expression and circulating frequencies of
gMDSC (gure 5.5c). Given the relationship observed, it is plausible that a signicant rela-
tionship exists between NK cells and gMDSC via this pathway, but what is still unknown is
the functional outcome of such an interaction. gMDSC may further drive NK cell activation
through this pathway or it is may also be possible that gMDSC express varying densities of
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NKp30 ligand(s) that regulate a balance between inhibition and activation of the NK cell, in
line with data published by Hoechst et al. [195].
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Figure 5.5: NKp30 expression on NK cells positively correlates with circulating
gMDSC frequencies in CHB.
Cryopreserved PBMC samples from patients with CHB were used in whom
gMDSC frequencies were previously assessed. NK cells were subsequently
identied as: live, singlet, CD3 CD56+. A) Representative NKp30 staining on
NK cells (highlighted in red) from a patient with CHB and B) summary data
for all controls and patients with CHB where NKp30 expression on total NK
cells was determined. To establish gMDSC frequencies, freshly isolated PBMC
had previously been stained with CD33, CD11b, HLA-DR, CD14 and CD15
and gated as shown in gure 3.2a. C) Correlative analysis between circulating
frequencies of NKp30 and percentage expression of NKp30 on total NK cells.
Error bars represent the mean  SEM. Signicance testing was carried out
using either the: unpaired Students t test or the Pearson product-moment
correlation coecient, and where signicant indicated as: ** p<0.01.
5.5 Can MDSC promote T cell exhaustion in CHB?
As described in section 1.3.2, CHB is characterised by a dysregulated T cell response which
impacts on the antiviral response. Our group and others have extensively considered a role for
phenotypic and functional exhaustion in perpetuating this dysregulation. HBV-specic T cells
express high levels of a number of characteristic exhaustion markers, including PD-1, Tim3 and
CTLA-4 [59, 61, 49, 60]. In this study gMDSC suppression of both HBV-specic and bystander
T cell functionality was reported. The main focus of this thesis was concerned with the role
gMDSC play in limiting bystander T cell damage in the liver through metabolic regulation.
However, gMDSC may additionally limit the already dysfunctional specic antiviral T cells in
CHB through other mechanisms.
Alongside the gMDSC-mediated HBV-specic suppression data discussed in chapter 4, the fol-
lowing preliminary evidence supports the notion that gMDSC promote T cell exhaustion, fur-
thering T cell dysfunction through known receptor:ligand interactions.
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5.5.1 Is bi-directional signalling via galectin-9 on gMDSC important
in CHB?
The S-type lectin galectin-9 binds to the negative regulatory molecule Tim-3 on T cells and in-
duces their apoptotic deletion or functional inactivation. Although galectin-9 is widely accepted
to be the ligand for Tim-3, this role has been questioned recently in a single publication [294].
A role for galectin-9/Tim-3 interaction in the deletion and exhaustion of the antiviral response
in HBV has recently been proposed. An up-regulation of Tim-3 on CD4+ and CD8+ T cells
from patients with CHB compared to controls results in their functional inhibition or deletion
upon engaging with the ligand galectin-9. A further up-regulation of the receptor on HBV-
specic cells was also reported by our group and others [61, 295, 296]. The study by our group
also detected secreted galectin-9 at increased concentrations in the sera of patients with active
CHB-related inammation [61]. Tim-3 mediated inhibition of T cells may not just be solely
attributable to the triggering of cell death of IFN producing cells. Emerging lines of evidence
suggests T cells expressing Tim-3 may also indirectly be involved in the induction of gMDSC
[297]. Putting aside the controversy surrounding the potential for galectin-9 and Tim-3 not being
a physiological receptor:ligand interaction, gMDSC expression of galectin-9 could exacerbate T
cell exhaustion and/or MDSC induction. With this in mind it has also been proposed that the
molecule galectin-9 has the capacity for bi-directional signalling, aecting both the expressing
and interacting cell [297, 298].
Consideration therefore turned to whether gMDSC could express galectin-9 in CHB. Initial con-
rmation of gMDSC expression of galectin-9 was achieved using intracellular staining with an
antibody against the receptor (gure 5.6a) compared to a matched isotype control. As with
expression of the enzyme arginase I, percentage expression and expression levels (as quantied
by MFI) of gMDSC galectin-9 were variable and often extremely high on gMDSC from both con-
trols and patients with CHB (gure 5.6b). Despite the variability, particularly in patients with
CHB, stratication of the CHB cohort revealed nothing of note; galectin-9 expression appeared
to be analogous regardless of the extent of liver inammation (serum ALT levels), the presence of
HBeAg, or viral load (gure 5.6c). However, when taking into account the expanded proportion
of gMDSC in the context of CHB, the contribution galectin-9 expression could make to immune
suppression is more pronounced in CHB (gure 5.6d). Expression of galectin-9 on gMDSC is
signicantly enhanced on intrahepatic gMDSC compared to circulating gMDSC (gure 5.6e),
making this potential mechanism of immune suppression particularly relevant in the context of
hepatotropic infections.
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Figure 5.6: gMDSC express galectin-9 ex vivo.
A) Representative FACS plots showing galectin-9 staining ex vivo com-
pared to its matched isotype control in gMDSC from a patient with CHB. B)
Percentage and mean uorescence intensity (MFI), respectively, of gMDSC
expressing galectin-9 in controls and patients with CHB. C) Percentage of
gMDSC expressing galectin-9 from the cohort of patients with CHB were
further classied by serum ALT (IU/L), the presence of HBeAg, or viral load
(IU/ml). D) Cumulative data for galectin-9 levels in relation to the percentage
of galectin-9-expressing gMDSC as a proportion of the total myeloid cell
compartment (CD11bhighCD33+). E) Percentage of galectin-9 positive gMDSC
in circulating gMDSC (PBMC) and intrahepatic gMDSC (IHL). Error bars
represent the mean  SEM. Signicance testing was carried out using either
the: paired or unpaired Students t test, and where signicant indicated as: ***
p<0.001; ** p<0.01.
Most interesting was the striking association observed between the percentage of gMDSC express-
ing galectin-9 and their capacity to produce arginase I (gure 5.7). This raises the possibility of
two dierent scenarios: either back-signalling through galectin-9 on the gMDSC drives arginase
I expression, or co-expression of these two potentially suppressive mechanisms suggests a state of
gMDSC ˝activation and readiness for immune regulation. Both scenarios require investigation
and pose important future questions, especially since a denitive marker for MDSC activation
does not yet exist.
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Figure 5.7: gMDSC galectin-9 expression correlates with arginase I production
in CHB.
Correlative analysis showing the percentage of gMDSC expressing galectin-9
staining ex vivo against the proportion of those gMDSC producing arginase
I. Signicance testing was carried out using the Pearson product-moment
correlation coecient.
5.5.2 Can gMDSC promote T cell exhaustion through the PD-L1:PD-
1 pathway?
It is widely acknowledged that interaction through the PD-1:PD-L1 pathway results in the de-
livery of a co-inhibitory signal, and therefore promotes T-cell apoptosis, anergy and functional
exhaustion [53, 299]. The concept of MDSC interacting with T cells via this pathway is relatively
new. Preliminary ex vivo showed that gMDSC are capable of expressing the ligand, PD-L1 (g-
ure 5.8a). From this limited analysis expression of PD-L1 detectable on the surface of gMDSC
appears analogous between controls and patients with CHB (gure 5.8). The extent of PD-L1
on intrahepatic gMDSC has yet to be analysed and so it remains possible that an up-regulation
of PD-L1 could further promote the induction of T cell tolerance in the liver microenvironment.
This is in line with recent evidence for the PD-1:PD-L1 interaction of neutrophils and T cell func-
tion. de Kleijn et al. [300] recently demonstrated that IFN-stimulated neutrophils suppressed
T cell proliferation via an up-regulation of PD-L1 [300]. This study was rapidly followed up by
a study in HIV infection. The authors of this particularly study demonstrated that neutrophils
from patients with HIV-infection up-regulated PD-L1 expression, driven by both inactivated
HIV virions and TLR-7/8 ligand. Interestingly, the extent of PD-L1 on the CD15+ neutrophils
signicantly correlated with plasma levels of arginase I [301], suggesting an interaction via this
pathway may also be involved in neutrophil (or MDSC) activation and release of suppressive
mediators in vivo.
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Figure 5.8: gMDSC express PD-L1, a ligand capable of promoting T cell exhaus-
tion through interaction with PD-1.
Freshly isolated PBMC were stained for CD33, CD11b, HLA-DR, CD14
and CD15 and gated as shown in gure 3.2a to identify gMDSC. A) Representa-
tive example of PD-L1 expression on the surface of gMDSC from an uninfected
control. B) Summary data of 12 uninfected controls and 12 patients with CHB.
Error bars represent the mean  SEM. Signicance testing was carried out
using the unpaired Students t test and was deemed non-signicant.
5.6 What causes MDSC expansion & contraction?
5.6.1 A role for death-ligands in MDSC contraction
Despite being a short-lived population, a number of studies have demonstrated roles for death-
ligands in the contraction of gMDSC. It is possible that in the dierent phases of disease, or
by interventions such as antiviral therapy or peg-IFN treatment, that these ligands may be
dierentially regulated, promoting MDSC apoptosis.
One such pathway to consider is the Fas (CD95):Fas-ligand (FasL) pathway. Emerging lines of
evidence suggest a role for this death receptor pathway in the regulation of MDSC expansion and
contraction; a regulatory mechanism controlling the number of circulating MDSC. Apoptosis of
murine Fas+ MDSC was demonstrated in response to activated FasL expressing T cells in vivo.
The authors also showed that FasL decient mice have increased circulating MDSC frequencies
compared to their FasL competent counterparts [302]. Whether this is an important pathway
in CHB is a question of interest since gMDSC identied from three independent patients with
CHB showed high levels of Fas expression ex vivo (data not shown). The particular disease state
of these three patients were unknown. It is possible that this pathway may be important during
active CHB disease (much like in HCV infection), where an up-regulation of FasL on inltrating
lymphocytes [303, 304] may provide a direct mechanism for the deletion of gMDSC, which have
the potential to suppress immunopathology.
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Another death-ligand pathway implicated in the contraction of MDSC frequencies is the TRAIL
pathway. Interaction via this pathway could lead to TRAIL-mediated deletion, similar to that
occurring with hepatocytes and T cells [72, 63]. Condamine et al. [305] have recently shown that
MDSC apoptosis is increased as a result of enhanced expression of TRAIL receptors, specically
TRAIL-receptor 2, in both a murine model and on gMDSC identied from patients with non-
small cell lung cancer [305] . It remains unknown whether gMDSC in the context of CHB can
express TRAIL-receptors. This is of particular interest because previous work by our group
showed that circulating NK cells up-regulate TRAIL when liver damage is ongoing, with further
increases in expression on intraheptaic NK cells [72]. It is therefore plausible that in patients
with active CHB disease, an interaction of gMDSC expressing TRAIL-receptors inltrating into
the liver with TRAIL-expressing NK cells leads to their deletion. If TRAIL-expressing NK cells
can directly eliminate gMDSC, this may be one mechanism pertaining to a lack of gMDSC in
active CHB.
5.6.2 Dierentiation of MDSC aects circulating populations of ma-
ture myeloid populations
Finally, another question this study raises is in relation to the process of MDSC dierentiation
and its potential impact on mature myeloid cell dierentiation. As discussed in section 1.5 the
accumulation of MDSC often occurs upon pathological insult and is believed to be the result
of a disruption of the physiological process of myleopoeisis. More specically, MDSC accumu-
lation can arise from a halt in dierentiation and maturation of immature myeloid progenitors
into mature myeloid subsets (as depicted in gure 1.9). Perturbation of the physiological pro-
cess is thought to be driven by a number of growth factors, cytokines and chemokines. It is
conceivable that when MDSC populations increase/accumulate in the circulation of patients
with CHB there may be a concomitant decrease in the frequencies of mature myeloid sub-
sets. Using the markers already included in the original antibody panel for quantication of
gMDSC frequencies, it was possible to address this in a limited manner based on dierent gating
strategies [306]. Figure 5.9a demonstrates alternative gating strategies used to assess circulating
frequencies of non-classical monocytes (CD11b+CD33+CD14+CD16+) and classical monocytes
(CD11b+CD33+CD14+CD16-) respectively. Populations of classical granulocytes could not be
assessed due to the use of density centrifugation over Ficoll, which excludes these cells.
Using this approach to look at mature myeloid cell populations a decrease was observed in the
population of classical monocytes in patients with CHB compared to uninfected controls. This
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raises an interesting question: if MDSC with a granulocytic phenotype are the subset expand-
ing in CHB, why is a decrease in monocytes observed? Three potential scenarios arise: 1) an
expansion of gMDSC limits the pool of immature myeloid progenitors able to dierentiate into
mature monocytes, 2) the mature monocyte population provides a population of cells from which
suppressive MDSC can expand, either by a process of de-dierentiation of mature populations,
or 3) by further dierentiation of an mMDSC into gMDSC [115, 135].
An increase in non-classical (inammatory) monocytes was also noted, which may be related to
the suppressive nature of these cells (gure 5.9b). It is of note however that the gating strat-
egy used for gMDSC identication does not necessarily exclude low density neutrophils, which
can be identied as CD14-CD15+CD16+ (personal communication - Pascale Kropf), and may
therefore overlap phenotypically with gMDSC.
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Figure 5.9: Populations of mature myeloid cells are also altered in patients with
CHB.
A) Representative gating strategy used to identity CD14+CD16+ non-
classical monocytes and CD14+CD16- classical monocytes in freshly isolated
PBMC by ow cytometry. B) Relative frequencies of circulating subsets of
monocytes respectively represented as a percentage of myeloid cells. Error bars
represent the mean  SEM. Signicance testing was carried out using either
the unpaired Students t test, and where signicant indicated as: *** p<0.001;
* p<0.05.
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5.7 Further Exploration: gMDSC in animal models
Although mice hepatocytes lack the NTCP receptor and restriction factors necessary for natu-
ral HBV infection, two mouse models have been described that utilise adenoviral (AdHBV) or
adeno-associated virus (AAV-HBV) vectors to shuttle the HBV genome into murine hepatocytes
[307, 308, 309]. Particularly interesting future work to build on the data presented in this thesis
would entail looking at gMDSC function and development in either of these two models. These
two models are currently being implemented within the Maini group.
The rst of these, the AdHBV model provides an opportunity to tailor the outcome of HBV
infection, by using varying doses of AdHBV. By using a high or low viral dose of the AdHBV it
is possible to elicit either acute or chronic HBV infection, respectively. More specically a high
viral dose leads to a transient increase in ALT levels, reecting immune-mediated hepatocyte
damage [307]. In using this particular model the comparison of the induction and maintenance
of MDSC in acute resolving or during chronic HBV infection could be assessed. It would also be
interesting to consider, in more detail, their in vivo eect on disease outcome by depleting them,
or by simply blocking one mechanism of action at a time. Most pertinent would be to consider
arginase I-dependent suppression, using the inhibitor nor-NOHA (plus or minus the re-addition
of exogenous L-arginine). Infection of mice with the AAV-HBV construct mimics the state of
immunotolerance. The viral load in these mice is extremely high, HBeAg is produced and the
serum ALT levels are usually low [308]; whether this is primarily controlled by gMDSC, as pro-
posed by this study, would be interesting to consider.
Finally another possibility to establish the in vivo eects of gMDSC or to consider their de-
velopment and expansion is to utilise novel humanised mice models. In this case, these mice
have been reconstituted with both a human liver and a human immune system. This humanised
model is currently under development in a number of dierent groups. The study of gMDSC in
these mice compared to the other previously described models, oers one signicant advantage:
in these humanised mice it should in theory be possible to identify gMDSC using the same panel
of markers established during this thesis for use in our patient cohorts.
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5.8 Future Outlook: the therapeutic potential for gMDSC
In the context of chronic HBV infection there are two possibilities when it comes to harnessing or
exploiting the functionality of gMDSC. On the one hand it could be possible to take advantage
of MDSC-mediated suppression to dampen down immune-mediated damage in the liver, speci-
cally in patients undergoing severe hepatic ares that could ultimately lead to decompensation.
In these patients expansion and/or the activation of a suppressive MDSC population could pre-
vent or limit overwhelming liver damage mediated driven by the bystander immune response.
Therapeutic approaches to achieve this remain to be determined; it is possible that the local
induction of candidate cytokines may enable the perturbation of myeloid cell dierentiation,
allowing MDSC expansion in vivo. This approach may also be useful for other diseases where
immunosuppression is desirable such as auto-immune hepatitis, or after liver transplantation.
On the other hand however, of more widespread applicability in CHB, is the possibility of deplet-
ing MDSC to break immune tolerance. MDSC can suppress HBV-specic immunity, and may
also have the capacity to promote further T cell exhaustion. It may be particularly useful in
patients with immunotolerant disease, who are not currently considered suitable for treatment,
to remove suppressive MDSC to ˝break ongoing tolerance. This could make these patients more
amenable to treatment, by enhancing the limited and dysregulated anti-viral immunity normally
observed in CHB. One major caveat to this approach would be that by removing suppression on
the specic antiviral immune responses, a simultaneous enhancement of bystander T cell func-
tion would also occur, at the inevitable expense of promoting some liver damage. However this
is true of most immunotherapeutic approaches currently under consideration for the treatment
of CHB which all carry the risk of disrupting the homoeostatic balance between immunity and
immunopathology in the liver.
What we do not currently know is the eect antiviral therapy or peg-IFN have on MDSC
frequencies. No longitudinal studies have been carried out with patients where MDSC are par-
ticularly expanded, for example, the inactive patients or those with immunotolerant disease.
It is possible that if MDSC are not completely suppressed on therapy, cure rates would im-
prove by depleting MDSC and promoting successful immune responses. It is plausible that
use of small molecule inhibitors, or an approach based on recent research in mice, detailing
peptide-driven depletion may be the future for MDSC removal. The use of novel therapeutic
MDSC-specic peptide-Fc fusion (peptibody) reagents that have been to shown to successfully
deplete MDSC by a process of antibody-dependent cell-mediated cytotoxcitiy, from the blood,
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spleen and tumour-sites in murine tumour models [276], provides a potential approach that could
be translated into patients with CHB (or cancers of various origins) to alleviate MDSC-mediate
immune-suppression.
It is also possible that small molecules could be used therapeutically to deplete gMDSC or
block their production of metabolic mediators of immunosuppression, which would in turn allow
restoration of antiviral immunity. PI3K inhibitors such as the Gilead compound Idelalisib, that
is already licensed for the treatment of haematological malignancies, has recently been shown
to have ecacy in a murine model of solid tumours. Administration of this PI3K inhibitor
enhanced CD8+ T cell function by reducing the frequencies of both Treg and gMDSC, which
released antiviral T cells from inhibition [310]. Approaches such as this could potentially be
combined with other immunotherapeutic approaches currently being considered for CHB. For
example, inhibition of MDSC function has also been recently demonstrated to enhance the ther-
apeutic ecacy of using PD-1 blockade [311].
One therapeutic approach under current investigation in CHB is the use of gene therapy to
redirect the specicity of patient T cells in CHB using exogenous TCR transfer. The aim of
redirected T cells would be to overcome the dysregulated T cell response observed in patients
with CHB [312, 313]. The use of these immunotherapeutics are under development by a number
of groups and have recently been demonstrated to be safe for use in vivo in one patient with
HCC (Antonio Bertoletti - submitted). One problem, however, still remains regarding the use
of these cells and that is that although the infused T cells would then have the right specicity
they may still succumb to the same mechanisms driving the initial dysfunction. It may be
necessary to therefore alter the sensitivity of redirected HBV-specic T cells to conditions of
nutrient deprivation. The knowledge of any potential compensatory mechanisms that a T cell
may employ to overcome nutrient starvation (specically in the CHB liver) will be critical for
the future design of these cells. One such strategy for protecting against the ongoing milieu in
CHB may require the functional over-activation of pathways such as the mTOR pathway.
5.9 Overview of potential gMDSC-mediated immune reg-
ulation in the context of CHB
Throughout this thesis, a number of potential gMDSC immune-regulatory functions have been
considered. It is clear from data presented in chapters 3 and 4 that gMDSC have the capacity
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to modulate immunity by altering amino acid metabolism. What will have become clear from
reading this chapter however is that other mechanisms may synergise with this eect in CHB,
raising a number of hypotheses for ongoing research. Figure 5.10 summarises all the potential
MDSC-mediated functions that have been considered throughout.
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Those considered in the context of CHB in this thesis are shown in bold.
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Final Word
Final Word
Having completed this thesis, I am aware of how proud my family (and friends) are of me.
With that in mind I would like one nal word:
Family, if you have got this far and are reading this statement I am
equally as proud of you for getting through it!
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